Global burden of 292 causes of death in 204 countries and territories and 660 subnational locations, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023.

GBD 2023 produced estimates for each epidemiological quantity of interest for 292 causes of death by age-sex-location-year for 25 age groups from birth to 95 years and older; for males, females, and all sexes combined; in 204 countries and territories grouped into 21 regions and seven super-regions; and for every year from 1990 to 2023. GBD 2023 also includes subnational analyses for 20 countries and territories. This study drew on the expertise of a network of 14 410 international collaborators from more than 160 countries and territories who provide, review, and analyse the available data to generate these metrics. GBD 2023 produced updated estimates of health loss around the world using the best available data. For each GBD round, newly available data and updated methods are used to update the full time series of estimates from 1990 to the latest year of analysis. Consequently, GBD 2023 estimates supersede all previous estimates. The methods used to generate estimates for GBD 2023 closely followed those for GBD 2021. 14 These methods have been extensively peer reviewed over previous rounds of GBD 14 , 15 , 16 , 17 , 18 , 19 and concurrently as part of the peer review process for GBD 2023. Here, we provide an overview of the methods with an emphasis on the main methodological changes since GBD 2021; a comprehensive description of the analytical methods for GBD 2023 is provided in appendix 1 . The GBD 2023 cause-of-death estimates described here include cause-specific mortality, observed and expected mean ages at death, cause-specific probabilities of death before age 70 years, and the premature death metric YLLs. YLLs were calculated as the number of deaths for each cause-age-sex-location-year multiplied by the standard life expectancy at each age ( appendix 1 section 6.3). Standard life expectancy is calculated from the lowest age-specific mortality rate between countries. 7 In brief, cause-specific death rates for 214 causes were estimated using the Cause of Death Ensemble model (CODEm), while alternative strategies were used to model causes with very limited data, changes in reporting over the study period, or very specific epidemiology. The modelling strategy used for all cause of death estimates can be found in appendix 1 (table S8). CODEm is a modelling tool developed specifically for GBD that evaluates the out-of-sample predictive validity of different statistical models and covariate permutations and then combines the results from those evaluations to produce cause-specific fatal burden estimates. Methodological improvements for cause-of-death estimates in the current round of estimation focused on several key areas. First, a method for the identification and correction of causes displaying excess mortality spikes due to misclassified COVID-19 deaths was applied to all vital registration data between the years of 2020 and 2023. Second, we added 312 new country-years of vital registration data on cause of death, 3 country-years of surveillance data, 51 country-years of verbal autopsy data, and 144 country-years of other data types. Third, all CODEms were fitted to mortality rates rather than cause fractions. Fourth, we updated the modelling framework for COVID-19 to incorporate pandemic-era vital registration data and preliminary vital registration reporting. GBD classifies diseases and injuries into a hierarchy with four Levels that include both fatal and non-fatal causes. Level 1 causes include three broad aggregate categories (communicable, maternal, neonatal, and nutritional [CMNN] diseases; non-communicable diseases [NCDs]; and injuries); Level 2 disaggregates those categories into 22 clusters of causes, which are further disaggregated into Level 3 and Level 4 causes. At the most detailed Level, 292 fatal causes are estimated. For a full list of causes of death by Level, see appendix 1 (table S1). For GBD 2023, five causes of death were estimated for the first time: ulcerative colitis; Crohn's disease; thyroid disease; other endocrine, metabolic, blood, and immune disease; and electrocution. The GBD 2023 cause-of-death database included data sources identified in previous rounds of estimation in addition to 11 474 new sources, for a total of 55 761 data sources—these sources are detailed in appendix 1 (table S3) and can be accessed through the Global Health Data Exchange (GHDx) website . Multiple data types were included to capture the widest array of information, including vital registration data for all 292 causes, as well as verbal autopsy, survey, census, surveillance, cancer registry, and police record data; open-source databases; and minimally invasive tissue sampling. To standardise these data so that they could be compared by cause, age, sex, location, and time, a set of data processing corrections were applied. First, deaths with insufficient or missing age and sex detail underwent a process of distribution via age and sex splitting ( appendix 1 section 3.5). In addition, garbage codes, which are non-specific, implausible, or intermediate rather than underlying cause-of-death codes from the ICD, were redistributed to appropriate targets to assign the underlying cause of death. 20 Data sources with more than 50% of all deaths assigned to major garbage codes (class 1 or class 2 garbage codes) in any location-year were excluded to mitigate the potential for bias from these sources ( appendix 1 section 3.11). Assessing data completeness illustrates the coverage from a data source on overall mortality for the country. Vital registration and verbal autopsy data completeness—a source-specific estimate of the percentage of total cause-specific deaths that are reported in a given location and year—was assessed by location-year, and sources with less than 50% completeness were excluded. We excluded 283 country-years of data due to insufficient completeness or excessive garbage coding. The estimated all-cause mortality for each age-sex-location-year was then multiplied by the cause fraction for the corresponding age-sex-location-year to adjust all included sources to 100% completeness. GBD assesses the quality of all vital registration and verbal autopsy data using a star ranking system of one to five stars, based on the percentage of completeness and percentage of garbage coding. Vital registration and verbal autopsy data availability, completeness, and five-star quality rating for each location-year are available in appendix 1 (figures S4 and S5). Full details on all data processing corrections can be found in appendix 1 (section 3.16). Cause-specific mortality estimates for GBD 2023 are given in death counts and age-standardised rates per 100 000 population, calculated using the GBD standard population structure. 7 For changes over time, we present percentage changes over the period 1990–2023, and annualised rates of change as the difference in the natural log of the values at the start and end of the time interval divided by the number of years in the interval. 95% uncertainty intervals (UIs) for all metrics are computed using the 2·5th and 97·5th percentiles from a 250-draw distribution for each metric ( appendix 1 section 4.1.3). To reduce computing power and time, the number of computations per process was scaled back from 500 in GBD 2021 to 250 in GBD 2023, as simulation testing revealed that final estimates and their uncertainty were not affected by this reduction. See appendix 1 (section 4.1.3) for further details on this update. In accordance with the GBD framework, a death that occurs at any age before the standard (expected) life expectancy is classified as premature. To inform discussions and debates in the literature on premature deaths before age 70 years, in alignment with studies from WHO, 6 , 21 the US National Institutes of Health, 22 and the US Centers for Disease Control and Prevention, 23 we computed the probability of death from birth to age 70 years (70q0). The probability-of-death metric represents the chance of dying from a given cause in a specific age period, for a specific population. Methods for calculating all-cause probability of premature death have been described elsewhere. 7 For example, for males aged 0–70 years in Canada in 1990, a probability of death of 0·1 from ischaemic heart disease indicates a 10% chance of dying from this cause before age 70 years. Cause-specific probability of death can be calculated as follows: q x , c n = d e a t h s x , c n × q x n where q x , c n represents the probability of death for ages x to x  +  n in cause c , deaths x , c n represents deaths in cause fraction space for age group x to x  +  n in cause c ; and q x n represents the all cause probability of death for ages x to x  +  n . The Socio-demographic Index (SDI) is a composite measure of two demographic indicators (total fertility rate in people younger than 25 years and mean educational attainment for those aged 15 years and older) and an economic indicator (lag-distributed income per capita). 7 Values are given as a range between 0·0 and 1·0. Additional details describing the calculation of SDI for GBD 2023 are provided in appendix 1 (section 5) of our companion publication. 7 The calculation of mean age at death uses cause-specific GBD modelled death estimates. GBD produces cause-of-death estimates for every location-year-age-sex group, even when no reported cause-of-death data are available. GBD uses standard 5-year age groups (eg, 15–19, 20–24, and 25–29 years) from age 5 years to 94 years. The remaining non-standard age groups consist of 0–6 days, 7–27 days, 1–5 months, 6–11 months, 12–23 months, 2–4 years, and 95 years and older. For this calculation, each GBD age group is assigned a distinct age at death by taking the mean age of each age group. For example, the age group 15–19 years, which represents people from the day they turn 15 years of age to the day before they turn 20 years of age, was assigned to have a distinct age at death of 17·5 years. The only age group without a discernible mean is the 95 years and older group. For this age group, the distinct age at death was calculated by adding the life expectancy of the 95 years and older age group to 95 years by sex-year-location. The observed mean age at death uses GBD estimates directly, and each death can be assigned a distinct age at death. Distinct ages are then summed together for a given demographic consisting of a given location-year-sex-cause. This value is then divided by the total number of deaths for the same demographic to quantify the mean age at death. Expected deaths were calculated using cause-specific GBD global mortality rates by age and sex and applying them to each country's population. By multiplying the mortality rate on the population to calculate deaths, expected death estimates control for population structure. These expected death estimates are comparable to normal GBD estimates, consisting of the same age-sex groups. The same process used to calculate the observed mean age at death is then applied to the expected deaths to calculate the expected mean age at death. The relationship between mean age at death and SDI was explored by running linear regressions of SDI against the observed mean age at death as well as running linear regressions of SDI against the difference of observed and expected mean ages at death. Appendix 2 (table S14) reports the resulting r 2 , slope, and p values of each regression. An individual regression was run for each cause–sex combination, in which each observation represents a country in 1990, 2010, 2019, 2021, or 2023. By observing the relationship between SDI and the difference between observed and expected values, we are able to measure the correlation of SDI with the mean age at death while accounting for differences in population structure that might also be correlated with SDI. GBD 2023 received 83 country-years of vital registration data from 2020, 67 from 2021, and 38 from 2022. During these years, there is evidence that deaths due to COVID-19 were misclassified as other causes of death. 24 , 25 Relative to smooth prepandemic mortality trends, these misclassified COVID-19 deaths contributed to mortality spikes in the other causes of death. To systematically identify these spikes in other causes, we developed a Support Vector Machine, a machine-learning algorithm for identifying deviations from the established time trends in the years 2020–22. After we identified causes with mortality spikes during the COVID-19 pandemic years, we ascertained, for each cause of interest, whether the spike was a result of COVID-19 misclassification or a true increase in mortality. To do this, we evaluated the correlation between the rate of excess mortality in the cause of interest and the observed mortality rate of COVID-19. Mortality spikes identified to contain COVID-19 misclassification were then considered eligible for correction. When a mortality spike had been identified as being eligible for correction, we calculated the portion of excess mortality attributable to misclassified COVID-19. We first created an estimate of expected deaths absent of any pandemic effects using the mean of two counterfactual estimates: one calculated by a linear regression of the 5 years before the start of the pandemic (2015–19), and another calculated using a global relative rate of non-COVID-19 deaths, adapted from a previously published method used in the correction of misclassified HIV. 26 Total excess mortality could then be estimated by subtracting the expected death count total from the observed death count total. Finally, total excess mortality was then scaled according to the level of correlation between COVID-19 rate and excess mortality rate to calculate the amount of excess attributable to COVID-19. The total excess attributable to COVID-19 was then subtracted from the cause of interest and reassigned to COVID-19. The full details regarding the identification and correction of misclassified COVID-19 can be found in appendix 1 (section 3.8), appendix 2 (table S2), and appendix 3 . Detailed results of this process can be found in appendix 2 (table S3). For modelling COVID-19, we supplemented the corrected vital registration data described above with two other sources of data: 9 country-years of provisional vital registration data and 342 country-years of surveillance data that were reported during the pandemic (to 2022). We developed an analysis method using OneMod, a modelling tool that combines robust feature selection, correlated time-series splines, and covariate effect sizes across age groups, in addition to kernel regression for residual smoothing. It included the following candidate covariates: total COVID-19 infections and variant prevalence; COVID-19 vaccinations; 27 COVID-19 infection detection rate; 27 Healthcare Access and Quality Index; 28 and prevalence of risk factors and comorbidities including obesity, smoking, cancer, cardiovascular disease, chronic kidney disease, chronic obstructive pulmonary disease, and diabetes. 29 , 30 In the first stage of this model pipeline, we used only the corrected vital registration data to estimate age patterns and sex ratios, which were then used to split the provisional vital registration by age and sex, and split the surveillance data that did not contain detailed age and sex information into the 25 granular GBD age groups. We then ran the models using the entire dataset, setting the infection detection rate to 100% for the corrected vital registration data. After fitting these models, we made predictions assuming that the infection detection rate was 100% in all locations. Details on the estimation of COVID-19 deaths can be found in appendix 1 (section 5). This study used de-identified data and was approved by the University of Washington Institutional Review Board (study number 9060). GBD 2023 complies with the Guidelines for Accurate and Transparent Health Estimates Reporting (GATHER) statement ( appendix 1 section 2.4). 31 A completed GATHER checklist is provided in appendix 1 (table S13). Software packages used in the cause of death analysis for GBD 2023 were Python version 3.10.4, Stata version 13.1, and R version 4.4.0. Statistical code used for GBD estimation is publicly available online at the GHDx website . The funders of this study had no role in the study design, data collection, data analysis, data interpretation, or the writing of the report. The corresponding author had full access to the data in the study and final responsibility for the decision to submit for publication.

Detailed results for each cause of death in this analysis are available in downloadable form through the GBD Results tool and via visual exploration through the GBD Compare tool . Relative to the rate in 1990, the percentage change in annual age-standardised mortality rate from 1991–2019 globally for all causes of death fluctuated between a decrease of 2·9% (95% UI –3·5 to –2·3) and a slight increase of 0·1% (–0·7 to 1·0; appendix 2 figure S1). A notable increase occurred between 2019 and 2020 (6·5% [5·9 to 7·1]) and 2020 and 2021 (7·0% [6·5 to 7·6]), followed by a large decrease between 2021 and 2022 (–9·5% [–10·7 to –8·2]). The total number of global deaths for all sexes and all age groups increased from 47·9 million (47·6–48·3) in 1990 to 55·2 million (54·8–55·5) in 2019. An increase occurred during the initial years of the COVID-19 pandemic, with global deaths reaching 65·9 million (65·6–66·2) in 2021. As the pandemic subsided, the annual global death toll decreased to 60·0 million (59·0–61·2) in 2023. From 2000 to 2023, this represents an overall decline of 30·5% (29·0–31·7), in which the global age-standardised mortality rate for all sexes and age groups dropped from 1009·0 (1002·5–1015·2) deaths per 100 000 to 701·5 (690·2–714·9) deaths per 100 000 ( table 1 , appendix 2 table S7). Table 1 Global death and YLL numbers, age-standardised rates per 100 000, and percentage change between 2000 and 2023 for all sexes combined for all GBD causes and Levels 1–4 of the cause hierarchy All-age deaths, thousands Age-standardised death rate per 100 000 population All-age YLLs, thousands Age-standardised YLL rate per 100 000 population 2000 2023 Percentage change, 2000–23 2000 2023 Percentage change, 2000–23 2000 2023 Percentage change, 2000–23 2000 2023 Percentage change, 2000–23 All causes 50 746·1 (50 430·8 to 51 060·8) 60 043·1 (59 045·4 to 61 239·8) 18·3% (16·1 to 20·8) * 1009·0 (1002·5 to 1015·2) 701·5 (690·2 to 714·9) –30·5% (−31·7 to −29·0) * 2 058 941·2 (2 046 424·5 to 2 073 121·2) 1 808 856·0 (1 784 551·7 to 1 836 374·3) –12·1% (−13·3 to −10·7) * 36 126·3 (35 903·4 to 36 364·3) 22 647·5 (22 371·3 to 22 958·5) –37·3% (−38·1 to −36·3) * Communicable, maternal, neonatal, and nutritional diseases 15 054·6 (14 495·6 to 15 946·2) 10 326·0 (9761·6 to 11 100·0) –31·1% (−34·7 to −27·2) * 263·4 (252·2 to 280·2) 136·9 (129·9 to 146·0) –47·8% (−50·4 to −45·2) * 1 005 458·1 (980 016·4 to 1 042 665·5) 553 137·9 (526 426·5 to 581 083·9) –44·9% (−47·2 to −42·7) * 16 568·9 (16 142·1 to 17 230·8) 8024·1 (7654·4 to 8382·4) –51·5% (−53·6 to −49·6) * HIV/AIDS and sexually transmitted infections 1578·2 (1462·9 to 1719·2) 917·2 (799·7 to 1072·2) –41·9% (−49·0 to −34·1) * 26·1 (24·2 to 28·4) 11·2 (9·7 to 13·1) –57·1% (−62·5 to −51·3) * 90 307·6 (83 037·7 to 100 135·0) 47 785·7 (40 824·0 to 56 588·0) –47·1% (−53·4 to −40·5) * 1466·2 (1347·8 to 1623·3) 610·4 (519·2 to 732·2) –58·4% (−63·8 to −53·0) * HIV/AIDS 1489·3 (1387·8 to 1620·1) 833·4 (727·1 to 959·0) −44·1% (−50·8 to −36·5) * 24·6 (22·9 to 26·8) 9·9 (8·6 to 11·3) −59·9% (−64·7 to −54·7) * 82 763·4 (76 737·0 to 90 409·0) 40 794·5 (35 907·8 to 46 637·8) −50·7% (−56·0 to −44·6) * 1343·9 (1246·5 to 1465·6) 497·8 (439·2 to 568·8) −63·0% (−66·9 to −58·6) * HIV/AIDS and drug-susceptible tuberculosis co-infection 477·2 (340·6 to 569·7) 190·5 (125·2 to 252·6) −60·1% (−68·6 to −49·1) * 7·9 (5·6 to 9·4) 2·3 (1·5 to 3·0) −71·3% (−77·5 to −63·5) * 26 632·9 (18 980·6 to 31 911·6) 9365·2 (6135·8 to 12 463·7) −64·8% (−72·6 to −55·4) * 432·4 (307·9 to 517·9) 114·5 (74·9 to 152·5) −73·5% (−79·4 to −66·5) * HIV/AIDS and multidrug-resistant tuberculosis without extensive drug resistance co-infection 29·9 (7·8 to 81·5) 18·8 (6·5 to 38·9) −37·2% (−73·3 to 82·7) 0·5 (0·1 to 1·4) 0·2 (0·1 to 0·5) −55·0% (−80·8 to 31·4) 1656·9 (434·8 to 4546·7) 927·2 (319·3 to 1921·4) −44·0% (−75·7 to 61·2) 26·9 (7·1 to 74·0) 11·3 (3·9 to 23·5) −57·9% (−81·6 to 20·0) HIV/AIDS and extensively drug-resistant tuberculosis co-infection 0·4 (0·1 to 0·9) 0·8 (0·3 to 1·6) 125·1% (4·4 to 443·7) * 0·0 (0·0 to 0·0) 0·0 (0·0 to 0·0) 61·2% (−24·9 to 286·1) 19·0 (5·2 to 46·4) 39·3 (15·5 to 78·1) 107·0% (−3·4 to 402·6) 0·3 (0·1 to 0·8) 0·5 (0·2 to 0·9) 54·0% (−27·8 to 272·7) HIV/AIDS resulting in other diseases 981·9 (863·6 to 1174·0) 623·3 (519·2 to 770·0) −36·5% (−48·1 to −24·5) * 16·2 (14·3 to 19·4) 7·4 (6·2 to 9·1) −54·5% (−62·8 to −46·0) * 54 454·7 (47 620·4 to 64 665·7) 30 462·9 (25 561·4 to 37 382·8) −44·1% (−53·5 to −33·4) * 884·3 (772·9 to 1048·7) 371·5 (311·5 to 454·2) −58·0% (−65·0 to −50·2) * Sexually transmitted infections excluding HIV 88·9 (39·6 to 164·0) 83·7 (35·7 to 154·3) −5·8% (−21·2 to 7·1) 1·5 (0·7 to 2·7) 1·3 (0·5 to 2·5) −9·4% (−25·8 to 2·4) 7544·2 (3116·7 to 14 412·4) 6991·2 (2728·7 to 13 257·7) −7·3% (−21·0 to 5·3) 122·2 (50·6 to 233·3) 112·6 (43·1 to 214·8) −7·9% (−22·1 to 4·7) Syphilis 82·9 (33·2 to 159·9) 77·0 (29·5 to 147·5) −7·1% (−21·1 to 6·4) 1·3 (0·5 to 2·6) 1·2 (0·5 to 2·4) −8·0% (−22·1 to 4·5) 7283·1 (2827·8 to 14 218·5) 6725·4 (2488·9 to 12 994·1) −7·7% (−21·8 to 6·1) 117·9 (45·8 to 230·1) 109·4 (40·2 to 211·6) −7·2% (−21·9 to 6·7) Chlamydial infection 1·3 (0·7 to 2·6) 1·5 (0·9 to 2·6) 11·0% (−51·0 to 135·0) 0·0 (0·0 to 0·0) 0·0 (0·0 to 0·0) −26·1% (−67·1 to 54·7) 63·0 (32·0 to 126·6) 62·8 (34·9 to 115·3) −0·3% (−58·5 to 122·2) 1·0 (0·5 to 2·0) 0·8 (0·4 to 1·4) −25·7% (−69·0 to 64·3) Gonococcal infection 0·6 (0·3 to 1·0) 0·6 (0·4 to 1·0) 7·8% (−41·6 to 91·3) 0·0 (0·0 to 0·0) 0·0 (0·0 to 0·0) −29·0% (−61·0 to 25·3) 26·7 (14·7 to 49·0) 25·9 (15·5 to 45·2) −3·0% (−51·3 to 80·2) 0·4 (0·2 to 0·8) 0·3 (0·2 to 0·6) −27·4% (−63·7 to 35·7) Other sexually transmitted infections 4·0 (2·3 to 7·7) 4·6 (2·8 to 8·0) 15·0% (−46·8 to 127·4) 0·1 (0·0 to 0·1) 0·1 (0·0 to 0·1) −27·4% (−66·0 to 40·7) 171·3 (91·5 to 335·0) 177·0 (101·3 to 317·3) 3·3% (−55·2 to 116·4) 2·9 (1·6 to 5·6) 2·1 (1·2 to 3·8) −26·8% (−68·1 to 51·8) Respiratory infections and tuberculosis 4446·2 (4000·3 to 4975·1) 4337·1 (3947·6 to 4723·1) –1·4% (−13·0 to 13·0) 84·0 (75·8 to 93·8) 52·9 (48·1 to 57·6) –36·4% (−43·4 to −27·4) * 233 209·3 (208 675·3 to 263 016·9) 156 730·3 (138 940·5 to 173 994·9) –32·5% (−41·5 to −20·9) * 3962·0 (3548·2 to 4466·5) 2106·8 (1864·0 to 2361·4) –46·6% (−54·1 to −37·6) * Tuberculosis 1760·3 (1397·6 to 2165·4) 1010·5 (806·6 to 1244·7) −42·6% (−57·8 to −20·2) * 32·7 (26·0 to 40·3) 11·6 (9·2 to 14·4) −64·4% (−73·7 to −50·8) * 72 482·5 (56 508·1 to 91 015·3) 37 633·5 (29 040·2 to 46 853·0) −48·1% (−62·7 to −28·3) * 1249·9 (977·5 to 1562·4) 455·2 (349·3 to 570·1) −63·6% (−73·8 to −49·8) * Drug-susceptible tuberculosis 1629·6 (1241·5 to 2010·7) 908·3 (670·6 to 1140·9) −44·3% (−61·0 to −18·8) * 30·3 (23·1 to 37·7) 10·5 (7·7 to 13·2) −65·4% (−75·8 to −49·9) * 67 228·8 (50 572·5 to 84 499·1) 33 952·7 (24 886·5 to 43 347·3) −49·5% (−65·7 to −27·8) * 1158·9 (874·0 to 1451·8) 411·2 (300·0 to 528·0) −64·5% (−75·9 to −49·5) * Multidrug-resistant tuberculosis without extensive drug resistance 127·1 (35·2 to 305·7) 95·5 (28·9 to 224·1) −24·9% (−76·0 to 147·9) 2·4 (0·7 to 5·7) 1·1 (0·3 to 2·6) −53·8% (−85·3 to 51·1) 5112·2 (1376·5 to 12 610·0) 3448·2 (1093·5 to 7932·4) −32·5% (−76·7 to 118·8) 88·6 (24·0 to 217·4) 41·3 (13·2 to 94·0) −53·4% (−83·9 to 50·0) Extensively drug-resistant tuberculosis 3·6 (1·1 to 8·8) 6·8 (2·6 to 14·5) 86·6% (−21·9 to 400·0) 0·1 (0·0 to 0·2) 0·1 (0·0 to 0·2) 13·5% (−52·4 to 199·2) 141·5 (41·2 to 346·0) 232·6 (92·1 to 503·8) 64·5% (−30·6 to 336·4) 2·5 (0·7 to 6·0) 2·7 (1·1 to 5·9) 10·5% (−53·2 to 191·5) Lower respiratory infections 2646·6 (2369·3 to 2950·0) 2501·3 (2241·0 to 2812·2) −5·5% (−19·0 to 9·4) 50·5 (45·6 to 55·7) 31·6 (28·3 to 35·3) −37·5% (−46·0 to −28·1) * 158 286·0 (136 227·6 to 182 886·1) 98 421·5 (87 415·4 to 111 734·7) −37·8% (−48·2 to −24·7) * 2671·2 (2305·3 to 3075·7) 1391·9 (1215·8 to 1601·7) −47·9% (−56·6 to −36·7) * Upper respiratory infections 38·3 (7·1 to 93·9) 27·1 (6·1 to 77·3) −29·4% (−68·7 to 48·4) 0·7 (0·1 to 1·7) 0·4 (0·1 to 1·1) −46·9% (−76·8 to 6·8) 2389·4 (387·8 to 6402·0) 1727·4 (277·4 to 5097·2) −27·7% (−69·3 to 65·7) 40·1 (6·6 to 106·4) 25·9 (3·9 to 76·6) −35·4% (−72·7 to 47·4) Otitis media 1·0 (0·3 to 3·7) 0·7 (0·3 to 1·7) −35·3% (−78·8 to 166·6) 0·0 (0·0 to 0·1) 0·0 (0·0 to 0·0) −56·0% (−85·2 to 83·5) 51·3 (11·9 to 206·6) 31·9 (10·2 to 94·8) −37·9% (−81·5 to 219·9) 0·9 (0·2 to 3·5) 0·4 (0·1 to 1·3) −49·7% (−85·1 to 156·2) COVID-19 0·0 (0·0 to 0·0) 797·6 (722·9 to 857·0) 0·0% (0·0 to 0·0) 0·0 (0·0 to 0·0) 9·3 (8·4 to 10·0) 0·0% (0·0 to 0·0) 0·0 (0·0 to 0·0) 18 916·1 (17 699·8 to 19 764·2) 0·0% (0·0 to 0·0) 0·0 (0·0 to 0·0) 233·3 (219·0 to 244·0) 0·0% (0·0 to 0·0) Enteric infections 2658·5 (2142·0 to 3452·1) 1268·6 (962·6 to 1683·3) –52·3% (−61·9 to −40·0) * 48·4 (39·1 to 64·1) 16·4 (12·6 to 21·3) –66·1% (−72·4 to −57·5) * 165 871·4 (133 972·2 to 201 264·5) 61 613·6 (48 551·8 to 78 598·2) –62·9% (−70·1 to −52·3) * 2769·9 (2241·4 to 3358·4) 879·9 (694·4 to 1126·1) –68·2% (−74·7 to −59·0) * Diarrhoeal diseases 2336·2 (1838·9 to 3112·9) 1107·1 (810·5 to 1535·9) −52·6% (−63·3 to −38·5) * 43·2 (33·8 to 59·0) 14·2 (10·6 to 19·2) −67·2% (−74·1 to −57·7) * 140 734·9 (108 979·9 to 177 999·5) 49 534·6 (37 596·6 to 65 658·5) −64·8% (−73·3 to −52·6) * 2365·9 (1833·8 to 2982·2) 706·0 (531·1 to 931·4) −70·2% (−77·4 to −59·1) * Typhoid and paratyphoid 231·3 (122·0 to 378·2) 82·8 (43·4 to 135·4) −64·2% (−68·2 to −58·6) * 3·7 (2·0 to 6·1) 1·1 (0·6 to 1·9) −69·2% (−72·5 to −64·7) * 18 217·0 (9546·2 to 30 015·7) 6154·0 (3217·3 to 9994·0) −66·2% (−70·0 to −61·0) * 291·2 (153·4 to 480·7) 86·9 (45·6 to 141·2) −70·1% (−73·6 to −65·4) * Typhoid fever 196·9 (101·7 to 326·2) 72·0 (38·1 to 118·6) −63·5% (−67·5 to −57·7) * 3·2 (1·6 to 5·2) 1·0 (0·5 to 1·6) −68·5% (−72·0 to −63·9) * 15 503·9 (7911·3 to 25 488·6) 5352·6 (2773·7 to 8719·9) −65·5% (−69·5 to −60·1) * 247·9 (125·7 to 407·8) 75·6 (39·0 to 122·4) −69·5% (−73·1 to −64·8) * Paratyphoid fever 34·4 (16·0 to 64·7) 10·9 (5·2 to 20·9) −68·5% (−72·5 to −62·5) * 0·6 (0·3 to 1·0) 0·1 (0·1 to 0·3) −72·8% (−76·3 to −67·9) * 2713·1 (1252·9 to 5065·2) 801·4 (379·4 to 1567·5) −70·5% (−74·4 to −64·7) * 43·3 (19·9 to 80·5) 11·3 (5·3 to 22·4) −73·9% (−77·5 to −69·0) * Invasive non-typhoidal salmonella 89·5 (72·5 to 112·2) 76·7 (60·1 to 100·1) −14·3% (−23·9 to −4·0) * 1·5 (1·2 to 1·8) 1·1 (0·8 to 1·4) −25·9% (−35·3 to −16·8) * 6834·5 (5356·2 to 8716·2) 5843·9 (4441·4 to 7770·4) −14·5% (−25·0 to −3·3) * 111·4 (87·2 to 142·0) 85·9 (64·3 to 115·6) −22·8% (−32·5 to −12·5) * Other intestinal infectious diseases 1·5 (1·2 to 1·9) 1·9 (1·4 to 2·4) 27·5% (−13·5 to 82·5) 0·0 (0·0 to 0·0) 0·0 (0·0 to 0·0) −14·9% (−41·8 to 23·6) 85·0 (62·3 to 111·7) 81·0 (59·0 to 105·1) −4·7% (−41·4 to 46·5) 1·4 (1·0 to 1·8) 1·1 (0·8 to 1·4) −24·5% (−53·6 to 16·2) Neglected tropical diseases and malaria 1050·3 (652·3 to 1601·1) 804·9 (394·2 to 1392·4) –23·4% (−40·1 to −11·4) * 17·5 (10·9 to 26·6) 11·3 (5·4 to 19·5) –35·5% (−50·0 to −25·6) * 79 141·6 (47 827·7 to 122 595·4) 56 346·7 (26 007·0 to 98 093·7) –28·8% (−44·8 to −17·9) * 1295·3 (783·7 to 2006·4) 829·8 (378·5 to 1443·5) –35·9% (−51·1 to −26·1) * Malaria 881·4 (478·4 to 1450·7) 670·0 (261·2 to 1257·9) −24·0% (−46·2 to −11·3) * 14·6 (8·0 to 24·0) 9·6 (3·7 to 17·9) −34·5% (−54·1 to −23·8) * 68 625·0 (36 825·2 to 112 650·3) 49 102·3 (18 837·4 to 91 563·7) −28·4% (−49·6 to −16·1) * 1124·7 (604·9 to 1843·1) 732·1 (280·5 to 1358·1) −34·9% (−54·2 to −23·9) * Chagas disease 10·6 (9·8 to 11·6) 8·4 (7·5 to 9·4) −20·5% (−27·2 to −13·9) * 0·2 (0·2 to 0·2) 0·1 (0·1 to 0·1) −57·0% (−60·5 to −53·3) * 295·2 (273·9 to 321·8) 190·7 (171·5 to 210·9) −35·4% (−40·5 to −30·5) * 5·6 (5·2 to 6·1) 2·1 (1·9 to 2·3) −62·8% (−65·8 to −59·9) * Leishmaniasis 10·1 (2·5 to 24·2) 4·6 (1·9 to 8·7) −54·1% (−67·8 to −17·0) * 0·2 (0·0 to 0·4) 0·1 (0·0 to 0·1) −61·8% (−74·1 to −27·2) * 738·5 (194·5 to 1743·9) 332·1 (141·3 to 610·1) −55·0% (−69·8 to −17·1) * 11·9 (3·1 to 28·2) 4·6 (2·0 to 8·4) −61·1% (−74·4 to −26·4) * Visceral leishmaniasis 10·1 (2·5 to 24·2) 4·6 (1·9 to 8·7) −54·1% (−67·8 to −17·0) * 0·2 (0·0 to 0·4) 0·1 (0·0 to 0·1) −61·8% (−74·1 to −27·2) * 738·5 (194·5 to 1743·9) 332·1 (141·3 to 610·1) −55·0% (−69·8 to −17·1) * 11·9 (3·1 to 28·2) 4·6 (2·0 to 8·4) −61·1% (−74·4 to −26·4) * African trypanosomiasis 26·5 (13·4 to 45·8) 1·4 (0·7 to 2·5) −94·7% (−95·2 to −94·1) * 0·4 (0·2 to 0·7) 0·0 (0·0 to 0·0) −95·9% (−96·3 to −95·5) * 1620·1 (825·8 to 2806·8) 84·2 (40·1 to 147·4) −94·8% (−95·3 to −94·3) * 25·2 (12·8 to 43·8) 1·1 (0·5 to 1·9) −95·8% (−96·2 to −95·4) * Schistosomiasis 21·6 (19·8 to 23·9) 13·5 (12·3 to 14·8) −37·7% (−42·8 to −31·9) * 0·4 (0·4 to 0·4) 0·2 (0·1 to 0·2) −59·4% (−62·7 to −56·0) * 987·8 (898·1 to 1115·3) 564·3 (508·2 to 623·0) −42·9% (−47·7 to −37·9) * 16·5 (15·0 to 18·5) 6·8 (6·2 to 7·5) −58·5% (−61·9 to −55·1) * Cysticercosis 2·4 (1·8 to 3·2) 1·5 (1·1 to 2·1) −36·4% (−53·9 to −10·1) * 0·0 (0·0 to 0·1) 0·0 (0·0 to 0·0) −53·4% (−66·4 to −34·2) * 135·9 (99·2 to 194·0) 80·1 (55·6 to 114·4) −41·1% (−58·3 to −16·5) * 2·2 (1·6 to 3·1) 1·0 (0·7 to 1·4) −54·0% (−67·8 to −35·4) * Cystic echinococcosis 3·0 (2·3 to 3·8) 1·4 (1·0 to 1·8) −53·8% (−67·8 to −34·9) * 0·1 (0·0 to 0·1) 0·0 (0·0 to 0·0) −68·1% (−77·5 to −55·3) * 179·3 (134·7 to 227·6) 61·8 (41·9 to 82·6) −65·6% (−77·2 to −51·9) * 3·0 (2·2 to 3·8) 0·8 (0·5 to 1·1) −73·4% (−83·0 to −62·5) * Dengue 24·0 (9·0 to 60·2) 52·7 (25·2 to 108·9) 119·6% (−18·1 to 616·4) 0·4 (0·2 to 1·0) 0·7 (0·3 to 1·3) 60·9% (−40·0 to 415·1) 1612·3 (601·4 to 4086·4) 2655·6 (1233·0 to 5361·4) 64·7% (−39·5 to 442·1) 26·2 (9·8 to 66·3) 35·1 (16·2 to 70·8) 34·0% (−50·9 to 335·2) Yellow fever 12·6 (4·5 to 26·7) 4·4 (1·5 to 9·3) −65·0% (−71·0 to −58·8) * 0·2 (0·1 to 0·4) 0·1 (0·0 to 0·1) −70·9% (−75·8 to −65·6) * 901·0 (318·6 to 1930·3) 310·0 (108·7 to 652·8) −65·6% (−71·5 to −58·9) * 14·0 (5·0 to 30·1) 4·1 (1·4 to 8·7) −70·5% (−75·7 to −64·7) * Rabies 26·5 (13·9 to 44·0) 15·8 (6·7 to 27·4) −40·3% (−74·0 to 15·5) 0·4 (0·2 to 0·7) 0·2 (0·1 to 0·3) −55·7% (−80·5 to −14·4) * 1681·5 (851·8 to 2850·0) 870·9 (348·4 to 1588·3) −48·2% (−78·6 to 4·3) 27·0 (13·7 to 45·7) 11·3 (4·4 to 20·8) −58·1% (−82·6 to −15·3) * Intestinal nematode infections 14·3 (10·9 to 18·9) 5·0 (3·8 to 6·1) −65·3% (−69·5 to −59·6) * 0·2 (0·2 to 0·3) 0·1 (0·1 to 0·1) −68·6% (−72·6 to −63·4) * 1224·7 (925·4 to 1619·0) 409·0 (309·6 to 510·2) −66·6% (−70·9 to −61·0) * 20·2 (15·2 to 26·7) 6·2 (4·7 to 7·7) −69·3% (−73·2 to −64·1) * Ascariasis 14·3 (10·9 to 18·9) 5·0 (3·8 to 6·1) −65·3% (−69·5 to −59·6) * 0·2 (0·2 to 0·3) 0·1 (0·1 to 0·1) −68·6% (−72·6 to −63·4) * 1224·7 (925·4 to 1619·0) 409·0 (309·6 to 510·2) −66·6% (−70·9 to −61·0) * 20·2 (15·2 to 26·7) 6·2 (4·7 to 7·7) −69·3% (−73·2 to −64·1) * Ebola virus disease 0·3 (0·3 to 0·4) 0·0 (0·0 to 0·0) −100·0% (−100·0 to −100·0) * 0·0 (0·0 to 0·0) 0·0 (0·0 to 0·0) −100·0% (−100·0 to −100·0) * 18·1 (14·9 to 21·4) 0·0 (0·0 to 0·0) −100·0% (−100·0 to −100·0) * 0·3 (0·2 to 0·3) 0·0 (0·0 to 0·0) −100·0% (−100·0 to −100·0) * Zika virus disease 0·0 (0·0 to 0·0) 0·0 (0·0 to 0·0) 0·0% (0·0 to 0·0) 0·0 (0·0 to 0·0) 0·0 (0·0 to 0·0) 0·0% (0·0 to 0·0) 0·0 (0·0 to 0·0) 0·0 (0·0 to 0·0) 0·0% (0·0 to 0·0) 0·0 (0·0 to 0·0) 0·0 (0·0 to 0·0) 0·0% (0·0 to 0·0) Other neglected tropical diseases 16·9 (9·9 to 29·1) 26·3 (13·0 to 48·3) 55·1% (−31·6 to 234·7) 0·3 (0·2 to 0·5) 0·4 (0·2 to 0·7) 22·0% (−46·2 to 168·5) 1121·9 (595·1 to 2077·8) 1685·7 (699·5 to 3352·0) 50·3% (−41·1 to 256·5) 18·5 (9·9 to 34·2) 24·6 (9·9 to 49·6) 32·6% (−48·4 to 216·0) Other infectious diseases 1888·8 (1440·7 to 2382·5) 841·7 (682·3 to 1009·2) –55·4% (−62·5 to −44·9) * 31·4 (24·1 to 39·5) 11·6 (9·3 to 14·1) –62·9% (−68·6 to −54·7) * 148 686·9 (110 615·9 to 190 966·4) 56 632·6 (44 640·6 to 69 674·9) –61·9% (−68·3 to −52·4) * 2429·6 (1806·0 to 3120·1) 826·9 (639·9 to 1034·9) –66·0% (−71·7 to −57·3) * Meningitis 428·9 (341·9 to 547·5) 258·8 (202·2 to 334·6) −39·7% (−56·7 to −17·2) * 7·2 (5·7 to 9·1) 3·5 (2·7 to 4·6) −51·3% (−65·6 to −32·1) * 31 766·9 (24 209·5 to 41 522·9) 16 918·5 (13 198·7 to 22 556·0) −46·7% (−63·5 to −23·3) * 516·5 (393·3 to 676·7) 239·5 (185·0 to 326·9) −53·6% (−68·3 to −34·4) * Encephalitis 82·0 (52·0 to 119·1) 76·5 (54·7 to 113·4) −6·7% (−43·1 to 38·0) 1·4 (0·9 to 2·1) 1·0 (0·7 to 1·4) −33·5% (−59·4 to −1·4) * 4995·7 (3183·0 to 7374·9) 3683·9 (2525·8 to 5765·2) −26·3% (−56·1 to 14·0) 82·4 (52·5 to 121·5) 50·0 (34·1 to 79·1) −39·3% (−64·0 to −5·9) * Diphtheria 23·3 (18·0 to 29·6) 4·0 (3·0 to 5·3) −82·8% (−86·7 to −78·1) * 0·4 (0·3 to 0·5) 0·1 (0·0 to 0·1) −84·5% (−88·1 to −80·2) * 1960·7 (1506·4 to 2513·8) 329·7 (242·6 to 440·7) −83·2% (−87·2 to −78·5) * 32·0 (24·5 to 41·1) 4·9 (3·6 to 6·6) −84·7% (−88·4 to −80·2) * Pertussis 205·9 (111·4 to 328·6) 115·2 (66·6 to 189·2) −44·0% (−68·8 to −4·2) * 3·4 (1·8 to 5·4) 1·8 (1·0 to 2·9) −46·8% (−70·4 to −9·1) * 17 890·3 (9682·8 to 28 542·9) 10 001·5 (5766·0 to 16 405·3) −44·1% (−68·9 to −4·3) * 292·3 (158·3 to 466·3) 155·9 (89·8 to 256·0) −46·7% (−70·3 to −8·9) * Tetanus 126·4 (91·1 to 179·2) 19·8 (11·7 to 31·0) −84·4% (−90·8 to −74·3) * 2·1 (1·5 to 3·0) 0·3 (0·2 to 0·4) −87·3% (−92·5 to −79·8) * 9792·2 (6895·6 to 13 888·7) 1239·8 (745·3 to 1917·7) −87·3% (−92·8 to −79·6) * 158·6 (111·8 to 225·2) 17·8 (10·8 to 27·3) −88·8% (−93·6 to −82·0) * Measles 762·8 (347·4 to 1338·5) 143·6 (58·6 to 255·2) −81·2% (−84·4 to −78·3) * 12·5 (5·7 to 21·9) 2·2 (0·9 to 3·9) −82·3% (−85·3 to −79·6) * 66 032·7 (30 137·0 to 115 712·6) 12 431·7 (5068·1 to 22 097·5) −81·2% (−84·4 to −78·3) * 1081·2 (493·8 to 1893·1) 191·9 (78·2 to 341·2) −82·2% (−85·3 to −79·5) * Varicella and herpes zoster 15·3 (14·0 to 16·5) 13·7 (12·2 to 14·8) −10·4% (−17·9 to −2·5) * 0·3 (0·3 to 0·3) 0·2 (0·2 to 0·2) −41·0% (−45·3 to −36·3) * 872·2 (789·1 to 966·6) 598·8 (534·3 to 662·1) −31·4% (−37·6 to −23·8) * 14·7 (13·4 to 16·3) 8·6 (7·6 to 9·6) −41·7% (−47·1 to −35·0) * Acute hepatitis 171·7 (124·5 to 227·8) 93·1 (65·4 to 123·4) −45·8% (−64·5 to −19·6) * 2·9 (2·1 to 3·9) 1·2 (0·8 to 1·6) −59·7% (−73·8 to −40·0) * 10 991·5 (7719·8 to 14 818·4) 5146·2 (3538·2 to 6952·0) −53·2% (−71·5 to −28·7) * 179·1 (126·1 to 241·8) 69·0 (46·7 to 94·0) −61·5% (−76·8 to −41·1) * Acute hepatitis A 103·8 (75·1 to 147·2) 35·6 (21·8 to 52·0) −65·7% (−80·3 to −45·6) * 1·7 (1·3 to 2·5) 0·5 (0·3 to 0·7) −73·2% (−84·7 to −57·2) * 7122·9 (4960·5 to 10 188·7) 2170·2 (1293·2 to 3222·5) −69·5% (−82·9 to −50·7) * 115·5 (80·5 to 165·6) 30·0 (17·7 to 45·3) −74·1% (−85·5 to −57·6) * Acute hepatitis B 54·1 (31·1 to 87·3) 45·9 (28·0 to 66·9) −15·2% (−53·0 to 53·2) 0·9 (0·5 to 1·5) 0·6 (0·3 to 0·8) −38·8% (−66·5 to 8·1) 3169·3 (1652·8 to 5272·4) 2403·0 (1395·3 to 3610·2) −24·2% (−60·0 to 43·3) 52·0 (27·5 to 86·2) 31·6 (18·0 to 47·9) −39·1% (−68·0 to 13·5) Acute hepatitis C 10·4 (5·0 to 18·1) 7·2 (3·8 to 11·9) −30·5% (−65·7 to 27·1) 0·2 (0·1 to 0·3) 0·1 (0·0 to 0·1) −55·0% (−77·6 to −17·2) * 483·3 (210·2 to 873·5) 312·1 (148·6 to 543·9) −35·4% (−67·6 to 23·6) 8·2 (3·6 to 14·5) 3·8 (1·8 to 6·8) −53·1% (−76·5 to −12·5) * Acute hepatitis E 3·5 (1·6 to 6·5) 4·4 (2·1 to 8·1) 26·0% (−45·0 to 173·8) 0·1 (0·0 to 0·1) 0·1 (0·0 to 0·1) −4·3% (−57·7 to 116·7) 216·0 (93·2 to 443·9) 260·9 (119·4 to 490·9) 20·8% (−50·7 to 180·6) 3·5 (1·5 to 7·2) 3·6 (1·6 to 6·8) 1·7% (−58·5 to 144·7) Other unspecified infectious diseases 72·5 (41·4 to 115·1) 117·0 (65·3 to 191·9) 61·4% (3·4 to 144·9) * 1·3 (0·7 to 2·0) 1·5 (0·8 to 2·5) 18·2% (−24·2 to 81·2) 4384·6 (2323·4 to 7276·8) 6282·5 (3183·3 to 10 888·1) 43·3% (−15·8 to 131·4) 72·6 (38·8 to 120·2) 89·1 (44·2 to 156·6) 22·7% (−28·3 to 100·6) Maternal and neonatal disorders 3007·2 (2877·3 to 3149·7) 1867·9 (1739·6 to 1993·0) –37·9% (−42·5 to −33·6) * 48·2 (46·1 to 50·5) 29·7 (27·6 to 31·7) –38·5% (−43·0 to −34·0) * 259 274·7 (247 935·5 to 271 583·0) 160 961·8 (149 602·1 to 171 949·9) –37·9% (−42·5 to −33·3) * 4162·7 (3979·9 to 4360·5) 2581·6 (2402·3 to 2761·6) –38·0% (−42·6 to −33·3) * Maternal disorders 396·7 (355·3 to 438·6) 239·9 (207·8 to 280·3) −39·5% (−48·1 to −27·9) * 6·1 (5·4 to 6·7) 3·0 (2·6 to 3·5) −50·8% (−57·7 to −41·3) * 24 511·9 (21 945·7 to 27 102·5) 14 559·5 (12 630·9 to 16 968·2) −40·6% (−48·8 to −29·1) * 374·3 (335·1 to 413·9) 182·7 (158·5 to 212·8) −51·2% (−57·8 to −41·7) * Maternal haemorrhage 133·9 (102·0 to 165·4) 52·0 (35·8 to 70·0) −61·2% (−74·3 to −43·7) * 2·1 (1·6 to 2·5) 0·6 (0·4 to 0·9) −68·5% (−79·2 to −54·4) * 8217·9 (6262·5 to 10 169·5) 3127·0 (2160·9 to 4205·8) −61·9% (−74·9 to −44·7) * 125·7 (95·8 to 155·5) 39·1 (27·1 to 52·7) −68·9% (−79·5 to −54·8) * Maternal sepsis and other pregnancy-related infections 43·6 (30·6 to 61·2) 26·7 (19·0 to 37·1) −38·7% (−58·2 to −8·0) * 0·7 (0·5 to 0·9) 0·3 (0·2 to 0·5) −49·9% (−65·7 to −24·8) * 2719·9 (1902·2 to 3807·8) 1627·1 (1156·8 to 2253·8) −40·2% (−59·2 to −10·2) * 41·4 (29·0 to 58·0) 20·4 (14·5 to 28·3) −50·6% (−66·2 to −25·9) * Maternal hypertensive disorders 68·9 (53·9 to 85·1) 48·2 (37·3 to 59·9) −30·0% (−49·1 to −5·6) * 1·1 (0·8 to 1·3) 0·6 (0·5 to 0·8) −42·7% (−58·4 to −22·7) * 4299·7 (3367·0 to 5317·2) 2940·4 (2275·4 to 3662·6) −31·6% (−50·3 to −8·0) * 65·5 (51·3 to 80·9) 37·0 (28·6 to 46·1) −43·5% (−59·0 to −24·0) * Maternal obstructed labour and uterine rupture 22·1 (13·4 to 33·4) 12·2 (7·5 to 18·4) −44·8% (−69·7 to 5·3) 0·3 (0·2 to 0·5) 0·2 (0·1 to 0·2) −55·4% (−75·4 to −14·9) * 1342·8 (806·8 to 2039·5) 736·3 (452·0 to 1119·2) −45·2% (−70·0 to 4·9) 20·6 (12·4 to 31·3) 9·2 (5·7 to 14·0) −55·2% (−75·5 to −14·4) * Maternal abortive outcome 43·4 (29·1 to 64·0) 19·6 (12·2 to 30·8) −54·8% (−71·2 to −19·8) * 0·7 (0·4 to 1·0) 0·2 (0·2 to 0·4) −63·2% (−76·6 to −34·9) * 2675·5 (1786·7 to 3944·6) 1205·0 (748·7 to 1890·4) −55·0% (−71·4 to −20·1) * 40·9 (27·4 to 60·3) 15·1 (9·4 to 23·7) −63·0% (−76·5 to −34·3) * Ectopic pregnancy 9·9 (6·6 to 14·1) 12·7 (8·5 to 17·8) 28·6% (−22·4 to 99·5) 0·2 (0·1 to 0·2) 0·2 (0·1 to 0·2) 4·8% (−36·7 to 62·5) 613·2 (410·2 to 872·7) 776·7 (520·9 to 1079·9) 26·7% (−23·5 to 96·4) 9·4 (6·3 to 13·3) 9·8 (6·5 to 13·5) 4·3% (−37·0 to 61·6) Indirect maternal deaths 29·7 (19·6 to 42·7) 23·0 (16·3 to 32·7) −22·5% (−47·7 to 20·4) 0·5 (0·3 to 0·7) 0·3 (0·2 to 0·4) −36·5% (−57·1 to −1·3) * 1860·5 (1228·0 to 2667·9) 1409·4 (1002·3 to 2002·6) −24·2% (−48·7 to 18·0) 28·3 (18·7 to 40·7) 17·7 (12·6 to 25·2) −37·4% (−57·7 to −2·5) * Late maternal deaths 7·2 (6·1 to 8·9) 8·0 (6·8 to 9·9) 10·8% (−3·3 to 29·3) 0·1 (0·1 to 0·1) 0·1 (0·1 to 0·1) −10·0% (−21·2 to 5·2) 447·0 (371·7 to 549·3) 484·1 (404·2 to 596·5) 8·3% (−6·1 to 26·5) 6·8 (5·7 to 8·4) 6·1 (5·0 to 7·5) −11·1% (−22·5 to 3·9) Maternal deaths aggravated by HIV/AIDS 2·7 (1·7 to 3·6) 1·7 (1·0 to 2·3) −38·9% (−49·5 to −26·4) * 0·0 (0·0 to 0·1) 0·0 (0·0 to 0·0) −50·9% (−59·4 to −41·0) * 166·9 (105·8 to 223·3) 96·1 (60·2 to 134·9) −42·4% (−52·4 to −31·0) * 2·6 (1·6 to 3·4) 1·2 (0·7 to 1·7) −53·3% (−61·4 to −44·1) * Other direct maternal disorders 35·3 (23·1 to 51·0) 35·7 (25·2 to 51·8) 1·2% (−37·2 to 71·5) 0·5 (0·4 to 0·8) 0·4 (0·3 to 0·6) −17·8% (−49·1 to 39·2) 2168·5 (1419·8 to 3142·4) 2157·5 (1520·0 to 3142·4) −0·5% (−38·6 to 68·3) 33·2 (21·7 to 48·1) 27·0 (19·1 to 39·4) −18·5% (−49·7 to 37·9) Neonatal disorders 2610·4 (2495·1 to 2736·7) 1628·0 (1506·0 to 1748·0) −37·6% (−42·6 to −32·6) * 42·1 (40·3 to 44·2) 26·7 (24·7 to 28·6) −36·7% (−41·7 to −31·5) * 234 762·8 (224 399·3 to 246 110·0) 146 402·3 (135 446·8 to 157 187·9) −37·6% (−42·6 to −32·6) * 3788·5 (3620·9 to 3971·9) 2398·9 (2219·7 to 2575·4) −36·7% (−41·7 to −31·5) * Neonatal preterm birth 1064·4 (922·5 to 1244·7) 623·3 (509·7 to 735·0) −41·4% (−54·4 to −25·6) * 17·2 (14·9 to 20·1) 10·2 (8·4 to 12·0) −40·5% (−53·7 to −24·4) * 95 728·4 (82 962·8 to 111 938·1) 56 052·0 (45 839·1 to 66 086·5) −41·4% (−54·4 to −25·6) * 1544·6 (1338·6 to 1806·0) 918·4 (751·2 to 1082·6) −40·5% (−53·7 to −24·4) * Neonatal encephalopathy due to birth asphyxia and trauma 825·2 (676·6 to 995·4) 562·1 (471·4 to 678·7) −31·9% (−47·1 to −7·1) * 13·3 (10·9 to 16·1) 9·2 (7·7 to 11·1) −30·8% (−46·2 to −5·6) * 74 223·5 (60 862·4 to 89 528·0) 50 562·7 (42 408·8 to 61 048·3) −31·9% (−47·1 to −7·1) * 1196·9 (981·4 to 1444·0) 828·9 (695·3 to 1000·7) −30·7% (−46·2 to −5·6) * Neonatal sepsis and other neonatal infections 324·7 (213·8 to 466·6) 223·2 (155·6 to 315·2) −31·3% (−54·8 to 2·5) 5·2 (3·5 to 7·5) 3·7 (2·5 to 5·2) −30·3% (−54·2 to 3·8) 29 199·1 (19 224·7 to 41 953·3) 20 069·1 (13 989·7 to 28 336·6) −31·3% (−54·8 to 2·5) 471·9 (310·7 to 678·0) 328·7 (229·1 to 464·0) −30·3% (−54·2 to 3·8) Haemolytic disease and other neonatal jaundice 99·2 (54·4 to 180·0) 30·3 (16·7 to 47·8) −69·4% (−82·9 to −42·2) * 1·6 (0·9 to 2·9) 0·5 (0·3 to 0·8) −69·0% (−82·7 to −41·4) * 8913·3 (4890·9 to 16 180·1) 2726·9 (1501·2 to 4296·3) −69·4% (−82·9 to −42·2) * 144·1 (79·1 to 261·5) 44·7 (24·6 to 70·4) −69·0% (−82·7 to −41·4) * Other neonatal disorders 296·9 (207·3 to 420·9) 189·0 (124·2 to 267·4) −36·4% (−59·3 to 1·7) 4·8 (3·3 to 6·8) 3·1 (2·0 to 4·4) −35·4% (−58·7 to 3·2) 26 698·5 (18 643·0 to 37 846·9) 16 991·7 (11 163·8 to 24 043·6) −36·4% (−59·3 to 1·7) 431·0 (301·0 to 610·8) 278·3 (182·8 to 393·9) −35·4% (−58·7 to 3·2) Nutritional deficiencies 425·4 (355·6 to 499·8) 288·6 (231·1 to 350·3) –32·2% (−47·4 to −12·6) * 7·7 (6·5 to 9·1) 3·8 (3·0 to 4·6) –51·5% (−62·4 to −37·5) * 28 966·7 (23 792·6 to 34 568·4) 13 067·2 (10 013·5 to 16 919·1) –54·9% (−66·7 to −39·4) * 483·1 (397·1 to 575·5) 188·6 (142·9 to 246·9) –61·0% (−71·2 to −47·6) * Protein-energy malnutrition 378·2 (316·6 to 448·9) 245·8 (195·9 to 300·8) −35·1% (−50·6 to −15·6) * 6·8 (5·7 to 8·1) 3·3 (2·6 to 4·1) −52·4% (−63·9 to −38·7) * 26 783·9 (21 969·1 to 32 265·2) 11 799·0 (8808·0 to 15 515·0) −56·0% (−68·5 to −41·4) * 445·7 (365·8 to 536·0) 172·7 (127·5 to 229·0) −61·3% (−72·3 to −48·2) * Other nutritional deficiencies 47·2 (36·0 to 61·1) 42·8 (30·1 to 58·5) −9·4% (−36·5 to 34·5) 0·9 (0·7 to 1·2) 0·5 (0·4 to 0·7) −45·2% (−61·9 to −19·1) * 2182·8 (1568·7 to 3015·5) 1268·2 (859·0 to 1769·6) −41·9% (−62·0 to −7·4) * 37·4 (27·1 to 51·4) 15·9 (10·8 to 22·2) −57·4% (−72·5 to −31·2) * Non-communicable diseases 31 130·5 (30 469·8 to 31 722·1) 44 842·6 (43 824·4 to 46 047·5) 43·9% (39·5 to 48·6) * 666·6 (653·0 to 678·2) 506·2 (494·7 to 519·3) –24·1% (−26·4 to −21·7) * 813 992·9 (789 034·7 to 837 268·3) 1 035 074·3 (1 009 265·1 to 1 063 890·6) 27·1% (22·2 to 32·4) * 15 672·8 (15 242·2 to 16 077·7) 11 866·9 (11 560·1 to 12 221·0) –24·3% (−27·1 to −21·4) * Neoplasms 7072·9 (6679·9 to 7356·8) 10 567·9 (9726·9 to 11 166·9) 49·3% (41·2 to 57·8) * 143·9 (135·8 to 150·0) 117·0 (107·7 to 123·5) –18·8% (−22·6 to −14·4) * 197 152·6 (187 838·8 to 204 021·0) 267 421·9 (252 512·2 to 280 600·0) 35·6% (29·5 to 43·6) * 3734·1 (3556·7 to 3868·0) 2984·7 (2819·7 to 3129·3) –20·1% (−23·5 to −15·3) * Lip and oral cavity cancer 120·6 (108·1 to 131·0) 225·7 (198·6 to 262·3) 87·1% (60·6 to 124·1) * 2·4 (2·2 to 2·6) 2·5 (2·2 to 2·9) 3·0% (−11·5 to 23·0) 3545·0 (3170·0 to 3892·6) 6290·1 (5461·5 to 7446·1) 77·4% (51·0 to 114·4) * 67·0 (60·0 to 73·4) 69·5 (60·3 to 82·4) 3·7% (−11·8 to 25·5) Nasopharynx cancer 64·2 (56·3 to 71·5) 75·4 (63·3 to 89·1) 17·4% (−4·1 to 43·0) 1·2 (1·1 to 1·3) 0·8 (0·7 to 1·0) −31·1% (−43·8 to −15·9) * 2273·6 (1967·4 to 2553·2) 2495·5 (2058·5 to 2957·0) 9·7% (−11·4 to 36·3) 40·7 (35·4 to 45·7) 28·0 (23·1 to 33·2) −31·2% (−44·6 to −14·5) * Other pharynx cancer 54·2 (46·7 to 65·7) 113·9 (92·5 to 140·6) 110·2% (60·8 to 168·8) * 1·1 (0·9 to 1·3) 1·2 (1·0 to 1·5) 16·5% (−10·7 to 49·2) 1639·7 (1400·5 to 1993·3) 3273·8 (2635·2 to 4090·5) 99·6% (52·0 to 159·1) * 31·1 (26·6 to 37·9) 35·8 (28·8 to 44·7) 14·9% (−12·5 to 48·8) Oesophageal cancer 443·5 (380·3 to 481·6) 577·8 (505·7 to 643·2) 29·8% (15·0 to 51·9) * 9·0 (7·7 to 9·8) 6·3 (5·5 to 7·0) −30·0% (−37·9 to −18·1) * 11 478·2 (9812·4 to 12 479·0) 13 899·3 (12 424·2 to 15 658·7) 20·8% (7·0 to 43·2) * 223·7 (191·7 to 243·5) 151·2 (135·0 to 170·7) −32·6% (−40·3 to −20·4) * Stomach cancer 943·1 (808·3 to 1042·2) 935·9 (797·9 to 1083·5) −0·9% (−12·2 to 15·3) 19·2 (16·5 to 21·3) 10·3 (8·8 to 11·9) −46·6% (−52·7 to −38·1) * 24 561·0 (20 779·6 to 26 982·5) 22 182·4 (19 028·7 to 25 650·1) −9·8% (−21·1 to 4·9) 474·3 (402·0 to 521·7) 243·2 (208·1 to 281·4) −48·8% (−55·2 to −40·4) * Colon and rectum cancer 704·3 (655·8 to 742·9) 1107·1 (997·7 to 1214·9) 57·1% (46·5 to 68·9) * 14·9 (13·8 to 15·8) 12·3 (11·0 to 13·5) −17·9% (−23·5 to −12·0) * 16 986·2 (15 891·8 to 17 911·6) 25 041·4 (22 808·4 to 27 266·0) 47·4% (35·7 to 59·8) * 333·9 (312·4 to 351·9) 275·5 (250·7 to 300·3) −17·5% (−24·0 to −10·7) * Liver cancer 325·8 (297·8 to 357·9) 507·7 (442·4 to 570·0) 55·9% (34·6 to 79·0) * 6·4 (5·9 to 7·0) 5·6 (4·9 to 6·3) −13·0% (−24·8 to −0·4) * 9798·0 (8817·8 to 10 941·2) 13 782·5 (11 945·8 to 15 939·9) 40·7% (18·6 to 65·0) * 182·9 (165·1 to 203·6) 153·3 (132·4 to 178·3) −16·2% (−29·4 to −1·7) * Liver cancer due to hepatitis B 141·4 (123·5 to 162·0) 188·3 (161·3 to 220·6) 33·4% (13·6 to 55·5) * 2·7 (2·3 to 3·1) 2·1 (1·8 to 2·4) −22·4% (−33·8 to −9·1) * 4851·2 (4219·9 to 5543·1) 5956·2 (5089·8 to 6886·3) 22·9% (3·2 to 44·1) * 87·8 (76·3 to 100·2) 66·3 (56·6 to 76·8) −24·4% (−36·3 to −11·2) * Liver cancer due to hepatitis C 93·5 (82·0 to 107·7) 155·5 (131·1 to 186·4) 66·3% (45·9 to 87·6) * 2·0 (1·7 to 2·2) 1·7 (1·5 to 2·1) −12·5% (−22·8 to −1·6) * 2179·6 (1920·9 to 2566·2) 3355·5 (2790·7 to 4121·1) 53·8% (34·1 to 76·2) * 43·5 (38·2 to 51·0) 36·6 (30·5 to 45·0) −15·8% (−26·2 to −3·6) * Liver cancer due to alcohol use 51·1 (42·4 to 63·0) 95·1 (75·9 to 117·6) 86·1% (58·3 to 116·7) * 1·0 (0·8 to 1·3) 1·0 (0·8 to 1·3) 1·3% (−13·8 to 17·7) 1361·2 (1123·7 to 1695·5) 2413·0 (1899·3 to 3046·1) 77·3% (47·2 to 111·3) * 26·2 (21·7 to 32·6) 26·2 (20·5 to 33·1) 0·0% (−16·7 to 19·2) Liver cancer due to NASH 20·5 (16·3 to 25·4) 41·7 (31·6 to 52·6) 103·9% (69·0 to 138·6) * 0·4 (0·3 to 0·5) 0·5 (0·3 to 0·6) 10·8% (−7·6 to 29·5) 551·6 (439·7 to 686·3) 1045·7 (801·0 to 1337·1) 89·6% (53·9 to 125·3) * 10·5 (8·4 to 13·0) 11·5 (8·8 to 14·7) 9·6% (−10·9 to 30·4) Hepatoblastoma 3·9 (2·9 to 5·2) 3·5 (2·3 to 5·2) −10·9% (−44·5 to 45·1) 0·1 (0·0 to 0·1) 0·1 (0·0 to 0·1) −16·0% (−47·7 to 36·9) 343·5 (250·1 to 455·3) 306·0 (198·7 to 454·9) −10·9% (−44·6 to 45·2) 5·6 (4·1 to 7·5) 4·7 (3·1 to 7·0) −15·9% (−47·7 to 37·2) Liver cancer due to other causes 15·5 (13·0 to 18·5) 23·6 (18·4 to 29·7) 52·4% (27·4 to 76·4) * 0·3 (0·2 to 0·4) 0·3 (0·2 to 0·3) −12·6% (−25·5 to 1·4) 510·9 (423·9 to 623·8) 706·0 (541·5 to 886·1) 38·2% (14·7 to 67·0) * 9·3 (7·7 to 11·3) 7·9 (6·1 to 9·9) −14·7% (−29·6 to 2·6) Gallbladder and biliary tract cancer 118·6 (105·8 to 132·7) 184·1 (159·8 to 220·6) 55·2% (40·4 to 69·6) * 2·5 (2·3 to 2·8) 2·0 (1·8 to 2·4) −19·5% (−27·0 to −12·0) * 2709·1 (2406·6 to 3056·5) 3948·6 (3411·9 to 4727·4) 45·7% (30·1 to 60·0) * 54·2 (48·3 to 60·8) 43·1 (37·3 to 51·6) −20·5% (−28·9 to −12·5) * Pancreatic cancer 280·5 (262·5 to 294·3) 552·7 (501·8 to 588·7) 96·9% (85·9 to 108·2) * 5·9 (5·4 to 6·2) 6·1 (5·5 to 6·5) 3·1% (−2·3 to 8·8) 6706·1 (6336·4 to 7017·3) 12 167·8 (11 281·6 to 12 986·1) 81·3% (70·8 to 92·7) * 132·7 (125·0 to 139·0) 132·4 (122·7 to 141·4) −0·4% (−5·9 to 5·7) Larynx cancer 87·9 (77·7 to 98·8) 130·8 (112·1 to 156·4) 48·7% (27·4 to 76·0) * 1·8 (1·6 to 2·0) 1·4 (1·2 to 1·7) −19·5% (−31·0 to −4·7) * 2408·8 (2122·0 to 2724·1) 3434·1 (2894·3 to 4138·7) 42·5% (20·4 to 70·9) * 46·6 (41·0 to 52·6) 37·3 (31·4 to 45·0) −19·9% (−32·3 to −4·0) * Tracheal, bronchus, and lung cancer 1322·0 (1243·4 to 1408·8) 2037·1 (1857·7 to 2212·9) 53·9% (41·9 to 65·1) * 27·0 (25·3 to 28·7) 22·2 (20·2 to 24·1) −17·8% (−24·0 to −11·9) * 33 085·6 (30 779·3 to 35 405·5) 46 132·3 (41 948·2 to 50 238·8) 39·3% (28·5 to 49·9) * 647·1 (602·6 to 692·3) 499·5 (453·8 to 544·3) −22·9% (−28·8 to −17·0) * Malignant skin melanoma 41·9 (38·7 to 45·5) 66·6 (59·9 to 75·2) 58·7% (47·4 to 70·1) * 0·9 (0·8 to 0·9) 0·7 (0·7 to 0·8) −12·8% (−19·0 to −6·3) * 1212·0 (1107·5 to 1334·2) 1680·0 (1484·3 to 1954·4) 38·6% (26·3 to 50·2) * 22·7 (20·8 to 24·8) 18·8 (16·6 to 21·9) −17·1% (−24·5 to −10·0) * Non-melanoma skin cancer 30·2 (27·2 to 33·7) 63·9 (54·4 to 71·6) 111·1% (83·2 to 138·5) * 0·7 (0·6 to 0·8) 0·7 (0·6 to 0·8) 6·5% (−7·2 to 20·1) 678·1 (604·1 to 763·1) 1239·4 (1044·5 to 1409·7) 82·5% (55·1 to 111·2) * 13·7 (12·2 to 15·3) 13·8 (11·6 to 15·7) 1·0% (−13·9 to 17·0) Non-melanoma skin cancer (squamous-cell carcinoma) 30·2 (27·2 to 33·7) 63·9 (54·4 to 71·6) 111·1% (83·2 to 138·5) * 0·7 (0·6 to 0·8) 0·7 (0·6 to 0·8) 6·5% (−7·2 to 20·1) 678·1 (604·1 to 763·1) 1239·4 (1044·5 to 1409·7) 82·5% (55·1 to 111·2) * 13·7 (12·2 to 15·3) 13·8 (11·6 to 15·7) 1·0% (−13·9 to 17·0) Soft tissue and other extraosseous sarcomas 37·9 (31·1 to 48·9) 60·9 (49·0 to 75·8) 60·8% (19·9 to 101·6) * 0·7 (0·6 to 0·9) 0·7 (0·6 to 0·9) −1·8% (−26·4 to 22·9) 1535·8 (1215·1 to 2079·6) 2151·0 (1655·4 to 2783·7) 40·1% (−2·5 to 84·4) 26·4 (21·1 to 35·5) 25·9 (19·7 to 33·9) −1·9% (−31·5 to 29·1) Malignant neoplasm of bone and articular cartilage 49·0 (40·5 to 61·5) 76·7 (60·8 to 96·4) 56·3% (16·7 to 98·9) * 0·9 (0·7 to 1·1) 0·9 (0·7 to 1·1) −0·8% (−25·2 to 25·0) 2161·9 (1708·1 to 2857·2) 2942·0 (2216·9 to 3849·4) 36·0% (−4·8 to 81·7) 35·8 (28·6 to 46·8) 35·3 (26·2 to 46·5) −1·6% (−31·3 to 31·8) Breast cancer 446·4 (408·7 to 481·8) 780·2 (685·7 to 871·0) 74·7% (55·2 to 95·7) * 9·0 (8·2 to 9·7) 8·7 (7·6 to 9·7) −3·4% (−13·9 to 8·3) 13 394·8 (12 216·4 to 14 561·3) 23 024·3 (19 985·8 to 25 997·2) 71·9% (49·2 to 97·7) * 250·8 (229·4 to 271·8) 258·0 (223·9 to 291·7) 2·8% (−10·7 to 18·5) Cervical cancer 235·7 (190·6 to 300·7) 369·5 (291·7 to 474·5) 56·7% (20·6 to 105·5) * 4·5 (3·6 to 5·7) 4·1 (3·3 to 5·3) −7·7% (−28·8 to 20·6) 8243·4 (6589·2 to 10 746·9) 12 876·8 (9852·7 to 16 768·3) 56·2% (16·4 to 107·0) * 147·9 (118·6 to 191·9) 146·1 (111·5 to 190·7) −1·2% (−26·4 to 31·2) Uterine cancer 67·2 (57·6 to 74·9) 108·6 (93·2 to 126·2) 61·6% (37·3 to 85·8) * 1·4 (1·2 to 1·5) 1·2 (1·0 to 1·4) −14·0% (−26·6 to −1·3) * 1741·3 (1464·8 to 1966·4) 2639·7 (2227·3 to 3105·3) 51·5% (26·0 to 79·4) * 33·7 (28·5 to 38·0) 28·8 (24·3 to 33·9) −14·6% (−28·9 to 0·5) Ovarian cancer 129·9 (117·1 to 142·7) 221·0 (191·6 to 255·0) 70·1% (48·1 to 96·3) * 2·6 (2·4 to 2·9) 2·4 (2·1 to 2·8) −7·1% (−19·3 to 6·9) 3699·3 (3315·2 to 4116·5) 6304·4 (5313·3 to 7450·7) 70·4% (43·9 to 102·3) * 70·0 (62·9 to 77·6) 70·1 (59·0 to 83·1) 0·0% (−15·9 to 18·7) Prostate cancer 274·4 (243·7 to 301·9) 473·0 (415·9 to 530·2) 72·4% (55·5 to 94·8) * 6·2 (5·5 to 6·9) 5·3 (4·6 to 5·9) −15·4% (−23·3 to −4·7) * 4863·4 (4357·1 to 5362·3) 8010·1 (6965·5 to 9037·7) 64·7% (46·0 to 88·0) * 104·1 (93·0 to 114·6) 87·7 (76·4 to 99·0) −15·7% (−25·0 to −3·7) * Testicular cancer 8·8 (7·2 to 10·9) 11·9 (9·6 to 14·7) 35·5% (2·0 to 76·8) * 0·2 (0·1 to 0·2) 0·1 (0·1 to 0·2) −6·6% (−29·4 to 21·6) 422·9 (344·0 to 536·9) 540·0 (429·0 to 678·7) 27·7% (−6·6 to 70·5) 6·8 (5·6 to 8·6) 6·5 (5·2 to 8·2) −4·4% (−29·7 to 27·6) Kidney cancer 101·1 (93·2 to 108·7) 165·4 (146·7 to 180·0) 63·5% (52·2 to 75·7) * 2·1 (1·9 to 2·2) 1·8 (1·6 to 2·0) −12·0% (−17·9 to −5·6) * 2704·6 (2467·2 to 2955·4) 3899·7 (3438·2 to 4322·7) 44·1% (31·5 to 57·5) * 52·1 (47·6 to 56·6) 43·7 (38·4 to 48·5) −16·1% (−23·4 to −8·3) * Bladder cancer 146·2 (135·1 to 156·8) 233·7 (208·5 to 257·6) 59·9% (48·2 to 75·5) * 3·2 (3·0 to 3·5) 2·6 (2·3 to 2·9) −18·8% (−24·6 to −11·0) * 3017·5 (2768·9 to 3254·1) 4330·4 (3953·5 to 4822·8) 43·5% (30·9 to 60·7) * 61·9 (57·0 to 66·6) 47·6 (43·3 to 53·0) −23·2% (−29·8 to −14·1) * Brain and central nervous system cancer 175·2 (150·9 to 200·1) 264·2 (230·5 to 313·2) 50·6% (37·4 to 63·0) * 3·3 (2·8 to 3·7) 3·0 (2·6 to 3·5) −8·3% (−16·2 to −0·6) * 7154·4 (6034·0 to 8243·3) 9028·2 (7915·8 to 10 869·8) 26·1% (12·7 to 39·1) * 123·9 (105·1 to 142·8) 106·5 (93·2 to 128·1) −14·1% (−23·4 to −5·1) * Eye cancer 9·5 (6·5 to 14·1) 10·1 (7·3 to 14·2) 6·2% (−33·5 to 68·4) 0·2 (0·1 to 0·3) 0·1 (0·1 to 0·2) −27·7% (−53·6 to 12·4) 520·5 (299·7 to 898·3) 476·9 (279·7 to 796·8) −8·4% (−51·7 to 77·4) 8·9 (5·2 to 15·1) 6·5 (3·6 to 11·5) −26·4% (−62·8 to 41·6) Retinoblastoma 4·0 (1·8 to 8·4) 3·2 (1·3 to 7·0) −18·9% (−71·3 to 130·7) 0·1 (0·0 to 0·1) 0·0 (0·0 to 0·1) −24·8% (−73·3 to 114·0) 344·5 (156·1 to 726·0) 279·9 (110·1 to 608·4) −18·7% (−71·2 to 131·0) 5·7 (2·6 to 12·0) 4·3 (1·7 to 9·3) −24·6% (−73·3 to 114·5) Other eye cancers 5·5 (4·3 to 7·1) 6·9 (5·4 to 8·8) 24·2% (1·1 to 52·6) * 0·1 (0·1 to 0·1) 0·1 (0·1 to 0·1) −29·5% (−42·7 to −13·7) * 175·9 (132·9 to 235·4) 197·0 (146·6 to 271·5) 12·0% (−15·5 to 42·5) 3·2 (2·4 to 4·2) 2·2 (1·7 to 3·1) −29·6% (−47·0 to −10·3) * Neuroblastoma and other peripheral nervous cell tumours 4·2 (3·5 to 5·0) 6·0 (5·0 to 7·6) 42·9% (15·7 to 79·2) * 0·1 (0·1 to 0·1) 0·1 (0·1 to 0·1) 4·3% (−16·2 to 31·0) 263·2 (214·8 to 316·7) 324·3 (261·2 to 429·6) 23·2% (−4·9 to 59·2) 4·3 (3·6 to 5·2) 4·4 (3·5 to 5·9) 1·6% (−22·6 to 31·7) Thyroid cancer 28·8 (25·7 to 33·5) 52·2 (44·7 to 61·5) 81·2% (51·9 to 123·3) * 0·6 (0·5 to 0·7) 0·6 (0·5 to 0·7) −0·7% (−16·7 to 21·7) 814·1 (710·2 to 975·7) 1415·2 (1192·5 to 1715·1) 73·8% (41·4 to 120·8) * 15·2 (13·3 to 18·1) 16·0 (13·4 to 19·4) 4·8% (−14·5 to 33·5) Mesothelioma 17·2 (15·6 to 19·2) 28·0 (24·8 to 30·9) 62·2% (43·5 to 82·1) * 0·4 (0·3 to 0·4) 0·3 (0·3 to 0·3) −13·2% (−23·0 to −2·7) * 427·0 (385·1 to 476·7) 615·3 (544·3 to 685·3) 44·0% (26·5 to 63·2) * 8·3 (7·5 to 9·3) 6·8 (6·0 to 7·5) −18·9% (−28·5 to −8·1) * Hodgkin lymphoma 28·8 (22·4 to 35·4) 27·2 (21·0 to 34·9) −5·7% (−27·9 to 15·4) 0·5 (0·4 to 0·6) 0·3 (0·2 to 0·4) −38·0% (−52·6 to −24·3) * 1310·0 (1006·9 to 1659·6) 1150·9 (837·0 to 1516·3) −12·2% (−35·8 to 12·2) 21·7 (16·7 to 27·4) 14·0 (10·1 to 18·5) −35·4% (−52·8 to −17·5) * Non-Hodgkin lymphoma 188·5 (173·9 to 209·5) 283·1 (247·5 to 320·5) 50·1% (26·9 to 71·3) * 3·8 (3·5 to 4·2) 3·2 (2·8 to 3·6) −15·2% (−28·1 to −3·1) * 6038·6 (5446·5 to 6866·0) 8039·7 (6845·8 to 9375·2) 33·1% (8·9 to 58·4) * 109·6 (99·4 to 124·2) 93·5 (79·1 to 109·6) −14·7% (−30·2 to 2·0) Burkitt lymphoma 5·0 (3·6 to 6·8) 6·7 (5·1 to 9·6) 34·0% (−8·9 to 94·4) 0·1 (0·1 to 0·1) 0·1 (0·1 to 0·1) −3·2% (−34·5 to 40·3) 305·6 (212·8 to 434·6) 365·9 (257·0 to 567·1) 19·7% (−25·9 to 88·3) 4·9 (3·4 to 7·0) 4·8 (3·3 to 7·5) −3·1% (−40·4 to 52·2) Other non-Hodgkin lymphoma 183·5 (169·0 to 203·9) 276·4 (241·6 to 312·8) 50·6% (27·6 to 72·0) * 3·7 (3·4 to 4·1) 3·1 (2·7 to 3·5) −15·5% (−27·8 to −3·2) * 5733·1 (5235·3 to 6499·7) 7673·8 (6582·3 to 8895·1) 33·8% (10·3 to 60·3) * 104·6 (95·7 to 118·1) 88·7 (75·8 to 103·6) −15·3% (−30·0 to 2·2) Multiple myeloma 68·2 (62·3 to 73·8) 125·1 (112·8 to 137·0) 83·3% (65·4 to 100·6) * 1·4 (1·3 to 1·6) 1·4 (1·2 to 1·5) −4·9% (−14·1 to 3·8) 1551·0 (1408·1 to 1694·9) 2701·7 (2426·4 to 2995·3) 74·2% (53·6 to 95·2) * 31·0 (28·2 to 33·8) 29·5 (26·5 to 32·7) −4·9% (−16·1 to 6·5) Leukaemia 291·9 (260·2 to 320·5) 342·0 (307·2 to 381·8) 17·1% (3·7 to 31·0) * 5·5 (4·9 to 6·0) 4·0 (3·6 to 4·4) −27·5% (−35·5 to −19·0) * 12 723·9 (11 104·5 to 14 146·2) 11 905·5 (10 517·9 to 13 661·0) −6·5% (−20·4 to 7·0) 215·3 (188·8 to 238·2) 145·4 (128·0 to 168·1) −32·5% (−42·5 to −22·8) * Acute lymphoid leukaemia 87·3 (64·5 to 111·6) 77·5 (54·2 to 98·7) −11·3% (−27·4 to 8·6) 1·5 (1·1 to 1·9) 1·0 (0·7 to 1·2) −33·4% (−45·1 to −17·7) * 5511·5 (4114·6 to 6944·4) 4318·8 (3077·5 to 5438·2) −21·7% (−37·2 to −3·0) * 88·0 (65·9 to 111·0) 56·7 (40·6 to 71·6) −35·6% (−48·3 to −19·7) * Chronic lymphoid leukaemia 37·5 (33·5 to 41·6) 44·8 (39·6 to 51·6) 19·5% (6·3 to 33·5) * 0·8 (0·7 to 0·9) 0·5 (0·4 to 0·6) −38·7% (−45·2 to −31·8) * 855·9 (734·5 to 969·5) 885·1 (779·6 to 1049·9) 3·3% (−10·8 to 22·1) 17·0 (14·8 to 19·1) 9·8 (8·6 to 11·7) −42·3% (−50·1 to −32·5) * Acute myeloid leukaemia 91·9 (75·5 to 108·0) 131·6 (112·6 to 152·5) 43·2% (25·3 to 62·8) * 1·7 (1·4 to 2·0) 1·5 (1·3 to 1·7) −13·3% (−23·6 to −2·1) * 3731·7 (2862·0 to 4654·8) 4161·7 (3387·0 to 5135·5) 11·5% (−7·1 to 33·5) 63·9 (50·0 to 78·5) 49·6 (39·9 to 62·1) −22·5% (−35·9 to −7·8) * Chronic myeloid leukaemia 34·3 (28·1 to 40·9) 26·3 (21·2 to 32·7) −23·2% (−39·3 to 1·6) 0·7 (0·6 to 0·8) 0·3 (0·2 to 0·4) −55·5% (−64·7 to −41·9) * 1187·5 (919·7 to 1486·7) 779·0 (585·9 to 1037·8) −34·4% (−51·5 to −9·6) * 21·0 (16·6 to 26·0) 9·1 (6·8 to 12·2) −56·9% (−68·2 to −41·3) * Other leukaemia 41·1 (33·0 to 53·7) 61·7 (49·3 to 77·0) 50·1% (20·7 to 93·1) * 0·8 (0·6 to 1·0) 0·7 (0·6 to 0·9) −12·7% (−28·7 to 10·8) 1437·2 (1103·7 to 1975·1) 1760·9 (1338·4 to 2323·2) 22·4% (−5·7 to 61·8) 25·4 (19·8 to 34·5) 20·3 (15·3 to 26·9) −20·3% (−38·2 to 4·3) Other malignant neoplasms 157·2 (142·0 to 174·1) 226·0 (196·9 to 251·0) 43·6% (23·7 to 66·1) * 3·1 (2·8 to 3·4) 2·6 (2·2 to 2·8) −17·5% (−28·9 to −5·2) * 5479·8 (4821·3 to 6210·0) 6520·7 (5597·1 to 7450·5) 18·9% (−1·3 to 40·6) 98·1 (86·8 to 110·8) 76·6 (65·7 to 87·9) −22·0% (−35·3 to −7·4) * Other neoplasms 69·9 (61·2 to 79·1) 124·5 (106·4 to 145·3) 78·0% (59·2 to 96·0) * 1·5 (1·3 to 1·7) 1·4 (1·2 to 1·7) −4·2% (−14·2 to 5·3) 2003·8 (1653·3 to 2380·4) 2957·9 (2467·6 to 3615·1) 47·5% (25·1 to 68·6) * 37·4 (31·3 to 43·8) 34·3 (28·4 to 42·1) −8·4% (−21·7 to 5·3) Myelodysplastic, myeloproliferative, and other haemopoietic neoplasms 26·1 (23·0 to 29·0) 62·0 (51·7 to 71·9) 137·2% (111·0 to 163·5) * 0·6 (0·5 to 0·7) 0·7 (0·6 to 0·8) 16·1% (3·1 to 29·2) * 503·0 (433·2 to 564·6) 1058·9 (900·6 to 1244·8) 110·4% (86·3 to 135·2) * 10·5 (9·2 to 11·7) 11·9 (10·1 to 14·0) 13·4% (0·5 to 26·5) * Other benign and in-situ neoplasms 43·8 (35·8 to 52·8) 62·5 (49·1 to 79·0) 42·6% (18·6 to 70·1) * 0·9 (0·7 to 1·0) 0·7 (0·6 to 0·9) −18·4% (−31·8 to −3·7) * 1500·8 (1140·1 to 1879·8) 1899·1 (1431·7 to 2501·8) 26·5% (0·3 to 55·0) * 26·9 (20·8 to 33·4) 22·3 (16·7 to 29·6) −16·9% (−34·2 to 2·2) Cardiovascular diseases 14 562·6 (13 675·2 to 15 351·9) 19 159·2 (17 364·3 to 20 420·7) 31·4% (21·3 to 41·7) * 322·0 (298·9 to 340·4) 215·2 (194·3 to 229·8) –33·2% (−37·9 to −28·3) * 324 658·5 (305 331·0 to 346 523·1) 395 762·2 (364 152·2 to 424 474·4) 21·8% (11·3 to 33·6) * 6527·3 (6126·6 to 6937·0) 4411·0 (4053·4 to 4736·6) –32·5% (−38·1 to −26·3) * Rheumatic heart disease 437·4 (347·4 to 541·2) 388·9 (261·0 to 554·4) −11·1% (−37·1 to 22·8) 8·5 (6·9 to 10·5) 4·4 (3·0 to 6·3) −48·4% (−63·9 to −28·9) * 15 177·2 (11 748·8 to 19 150·7) 11 820·6 (7609·9 to 17 181·5) −22·1% (−46·6 to 10·2) 269·8 (209·7 to 338·4) 136·6 (88·5 to 199·2) −49·4% (−65·0 to −28·8) * Ischaemic heart disease 6286·6 (5802·6 to 6713·4) 8905·9 (8043·9 to 9659·6) 41·5% (30·2 to 53·6) * 140·1 (129·0 to 149·5) 99·8 (89·9 to 108·4) −28·9% (−34·1 to −22·9) * 136 804·5 (126 478·8 to 147 444·0) 182 550·6 (167 559·7 to 199 538·9) 33·3% (20·3 to 46·9) * 2778·4 (2582·7 to 2973·5) 2020·0 (1852·7 to 2212·8) −27·4% (−34·2 to −19·9) * Stroke 6059·2 (5579·8 to 6549·6) 6793·2 (6064·9 to 7467·6) 12·0% (0·1 to 24·2) * 133·0 (122·9 to 143·6) 75·9 (67·8 to 83·5) −43·0% (−49·0 to −36·9) * 131 886·2 (120 831·0 to 143 533·8) 139 860·2 (124 616·6 to 154 296·3) 6·0% (−6·9 to 20·1) 2663·6 (2441·1 to 2894·2) 1552·5 (1381·1 to 1713·2) −41·8% (−48·9 to −34·1) * Ischaemic stroke 2853·9 (2602·5 to 3179·8) 3279·0 (2869·9 to 3689·1) 14·7% (1·0 to 29·6) * 66·4 (60·5 to 73·8) 37·0 (32·4 to 41·7) −44·4% (−50·8 to −37·4) * 50 456·2 (45 793·6 to 56 641·0) 54 733·9 (48 138·2 to 61 730·7) 8·3% (−6·5 to 24·7) 1084·8 (982·9 to 1212·7) 606·9 (532·2 to 685·6) −44·2% (−51·6 to −35·8) * Intracerebral haemorrhage 2857·0 (2539·1 to 3198·6) 3156·7 (2752·8 to 3546·9) 10·4% (−4·4 to 30·3) 59·4 (52·7 to 66·2) 34·9 (30·4 to 39·3) −41·3% (−49·1 to −31·1) * 71 650·8 (62 936·0 to 81 253·0) 75 460·6 (65 335·9 to 85 395·0) 5·3% (−11·6 to 26·3) 1394·1 (1228·3 to 1566·3) 836·2 (723·7 to 946·8) −40·0% (−49·4 to −28·3) * Subarachnoid haemorrhage 348·4 (245·3 to 428·2) 357·5 (303·7 to 430·2) 2·5% (−18·1 to 43·5) 7·1 (5·0 to 8·8) 4·0 (3·4 to 4·8) −44·1% (−55·3 to −21·3) * 9779·2 (7247·7 to 12 102·1) 9665·7 (8021·1 to 12 175·6) −1·2% (−22·0 to 31·6) 184·6 (135·3 to 228·2) 109·4 (90·3 to 138·2) −40·7% (−53·1 to −20·5) * Hypertensive heart disease 797·5 (643·5 to 953·1) 1485·0 (1179·4 to 1825·7) 86·1% (50·7 to 126·4) * 18·1 (14·5 to 21·6) 16·8 (13·4 to 20·7) −7·2% (−24·6 to 12·6) 16 085·1 (12 843·2 to 19 689·6) 27 326·2 (21 762·9 to 34 181·3) 69·8% (34·7 to 110·8) * 333·9 (267·7 to 403·3) 303·6 (241·5 to 380·2) −9·1% (−27·5 to 12·1) Non-rheumatic valvular heart disease 97·5 (85·8 to 107·2) 191·3 (157·0 to 214·6) 96·1% (76·6 to 116·1) * 2·4 (2·1 to 2·6) 2·2 (1·8 to 2·5) −7·7% (−16·0 to 1·0) 1741·9 (1536·7 to 1934·4) 3035·5 (2581·4 to 3528·7) 74·3% (50·5 to 98·0) * 37·8 (33·0 to 42·0) 34·6 (29·4 to 40·3) −8·3% (−19·7 to 4·1) Non-rheumatic calcific aortic valve disease 71·3 (61·2 to 78·4) 149·4 (120·1 to 166·0) 109·6% (89·9 to 129·6) * 1·8 (1·5 to 2·0) 1·7 (1·4 to 1·9) −3·6% (−12·1 to 5·2) 1158·7 (1020·8 to 1275·0) 2169·7 (1837·7 to 2474·0) 87·3% (65·7 to 112·0) * 26·1 (22·9 to 28·7) 24·8 (20·9 to 28·3) −5·0% (−15·6 to 7·2) Non-rheumatic degenerative mitral valve disease 25·3 (21·7 to 29·2) 39·7 (32·4 to 50·7) 57·0% (26·9 to 92·7) * 0·6 (0·5 to 0·7) 0·5 (0·4 to 0·6) −21·5% (−35·9 to −3·9) * 558·2 (471·0 to 683·5) 815·6 (640·0 to 1100·6) 46·2% (9·3 to 88·8) * 11·2 (9·5 to 13·5) 9·3 (7·3 to 12·5) −17·2% (−37·2 to 7·6) Other non-rheumatic valve diseases 0·9 (0·6 to 1·6) 2·1 (1·3 to 3·3) 133·0% (63·5 to 251·5) * 0·0 (0·0 to 0·0) 0·0 (0·0 to 0·0) 24·3% (−11·1 to 89·3) 25·0 (16·4 to 41·2) 50·2 (31·9 to 81·1) 100·9% (31·2 to 213·3) * 0·5 (0·3 to 0·8) 0·6 (0·4 to 0·9) 22·4% (−19·0 to 92·5) Cardiomyopathy and myocarditis 335·7 (295·6 to 388·6) 399·9 (338·4 to 465·1) 19·1% (−2·0 to 44·7) 7·1 (6·3 to 8·2) 4·6 (3·9 to 5·3) −35·9% (−47·4 to −21·8) * 10 322·7 (8777·2 to 12 535·3) 11 541·4 (9460·2 to 13 920·1) 11·8% (−12·3 to 40·5) 191·5 (164·2 to 229·9) 136·0 (109·7 to 166·5) −29·0% (−44·8 to −11·1) * Myocarditis 21·6 (14·5 to 33·6) 16·9 (11·3 to 24·1) −21·9% (−46·1 to 20·7) 0·4 (0·3 to 0·6) 0·2 (0·1 to 0·3) −50·9% (−65·6 to −25·6) * 1015·0 (656·8 to 1588·1) 624·3 (414·2 to 940·0) −38·5% (−62·2 to −4·0) * 17·2 (11·1 to 26·8) 8·1 (5·3 to 12·2) −53·0% (−71·2 to −27·5) * Alcoholic cardiomyopathy 76·5 (68·6 to 86·0) 62·3 (56·0 to 71·6) −18·6% (−28·8 to −7·4) * 1·4 (1·3 to 1·6) 0·7 (0·6 to 0·8) −52·3% (−58·3 to −45·7) * 2727·3 (2448·9 to 3040·3) 2108·8 (1889·5 to 2420·0) −22·7% (−32·4 to −11·9) * 49·0 (44·0 to 54·7) 23·6 (21·2 to 27·2) −51·8% (−57·8 to −45·1) * Other cardiomyopathy 237·6 (203·3 to 287·4) 320·7 (260·3 to 380·7) 35·0% (6·2 to 69·4) * 5·3 (4·5 to 6·3) 3·7 (3·0 to 4·4) −30·2% (−44·5 to −13·6) * 6580·4 (5359·5 to 8558·1) 8808·3 (6840·4 to 10 925·2) 33·9% (−1·0 to 77·5) 125·3 (103·8 to 160·1) 104·3 (80·2 to 130·9) −16·8% (−38·9 to 9·4) Pulmonary arterial hypertension 20·0 (15·0 to 27·0) 22·8 (17·5 to 29·8) 13·8% (−17·0 to 60·6) 0·4 (0·3 to 0·5) 0·3 (0·2 to 0·4) −33·4% (−50·6 to −5·8) * 778·6 (532·5 to 1147·1) 682·9 (494·1 to 978·5) −12·4% (−43·6 to 31·2) 13·7 (9·5 to 19·7) 8·5 (6·0 to 12·5) −37·6% (−59·6 to −7·0) * Atrial fibrillation and flutter 160·4 (144·5 to 174·3) 377·7 (319·0 to 424·2) 135·2% (112·7 to 157·0) * 4·2 (3·8 to 4·6) 4·4 (3·7 to 5·0) 3·9% (−5·7 to 13·2) 2213·1 (2033·2 to 2395·7) 4863·5 (4236·4 to 5380·4) 119·6% (98·6 to 138·7) * 53·7 (49·0 to 58·3) 55·5 (48·2 to 61·5) 3·3% (−6·0 to 12·3) Aortic aneurysm 109·6 (101·9 to 119·8) 167·4 (147·1 to 187·3) 52·8% (37·7 to 68·0) * 2·4 (2·2 to 2·6) 1·9 (1·6 to 2·1) −22·5% (−29·6 to −15·3) * 2303·7 (2122·4 to 2557·6) 3416·5 (3025·9 to 3838·3) 48·4% (30·4 to 64·9) * 46·8 (43·0 to 51·7) 37·8 (33·4 to 42·5) −19·2% (−28·8 to −10·4) * Lower extremity peripheral arterial disease 52·9 (47·8 to 57·6) 74·9 (66·1 to 83·1) 41·5% (27·5 to 55·5) * 1·3 (1·2 to 1·4) 0·9 (0·7 to 0·9) −34·4% (−40·7 to −27·9) * 871·1 (800·3 to 943·3) 1189·8 (1063·1 to 1332·8) 36·6% (21·1 to 53·5) * 19·5 (17·7 to 21·2) 13·2 (11·8 to 14·8) −32·4% (−39·7 to −24·4) * Endocarditis 52·4 (44·2 to 62·6) 86·2 (74·2 to 100·8) 64·7% (33·7 to 100·9) * 1·1 (0·9 to 1·3) 1·0 (0·9 to 1·2) −9·7% (−25·4 to 8·3) 1688·4 (1314·4 to 2173·5) 2302·6 (1918·6 to 2840·0) 36·4% (−1·1 to 83·6) 30·6 (24·4 to 38·7) 27·2 (22·5 to 33·8) −11·0% (−34·6 to 18·2) Other cardiovascular and circulatory diseases 153·3 (129·8 to 185·3) 265·9 (217·1 to 317·9) 73·4% (37·2 to 116·3) * 3·2 (2·8 to 3·8) 3·0 (2·5 to 3·6) −6·2% (−24·8 to 15·6) 4786·1 (3817·4 to 6161·9) 7172·3 (5626·5 to 8764·7) 49·9% (8·5 to 97·8) * 88·0 (71·0 to 111·7) 85·3 (66·0 to 105·5) −3·1% (−29·5 to 27·4) Chronic respiratory diseases 2885·3 (2366·5 to 3234·0) 4163·7 (3612·7 to 5138·2) 44·0% (20·3 to 85·9) * 63·4 (52·2 to 70·5) 46·8 (40·6 to 57·7) –26·4% (−38·1 to −5·5) * 61 339·5 (50 077·3 to 68 952·7) 78 935·2 (69 624·7 to 96 907·6) 28·5% (7·7 to 65·7) * 1243·6 (1021·6 to 1394·8) 882·8 (774·9 to 1083·8) –29·1% (−40·9 to −9·1) * Chronic obstructive pulmonary disease 2404·0 (1975·9 to 2700·6) 3426·1 (2955·2 to 4079·8) 42·1% (19·5 to 84·7) * 53·5 (44·1 to 60·1) 38·4 (33·2 to 45·8) −28·4% (−39·6 to −7·2) * 46 704·9 (38 738·6 to 52 933·2) 59 918·6 (51 344·7 to 71 728·7) 28·1% (7·8 to 67·1) * 972·5 (808·1 to 1097·6) 659·7 (563·7 to 788·5) −32·3% (−42·9 to −12·1) * Pneumoconiosis 15·8 (12·3 to 22·4) 18·7 (14·1 to 24·9) 18·1% (−18·8 to 57·5) 0·3 (0·3 to 0·5) 0·2 (0·2 to 0·3) −37·6% (−56·2 to −18·0) * 362·9 (268·6 to 542·3) 391·8 (288·8 to 521·1) 7·6% (−29·1 to 48·2) 7·2 (5·4 to 10·6) 4·3 (3·2 to 5·7) −39·9% (−59·6 to −18·2) * Silicosis 8·7 (6·4 to 13·1) 11·0 (7·7 to 15·2) 26·1% (−21·0 to 81·5) 0·2 (0·1 to 0·3) 0·1 (0·1 to 0·2) −32·8% (−57·1 to −5·5) * 205·9 (142·7 to 328·1) 241·5 (166·3 to 336·6) 16·8% (−29·7 to 81·1) 4·0 (2·8 to 6·3) 2·7 (1·8 to 3·7) −34·3% (−60·0 to −0·4) * Asbestosis 1·8 (1·5 to 2·4) 3·0 (2·4 to 4·0) 63·1% (22·1 to 110·6) * 0·0 (0·0 to 0·1) 0·0 (0·0 to 0·0) −16·2% (−36·8 to 7·4) 37·1 (28·9 to 50·5) 51·0 (40·0 to 71·9) 37·4% (0·3 to 88·5) * 0·8 (0·6 to 1·0) 0·6 (0·4 to 0·8) −25·6% (−45·3 to 1·5) Coal worker pneumoconiosis 3·3 (2·5 to 5·1) 2·3 (1·7 to 3·1) −30·5% (−57·8 to 3·8) 0·1 (0·1 to 0·1) 0·0 (0·0 to 0·0) −63·9% (−77·5 to −47·1) * 71·1 (49·1 to 117·8) 45·6 (31·5 to 61·9) −36·0% (−64·5 to 4·1) 1·4 (1·0 to 2·3) 0·5 (0·3 to 0·7) −65·0% (−80·1 to −44·0) * Other pneumoconiosis 1·9 (1·4 to 2·9) 2·4 (1·6 to 3·6) 22·8% (−27·1 to 87·9) 0·0 (0·0 to 0·1) 0·0 (0·0 to 0·0) −34·3% (−60·1 to 0·5) 48·9 (33·8 to 77·7) 53·8 (36·1 to 83·0) 10·0% (−35·9 to 72·1) 0·9 (0·7 to 1·5) 0·6 (0·4 to 0·9) −36·8% (−63·0 to −1·6) * Asthma 342·7 (221·6 to 503·5) 441·9 (305·8 to 665·1) 29·0% (−16·8 to 97·0) 7·0 (4·6 to 10·4) 5·0 (3·5 to 7·5) −29·1% (−53·8 to 7·6) 10 076·9 (6600·9 to 14 431·5) 11 758·2 (8323·7 to 16 923·2) 16·7% (−23·3 to 76·3) 187·6 (122·6 to 271·2) 135·7 (96·1 to 194·8) −27·7% (−51·9 to 9·8) Interstitial lung disease and pulmonary sarcoidosis 76·3 (62·5 to 111·0) 213·2 (176·1 to 261·2) 179·6% (96·2 to 241·6) * 1·7 (1·4 to 2·4) 2·4 (2·0 to 2·9) 43·2% (2·3 to 73·7) * 1663·0 (1328·0 to 2584·8) 3997·3 (3268·2 to 5136·7) 140·4% (59·0 to 205·6) * 33·5 (27·0 to 51·1) 44·4 (36·3 to 57·1) 32·7% (−11·1 to 67·6) Other chronic respiratory diseases 46·5 (34·7 to 66·7) 63·6 (46·6 to 90·1) 36·8% (−15·1 to 94·6) 0·9 (0·7 to 1·2) 0·8 (0·6 to 1·1) −9·4% (−41·9 to 28·4) 2531·7 (1808·6 to 3549·2) 2869·4 (2005·3 to 4285·7) 13·3% (−31·5 to 62·9) 42·9 (30·8 to 60·5) 38·7 (26·5 to 57·4) −9·9% (−44·7 to 28·6) Digestive diseases 2052·3 (1849·8 to 2264·3) 2416·3 (2151·6 to 2671·8) 17·7% (0·6 to 38·0) * 40·8 (36·9 to 44·9) 27·3 (24·2 to 30·2) –33·1% (−42·9 to −22·0) * 68 187·2 (60 449·9 to 75 780·1) 69 999·8 (61 560·7 to 78 001·8) 2·7% (−13·8 to 21·9) 1235·1 (1100·2 to 1367·0) 805·7 (705·4 to 899·9) –34·8% (−45·2 to −22·4) * Cirrhosis and other chronic liver diseases 1127·0 (1003·3 to 1275·7) 1282·0 (1141·9 to 1430·1) 13·8% (−3·9 to 35·5) 21·4 (19·1 to 24·2) 14·3 (12·7 to 16·0) −33·4% (−43·4 to −20·8) * 39 866·9 (35 267·0 to 45 423·6) 41 637·4 (36 506·1 to 47 053·8) 4·4% (−12·9 to 26·8) 713·2 (631·8 to 812·3) 473·2 (413·0 to 535·6) −33·7% (−44·6 to −19·7) * Chronic hepatitis B including cirrhosis 391·2 (332·4 to 464·5) 394·2 (324·6 to 464·5) 0·8% (−16·9 to 24·3) 7·4 (6·3 to 8·9) 4·4 (3·6 to 5·2) −41·1% (−51·8 to −27·6) * 13 496·9 (11 469·0 to 15 799·5) 12 747·5 (10 558·1 to 15 071·6) −5·6% (−24·1 to 18·3) 242·7 (207·0 to 285·7) 143·8 (118·7 to 170·7) −40·7% (−52·3 to −26·2) * Chronic hepatitis C including cirrhosis 283·6 (236·1 to 343·1) 334·5 (276·9 to 403·7) 18·0% (−1·9 to 40·1) 5·4 (4·5 to 6·5) 3·7 (3·1 to 4·5) −31·6% (−43·1 to −18·8) * 9665·1 (7973·5 to 11 667·2) 10 741·2 (8791·1 to 12 988·0) 11·1% (−8·0 to 35·1) 174·6 (144·6 to 210·6) 121·1 (98·5 to 146·6) −30·6% (−42·5 to −15·7) * Cirrhosis due to alcohol use 251·9 (215·4 to 291·7) 308·8 (259·4 to 358·2) 22·6% (6·3 to 41·5) * 4·8 (4·1 to 5·6) 3·4 (2·8 to 3·9) −29·9% (−39·5 to −19·3) * 8268·1 (7071·2 to 9724·4) 9473·6 (7963·9 to 11 068·1) 14·6% (−1·8 to 33·0) 152·2 (130·0 to 178·2) 104·9 (87·8 to 122·8) −31·1% (−41·2 to −20·0) * Non-alcoholic fatty liver disease including cirrhosis 52·3 (37·2 to 69·9) 89·8 (64·7 to 120·3) 71·8% (56·2 to 89·9) * 1·1 (0·7 to 1·4) 1·0 (0·7 to 1·3) −5·7% (−13·6 to 4·5) 1524·5 (1048·0 to 2082·8) 2459·8 (1710·6 to 3299·7) 61·4% (47·5 to 78·1) * 28·7 (19·8 to 38·9) 27·2 (19·0 to 36·3) −5·2% (−13·8 to 5·3) Cirrhosis due to other causes 148·1 (120·2 to 186·3) 154·7 (118·8 to 200·3) 4·5% (−15·7 to 28·9) 2·7 (2·1 to 3·4) 1·8 (1·4 to 2·3) −32·6% (−44·5 to −17·2) * 6912·3 (5638·5 to 8562·7) 6215·3 (4872·2 to 7830·9) −10·1% (−28·5 to 12·6) 115·1 (93·6 to 141·1) 76·1 (59·5 to 95·8) −33·9% (−47·1 to −16·8) * Upper digestive system diseases 316·1 (265·6 to 370·2) 265·4 (220·0 to 328·5) −16·1% (−34·2 to 7·7) 6·5 (5·5 to 7·6) 3·0 (2·5 to 3·7) −53·6% (−63·2 to −40·5) * 9368·2 (7717·1 to 11 147·1) 6795·7 (5464·0 to 8582·5) −27·5% (−45·3 to −3·4) * 173·5 (144·1 to 205·7) 77·7 (62·1 to 98·5) −55·2% (−66·0 to −40·5) * Peptic ulcer disease 273·7 (230·0 to 325·8) 222·4 (180·2 to 281·7) −18·8% (−38·0 to 7·4) 5·6 (4·7 to 6·6) 2·5 (2·0 to 3·2) −55·2% (−65·8 to −40·6) * 8019·7 (6460·1 to 9888·4) 5642·5 (4413·6 to 7489·3) −29·6% (−48·2 to −4·6) * 149·0 (121·6 to 182·8) 64·2 (49·9 to 85·8) −56·9% (−68·2 to −41·1) * Gastritis and duodenitis 42·3 (29·3 to 57·6) 42·9 (27·1 to 58·5) 1·4% (−27·6 to 46·8) 0·9 (0·6 to 1·2) 0·5 (0·3 to 0·7) −43·2% (−58·6 to −16·9) * 1348·4 (904·5 to 1906·6) 1153·2 (684·6 to 1724·0) −14·5% (−43·1 to 30·2) 24·6 (16·6 to 34·1) 13·6 (8·0 to 20·4) −44·7% (−63·2 to −15·3) * Appendicitis 33·2 (21·4 to 47·8) 31·0 (21·9 to 43·5) −6·7% (−36·7 to 46·4) 0·6 (0·4 to 0·9) 0·4 (0·3 to 0·5) −40·6% (−59·2 to −7·9) * 1498·4 (900·8 to 2229·2) 1174·6 (815·5 to 1725·4) −21·6% (−49·0 to 30·6) 24·9 (15·3 to 36·8) 14·2 (9·9 to 21·0) −43·0% (−62·6 to −5·9) * Paralytic ileus and intestinal obstruction 184·9 (152·8 to 221·6) 243·7 (201·6 to 286·2) 31·8% (3·5 to 72·6) * 3·8 (3·2 to 4·4) 2·9 (2·4 to 3·4) −24·2% (−39·5 to −1·5) * 7095·3 (5679·0 to 8921·9) 7030·5 (5498·7 to 8614·0) −0·9% (−26·5 to 37·0) 125·4 (101·3 to 156·0) 87·7 (68·4 to 107·3) −30·1% (−47·6 to −3·7) * Inguinal, femoral, and abdominal hernia 39·0 (30·0 to 51·9) 51·1 (38·9 to 67·4) 31·2% (−10·1 to 86·1) 0·8 (0·6 to 1·1) 0·6 (0·4 to 0·8) −28·5% (−50·2 to −0·2) * 1234·4 (906·7 to 1724·3) 1260·5 (923·4 to 1769·8) 2·1% (−34·7 to 57·5) 22·8 (16·9 to 31·3) 15·2 (11·1 to 21·5) −33·2% (−56·6 to 1·9) Inflammatory bowel disease 27·5 (22·9 to 32·9) 46·5 (40·4 to 53·1) 69·4% (37·2 to 103·5) * 0·6 (0·5 to 0·7) 0·5 (0·5 to 0·6) −12·5% (−28·4 to 4·5) 724·9 (569·0 to 893·6) 1031·8 (874·2 to 1235·1) 42·3% (9·1 to 78·3) * 13·9 (11·1 to 16·9) 11·9 (10·0 to 14·3) −14·4% (−33·7 to 5·9) Ulcerative colitis 22·7 (18·5 to 27·6) 39·6 (34·1 to 45·8) 74·0% (36·1 to 112·0) * 0·5 (0·4 to 0·6) 0·5 (0·4 to 0·5) −11·3% (−28·9 to 6·8) 580·6 (447·7 to 740·8) 836·6 (703·4 to 1019·5) 44·1% (7·1 to 84·4) * 11·2 (8·8 to 14·1) 9·6 (8·1 to 11·8) −14·3% (−35·5 to 8·3) Crohn's disease 4·7 (3·8 to 5·8) 7·0 (5·9 to 8·5) 47·1% (17·0 to 88·1) * 0·1 (0·1 to 0·1) 0·1 (0·1 to 0·1) −18·8% (−35·0 to 3·4) 144·2 (115·1 to 184·4) 195·2 (157·7 to 249·4) 35·3% (3·1 to 81·1) * 2·6 (2·1 to 3·3) 2·2 (1·8 to 2·9) −15·2% (−35·4 to 13·1) Vascular intestinal disorders 67·8 (61·3 to 73·8) 92·6 (82·4 to 102·5) 36·7% (23·9 to 48·4) * 1·6 (1·4 to 1·7) 1·0 (0·9 to 1·2) −33·4% (−39·3 to −27·9) * 1291·4 (1150·7 to 1428·0) 1670·7 (1519·1 to 1869·3) 29·4% (13·9 to 43·1) * 27·2 (24·3 to 29·9) 18·6 (16·9 to 20·9) −31·5% (−39·4 to −23·9) * Gallbladder and biliary diseases 74·1 (61·1 to 87·8) 146·7 (121·8 to 171·4) 98·1% (62·0 to 132·6) * 1·7 (1·4 to 2·0) 1·7 (1·4 to 2·0) −1·0% (−18·0 to 15·3) 1581·2 (1272·2 to 1894·0) 2682·4 (2235·9 to 3182·5) 69·7% (33·5 to 103·5) * 32·2 (26·1 to 38·2) 30·3 (25·2 to 35·9) −6·0% (−25·9 to 12·1) Pancreatitis 88·7 (75·8 to 110·6) 124·5 (107·8 to 147·3) 40·2% (13·8 to 74·3) * 1·7 (1·5 to 2·1) 1·4 (1·2 to 1·7) −18·6% (−34·0 to 0·7) 3037·6 (2554·9 to 3840·7) 3817·4 (3236·2 to 4664·5) 25·7% (0·2 to 59·2) * 54·1 (45·6 to 68·2) 43·6 (36·9 to 53·5) −19·5% (−36·1 to 2·1) Other digestive diseases 94·1 (77·9 to 117·0) 132·9 (113·6 to 154·5) 41·1% (13·6 to 71·1) * 2·1 (1·7 to 2·5) 1·5 (1·3 to 1·8) −27·1% (−40·3 to −12·6) * 2489·0 (1949·9 to 3230·7) 2898·9 (2418·3 to 3535·1) 16·5% (−13·8 to 53·1) 47·9 (38·2 to 61·4) 33·4 (27·8 to 40·7) −30·4% (−47·6 to −8·8) * Neurological disorders 1316·1 (623·0 to 2702·2) 3024·3 (1357·2 to 6102·8) 129·3% (116·2 to 142·1) * 32·8 (14·4 to 70·0) 35·2 (15·7 to 71·2) 7·0% (0·1 to 17·0) * 24 683·4 (14 830·2 to 43 397·8) 47 512·9 (25 997·7 to 86 959·8) 92·2% (65·1 to 109·6) * 526·2 (293·7 to 980·0) 553·8 (307·3 to 1002·1) 5·1% (−4·8 to 16·0) Alzheimer's disease and other dementias 934·3 (230·7 to 2338·9) 2214·6 (549·4 to 5363·7) 136·4% (124·0 to 153·2) * 24·9 (6·1 to 62·5) 25·9 (6·4 to 62·7) 3·7% (−2·0 to 10·9) 12 473·3 (3072·0 to 31 556·2) 27 638·4 (6912·9 to 67 708·7) 121·0% (107·9 to 135·8) * 307·2 (75·6 to 765·4) 315·8 (78·8 to 771·3) 2·6% (−2·8 to 9·3) Parkinson's disease 190·7 (173·2 to 206·8) 427·1 (379·1 to 469·9) 123·8% (105·9 to 139·8) * 4·5 (4·1 to 4·9) 4·8 (4·3 to 5·3) 8·1% (−0·4 to 15·6) 3030·0 (2784·8 to 3284·1) 6345·3 (5691·2 to 6953·1) 109·3% (92·5 to 123·6) * 67·0 (61·3 to 72·7) 70·7 (63·4 to 77·3) 5·4% (−2·9 to 12·6) Idiopathic epilepsy 118·7 (90·3 to 150·2) 159·4 (125·4 to 202·9) 34·3% (−2·7 to 80·8) 2·0 (1·5 to 2·5) 2·0 (1·5 to 2·5) −1·3% (−28·5 to 32·8) 6929·8 (5144·4 to 8895·3) 8186·6 (6217·1 to 10 738·7) 18·1% (−16·9 to 62·3) 110·6 (82·5 to 141·8) 105·3 (79·4 to 139·4) −4·8% (−33·1 to 31·0) Multiple sclerosis 12·2 (11·2 to 13·4) 19·1 (17·4 to 21·7) 56·5% (41·2 to 75·0) * 0·2 (0·2 to 0·3) 0·2 (0·2 to 0·2) −10·2% (−18·8 to 0·6) 409·2 (373·8 to 456·4) 551·3 (495·4 to 629·0) 34·7% (19·4 to 54·4) * 7·5 (6·8 to 8·3) 6·1 (5·5 to 7·0) −18·1% (−27·1 to −5·9) * Motor neuron disease 22·6 (20·2 to 24·7) 44·6 (40·8 to 50·0) 97·4% (78·9 to 116·7) * 0·5 (0·4 to 0·5) 0·5 (0·4 to 0·6) 8·7% (−1·2 to 19·8) 680·0 (583·5 to 765·6) 1158·0 (1046·7 to 1347·7) 70·3% (49·4 to 95·4) * 12·7 (11·0 to 14·2) 13·1 (11·8 to 15·4) 3·3% (−9·2 to 17·6) Other neurological disorders 37·7 (33·9 to 41·5) 159·5 (137·4 to 180·4) 323·0% (270·6 to 373·9) * 0·8 (0·7 to 0·9) 1·8 (1·6 to 2·1) 128·7% (101·1 to 156·1) * 1161·1 (1036·5 to 1273·0) 3633·3 (3290·0 to 4022·3) 212·7% (173·9 to 258·7) * 21·3 (19·0 to 23·4) 42·7 (38·5 to 47·5) 100·7% (77·1 to 130·6) * Mental disorders 0·2 (0·1 to 0·3) 0·2 (0·1 to 0·4) 8·6% (−20·1 to 42·2) 0·0 (0·0 to 0·0) 0·0 (0·0 to 0·0) –15·4% (−37·7 to 10·8) 12·3 (5·3 to 18·2) 13·2 (6·5 to 21·0) 7·4% (−20·8 to 40·9) 0·2 (0·1 to 0·3) 0·2 (0·1 to 0·3) –15·1% (−37·3 to 11·2) Eating disorders 0·2 (0·1 to 0·3) 0·2 (0·1 to 0·4) 8·6% (−20·1 to 42·2) 0·0 (0·0 to 0·0) 0·0 (0·0 to 0·0) −15·4% (−37·7 to 10·8) 12·3 (5·3 to 18·2) 13·2 (6·5 to 21·0) 7·4% (−20·8 to 40·9) 0·2 (0·1 to 0·3) 0·2 (0·1 to 0·3) −15·1% (−37·3 to 11·2) Anorexia nervosa 0·2 (0·1 to 0·3) 0·2 (0·1 to 0·4) 8·6% (−20·1 to 42·2) 0·0 (0·0 to 0·0) 0·0 (0·0 to 0·0) −15·4% (−37·7 to 10·8) 12·3 (5·3 to 18·2) 13·2 (6·5 to 21·0) 7·4% (−20·8 to 40·9) 0·2 (0·1 to 0·3) 0·2 (0·1 to 0·3) −15·1% (−37·3 to 11·2) Substance use disorders 254·5 (234·9 to 279·7) 344·1 (316·6 to 374·4) 35·2% (19·4 to 50·6) * 4·5 (4·1 to 4·9) 3·9 (3·6 to 4·3) –11·5% (−21·7 to −1·5) * 11 302·6 (10 393·2 to 12 449·2) 14 426·8 (13 200·2 to 15 765·4) 27·6% (12·1 to 43·2) * 190·0 (175·0 to 209·1) 168·3 (153·9 to 184·1) –11·4% (−22·1 to −0·6) * Alcohol use disorders 170·2 (155·8 to 190·1) 171·6 (154·5 to 197·0) 0·8% (−14·9 to 19·9) 3·0 (2·8 to 3·4) 1·9 (1·7 to 2·2) −36·7% (−46·6 to −24·5) * 7088·2 (6447·9 to 7992·7) 6460·2 (5727·4 to 7529·1) −8·9% (−24·1 to 9·9) 122·0 (111·3 to 137·2) 73·6 (65·1 to 86·1) −39·7% (−49·8 to −27·1) * Drug use disorders 84·3 (73·2 to 96·7) 172·5 (149·2 to 198·8) 104·5% (68·6 to 142·7) * 1·4 (1·2 to 1·6) 2·0 (1·7 to 2·3) 42·4% (17·6 to 69·2) * 4214·4 (3647·9 to 4824·1) 7966·6 (6900·5 to 9123·5) 89·0% (55·2 to 124·0) * 68·0 (58·9 to 77·9) 94·7 (82·1 to 108·4) 39·4% (14·5 to 64·9) * Opioid use disorders 57·0 (49·1 to 65·6) 125·9 (108·2 to 144·8) 120·9% (83·6 to 165·2) * 1·0 (0·8 to 1·1) 1·5 (1·3 to 1·7) 53·4% (27·7 to 83·6) * 2810·3 (2410·7 to 3260·9) 5833·0 (5027·1 to 6697·7) 107·6% (73·0 to 148·1) * 45·5 (39·1 to 52·6) 69·4 (59·9 to 79·7) 52·7% (27·5 to 82·7) * Cocaine use disorders 6·4 (4·9 to 8·3) 17·6 (13·9 to 21·7) 174·7% (91·8 to 280·3) * 0·1 (0·1 to 0·1) 0·2 (0·2 to 0·3) 90·0% (32·7 to 162·9) * 318·2 (245·3 to 412·1) 795·1 (632·4 to 972·2) 149·9% (75·8 to 245·5) * 5·2 (4·0 to 6·7) 9·4 (7·5 to 11·4) 81·5% (27·6 to 150·9) * Amphetamine use disorders 5·9 (3·9 to 9·6) 12·0 (9·6 to 15·0) 101·8% (21·8 to 221·3) * 0·1 (0·1 to 0·2) 0·1 (0·1 to 0·2) 43·0% (−13·7 to 126·9) 318·2 (207·1 to 514·5) 551·0 (441·8 to 685·2) 73·1% (5·3 to 173·8) * 5·0 (3·3 to 8·2) 6·5 (5·3 to 8·1) 29·6% (−21·3 to 105·4) Other drug use disorders 15·0 (11·6 to 20·1) 17·0 (14·7 to 20·6) 13·4% (−17·5 to 52·6) 0·3 (0·2 to 0·3) 0·2 (0·2 to 0·2) −20·2% (−41·7 to 6·6) 767·7 (588·7 to 1029·3) 787·5 (679·6 to 948·9) 2·6% (−26·0 to 38·0) 12·3 (9·4 to 16·5) 9·4 (8·1 to 11·4) −23·5% (−44·7 to 2·8) Diabetes and kidney diseases 1719·5 (1560·3 to 1893·2) 3535·6 (3142·0 to 3888·8) 105·5% (84·4 to 133·2) * 36·3 (33·0 to 40·1) 39·5 (35·0 to 43·4) 8·5% (−2·7 to 22·2) 44 977·7 (40 396·5 to 49 071·0) 82 210·8 (74 339·9 to 91 232·8) 82·7% (63·7 to 108·2) * 863·5 (779·1 to 943·9) 919·4 (831·2 to 1020·6) 6·4% (−4·2 to 21·3) Diabetes mellitus 911·2 (784·3 to 1036·0) 2004·5 (1693·2 to 2306·4) 119·8% (90·0 to 160·5) * 19·2 (16·5 to 21·9) 22·1 (18·7 to 25·5) 14·9% (−0·5 to 35·9) 22 415·9 (19 298·7 to 25 392·7) 45 981·4 (38 780·6 to 53 228·8) 105·0% (76·7 to 143·0) * 438·9 (377·6 to 497·5) 506·2 (426·9 to 586·5) 15·3% (−0·3 to 36·2) Type 1 diabetes mellitus 48·4 (40·6 to 60·3) 54·4 (42·3 to 71·6) 12·2% (−9·7 to 44·6) 0·8 (0·7 to 1·1) 0·6 (0·5 to 0·8) −23·0% (−38·1 to −0·8) * 2430·9 (2003·6 to 2963·8) 2556·8 (1980·0 to 3271·3) 5·2% (−15·3 to 36·3) 39·9 (32·8 to 48·7) 31·7 (24·5 to 40·4) −20·5% (−35·9 to 3·4) Type 2 diabetes mellitus 862·8 (740·0 to 985·7) 1950·1 (1646·3 to 2235·9) 125·9% (94·9 to 168·7) * 18·4 (15·8 to 21·0) 21·5 (18·1 to 24·7) 16·7% (0·8 to 38·4) * 19 985·0 (17 051·7 to 22 877·7) 43 424·6 (36 681·1 to 50 101·1) 117·2% (86·9 to 159·7) * 399·1 (341·0 to 456·2) 474·4 (401·0 to 548·0) 18·8% (2·3 to 41·7) * Chronic kidney disease 796·0 (701·6 to 902·0) 1520·1 (1331·1 to 1696·5) 90·9% (66·1 to 123·2) * 16·9 (14·7 to 19·1) 17·2 (15·1 to 19·2) 1·9% (−10·7 to 18·3) 22 063·1 (19 132·0 to 25 266·9) 35 905·8 (30 906·8 to 40 911·1) 62·7% (37·0 to 97·2) * 416·0 (362·4 to 475·7) 409·4 (351·1 to 466·8) −1·6% (−16·7 to 18·7) Chronic kidney disease due to type 1 diabetes mellitus 45·0 (35·2 to 57·9) 76·5 (56·4 to 98·4) 70·1% (42·3 to 106·9) * 0·8 (0·6 to 1·1) 0·9 (0·6 to 1·1) 4·1% (−12·3 to 25·6) 1750·8 (1375·2 to 2246·8) 2871·7 (2147·2 to 3677·5) 64·0% (34·9 to 103·4) * 30·8 (24·1 to 40·0) 32·6 (24·3 to 41·7) 5·7% (−12·0 to 30·1) Chronic kidney disease due to type 2 diabetes mellitus 159·1 (123·4 to 194·4) 343·2 (271·1 to 414·0) 115·7% (88·8 to 150·2) * 3·4 (2·7 to 4·2) 3·8 (3·0 to 4·6) 10·3% (−3·0 to 28·1) 3440·0 (2713·0 to 4265·4) 6906·2 (5505·2 to 8292·3) 100·8% (72·7 to 135·2) * 70·2 (55·2 to 86·9) 75·2 (60·1 to 90·2) 7·1% (−7·2 to 25·5) Chronic kidney disease due to hypertension 189·4 (153·9 to 229·6) 442·3 (358·5 to 530·1) 133·5% (100·4 to 175·1) * 4·4 (3·6 to 5·4) 5·0 (4·1 to 6·0) 13·3% (−1·1 to 32·8) 3714·7 (2947·7 to 4580·8) 7829·3 (6387·7 to 9431·1) 110·8% (78·6 to 154·9) * 78·2 (63·1 to 96·4) 87·5 (71·6 to 105·0) 12·0% (−4·8 to 34·6) Chronic kidney disease due to glomerulonephritis 123·3 (101·2 to 145·5) 193·9 (161·9 to 228·9) 57·2% (34·8 to 84·7) * 2·4 (2·0 to 2·8) 2·2 (1·9 to 2·6) −6·2% (−18·2 to 9·1) 4606·6 (3752·7 to 5506·5) 6352·6 (5165·6 to 7683·4) 37·9% (14·5 to 68·2) * 80·1 (65·4 to 95·7) 74·8 (60·6 to 89·8) −6·5% (−22·2 to 14·5) Chronic kidney disease due to other and unspecified causes 279·2 (237·8 to 321·8) 464·1 (387·6 to 545·1) 66·2% (44·2 to 93·0) * 5·8 (4·9 to 6·7) 5·3 (4·4 to 6·2) −8·8% (−20·0 to 6·1) 8550·9 (7197·2 to 10 086·6) 11 945·9 (9922·4 to 14 087·8) 39·7% (15·0 to 71·7) * 156·8 (133·8 to 183·6) 139·3 (115·7 to 163·9) −11·1% (−25·5 to 8·6) Acute glomerulonephritis 12·3 (7·9 to 18·4) 11·1 (7·5 to 14·7) −9·7% (−38·7 to 32·5) 0·2 (0·1 to 0·3) 0·1 (0·1 to 0·2) −45·0% (−62·9 to −18·8) * 498·7 (308·1 to 729·6) 323·6 (190·1 to 466·4) −35·1% (−55·7 to 2·4) 8·5 (5·3 to 12·6) 3·9 (2·2 to 5·6) −54·9% (−69·9 to −27·5) * Skin and subcutaneous diseases 66·0 (52·4 to 83·7) 161·1 (130·9 to 196·4) 144·2% (86·6 to 231·0) * 1·4 (1·2 to 1·8) 1·9 (1·5 to 2·3) 30·2% (1·6 to 75·2) * 2121·2 (1546·9 to 2956·1) 4110·4 (3136·7 to 5381·9) 93·8% (35·9 to 193·5) * 38·9 (29·0 to 53·1) 49·2 (37·0 to 65·4) 26·4% (−11·1 to 90·6) Bacterial skin diseases 40·1 (28·2 to 52·9) 101·7 (82·5 to 128·7) 153·8% (82·3 to 276·5) * 0·8 (0·6 to 1·1) 1·2 (0·9 to 1·5) 43·4% (4·5 to 107·0) * 1508·6 (1004·4 to 2158·2) 2763·4 (2067·2 to 3755·8) 83·2% (21·8 to 204·5) * 26·8 (18·1 to 37·8) 33·6 (24·7 to 46·4) 25·2% (−16·7 to 108·4) Cellulitis 15·8 (10·4 to 23·6) 39·7 (28·9 to 55·5) 150·7% (60·4 to 311·7) * 0·3 (0·2 to 0·5) 0·5 (0·3 to 0·6) 39·4% (−9·9 to 126·4) 537·4 (323·8 to 878·1) 1083·6 (728·7 to 1661·9) 101·7% (17·8 to 273·4) * 9·7 (6·0 to 15·6) 12·9 (8·5 to 20·0) 32·3% (−22·4 to 145·7) Pyoderma 24·2 (17·1 to 34·4) 62·0 (49·0 to 79·0) 155·9% (76·4 to 271·7) * 0·5 (0·4 to 0·7) 0·7 (0·6 to 0·9) 46·1% (2·6 to 108·2) * 971·2 (591·4 to 1459·5) 1679·8 (1222·9 to 2353·8) 73·0% (9·3 to 193·7) * 17·1 (10·7 to 25·4) 20·7 (14·7 to 29·7) 21·2% (−22·8 to 107·2) Decubitus ulcer 21·2 (16·3 to 27·8) 48·1 (36·3 to 62·8) 127·0% (65·8 to 213·6) * 0·5 (0·4 to 0·6) 0·5 (0·4 to 0·7) 8·2% (−17·9 to 44·9) 446·2 (309·0 to 651·9) 1010·4 (702·8 to 1440·1) 126·4% (44·0 to 260·4) * 9·1 (6·6 to 12·9) 11·5 (7·9 to 16·5) 26·1% (−17·0 to 92·3) Other skin and subcutaneous diseases 4·7 (2·8 to 8·3) 11·3 (6·9 to 17·6) 138·8% (14·2 to 384·7) * 0·1 (0·1 to 0·2) 0·1 (0·1 to 0·2) 32·9% (−35·6 to 164·1) 166·5 (83·7 to 338·4) 336·6 (190·9 to 584·5) 102·2% (−20·3 to 392·7) 3·0 (1·5 to 5·9) 4·1 (2·3 to 7·4) 38·5% (−45·7 to 228·7) Musculoskeletal disorders 80·2 (66·5 to 92·9) 131·7 (107·9 to 154·1) 64·1% (37·0 to 88·7) * 1·7 (1·4 to 1·9) 1·5 (1·2 to 1·7) –11·5% (−26·0 to 1·6) 2299·8 (1845·6 to 2683·2) 3173·8 (2620·9 to 3764·7) 38·0% (11·9 to 62·2) * 42·5 (34·5 to 49·5) 36·4 (30·0 to 43·3) –14·5% (−30·4 to 0·4) Rheumatoid arthritis 28·8 (20·7 to 36·4) 45·9 (32·7 to 57·9) 59·2% (27·7 to 99·0) * 0·6 (0·4 to 0·8) 0·5 (0·4 to 0·6) −17·6% (−33·9 to 3·3) 645·5 (447·7 to 820·4) 916·4 (640·7 to 1183·4) 41·9% (11·4 to 77·5) * 12·9 (9·0 to 16·3) 10·1 (7·1 to 13·1) −21·2% (−38·0 to −1·8) * Other musculoskeletal disorders 51·4 (42·1 to 60·6) 85·9 (67·9 to 103·6) 66·8% (37·1 to 97·7) * 1·1 (0·9 to 1·3) 1·0 (0·8 to 1·2) −8·0% (−23·2 to 8·5) 1654·3 (1330·9 to 1948·5) 2257·4 (1790·5 to 2757·1) 36·4% (11·3 to 63·9) * 29·7 (24·2 to 34·8) 26·2 (20·8 to 31·9) −11·6% (−27·1 to 5·9) Other non-communicable diseases 1121·0 (992·9 to 1256·6) 1338·5 (1191·5 to 1551·1) 19·4% (0·0 to 38·5) * 19·8 (17·7 to 22·1) 17·9 (15·8 to 21·0) –9·4% (−23·9 to 5·5) 77 258·0 (66 414·6 to 88 483·4) 71 507·3 (59 687·1 to 85 787·3) –7·4% (−26·5 to 13·9) 1271·3 (1094·4 to 1452·8) 1055·5 (866·7 to 1280·7) –17·0% (−34·1 to 2·8) Congenital birth defects 659·3 (547·7 to 792·5) 562·7 (441·3 to 709·6) −14·7% (−37·6 to 11·6) 10·7 (8·9 to 12·8) 8·8 (6·9 to 11·1) −17·8% (−40·1 to 7·7) 56 848·7 (47 133·0 to 68 446·9) 47 701·9 (37 217·6 to 60 416·6) −16·1% (−39·0 to 10·1) 919·0 (761·9 to 1106·5) 753·7 (586·8 to 956·6) −18·0% (−40·5 to 7·7) Neural tube defects 65·3 (39·4 to 107·4) 41·7 (24·6 to 69·1) −36·2% (−66·1 to 18·1) 1·1 (0·6 to 1·7) 0·7 (0·4 to 1·1) −36·6% (−66·4 to 17·4) 5791·5 (3488·4 to 9536·6) 3673·3 (2158·6 to 6101·7) −36·6% (−66·4 to 17·5) 93·6 (56·4 to 154·2) 59·2 (34·7 to 98·4) −36·7% (−66·5 to 17·3) Congenital heart anomalies 386·7 (307·5 to 471·0) 301·2 (233·4 to 390·5) −22·1% (−43·5 to 2·5) 6·2 (5·0 to 7·6) 4·7 (3·6 to 6·1) −25·3% (−45·9 to −1·6) * 33 161·2 (26 261·7 to 40 446·1) 25 455·6 (19 627·3 to 33 175·6) −23·2% (−44·6 to 1·3) 535·7 (424·1 to 653·5) 399·5 (307·3 to 522·4) −25·4% (−46·2 to −1·5) * Orofacial clefts 11·5 (4·1 to 30·6) 3·3 (0·7 to 10·1) −71·4% (−89·5 to −29·7) * 0·2 (0·1 to 0·5) 0·1 (0·0 to 0·2) −71·2% (−89·4 to −29·4) * 1027·7 (367·6 to 2745·2) 293·6 (63·7 to 901·6) −71·4% (−89·5 to −29·7) * 16·7 (6·0 to 44·6) 4·8 (1·0 to 14·7) −71·2% (−89·4 to −29·4) * Down syndrome 23·9 (15·4 to 34·4) 29·3 (17·8 to 43·7) 22·7% (−32·7 to 104·2) 0·4 (0·3 to 0·6) 0·4 (0·3 to 0·7) 10·1% (−39·8 to 84·2) 1951·1 (1233·5 to 2848·7) 2251·1 (1330·7 to 3487·0) 15·4% (−37·7 to 97·3) 31·7 (20·1 to 46·3) 34·3 (20·0 to 53·7) 8·1% (−42·1 to 85·6) Other chromosomal abnormalities 14·9 (10·1 to 22·1) 22·9 (15·4 to 36·0) 53·6% (−7·1 to 142·1) 0·2 (0·2 to 0·4) 0·4 (0·2 to 0·6) 49·4% (−10·0 to 135·6) 1291·8 (869·2 to 1924·2) 1956·0 (1300·4 to 3117·2) 51·4% (−9·4 to 139·4) 20·9 (14·1 to 31·1) 31·2 (20·6 to 49·8) 49·2% (−10·9 to 135·9) Congenital musculoskeletal and limb anomalies 10·0 (6·6 to 16·3) 9·7 (6·2 to 15·0) −3·4% (−43·6 to 73·9) 0·2 (0·1 to 0·3) 0·1 (0·1 to 0·2) −7·0% (−45·8 to 67·5) 853·2 (560·2 to 1387·9) 813·1 (513·6 to 1266·7) −4·7% (−44·8 to 72·9) 13·8 (9·0 to 22·4) 12·8 (8·1 to 20·0) −6·7% (−46·1 to 69·2) Urogenital congenital anomalies 12·9 (7·9 to 21·7) 16·9 (9·3 to 30·8) 30·7% (−32·1 to 167·1) 0·2 (0·1 to 0·4) 0·3 (0·1 to 0·5) 18·9% (−40·2 to 144·6) 1039·6 (610·4 to 1775·6) 1309·1 (675·8 to 2494·3) 25·9% (−38·8 to 177·0) 16·9 (10·0 to 28·9) 20·5 (10·4 to 39·6) 21·2% (−42·1 to 168·0) Digestive congenital anomalies 63·1 (40·9 to 97·6) 67·0 (42·0 to 97·1) 6·1% (−34·6 to 73·4) 1·0 (0·7 to 1·6) 1·1 (0·7 to 1·6) 5·6% (−35·0 to 72·6) 5606·3 (3633·0 to 8669·4) 5922·1 (3705·9 to 8592·1) 5·6% (−35·0 to 72·7) 90·9 (58·9 to 140·6) 96·0 (60·0 to 139·3) 5·6% (−35·2 to 72·8) Other congenital birth defects 71·1 (42·4 to 125·4) 70·9 (37·7 to 132·9) −0·3% (−32·6 to 41·8) 1·1 (0·7 to 2·0) 1·1 (0·6 to 2·1) −3·5% (−35·3 to 38·1) 6126·5 (3636·7 to 10 879·7) 6028·0 (3169·5 to 11 394·8) −1·6% (−34·1 to 40·9) 98·8 (58·7 to 175·6) 95·4 (49·9 to 181·0) −3·5% (−36·0 to 38·9) Urinary diseases and male infertility 180·8 (162·1 to 199·0) 396·2 (357·0 to 433·6) 119·2% (95·5 to 146·1) * 3·9 (3·5 to 4·3) 4·5 (4·1 to 5·0) 15·6% (4·0 to 28·8) * 5005·7 (4426·8 to 5604·2) 8495·7 (7768·6 to 9356·0) 69·8% (48·9 to 95·1) * 94·5 (83·5 to 105·4) 98·2 (89·7 to 108·1) 3·9% (−9·0 to 19·0) Urinary tract infections and interstitial nephritis 122·2 (106·7 to 137·0) 288·5 (258·0 to 318·6) 136·2% (108·0 to 171·5) * 2·7 (2·4 to 3·0) 3·3 (3·0 to 3·7) 21·7% (7·9 to 38·1) * 3223·8 (2739·6 to 3698·5) 5884·9 (5246·1 to 6590·9) 82·6% (54·7 to 118·5) * 61·7 (53·2 to 70·3) 67·9 (60·5 to 76·0) 10·1% (−6·7 to 30·3) Urolithiasis 14·6 (12·1 to 17·2) 24·9 (21·0 to 30·0) 71·0% (34·9 to 108·7) * 0·3 (0·2 to 0·3) 0·3 (0·2 to 0·3) −1·4% (−22·2 to 20·4) 500·4 (406·5 to 604·3) 685·2 (565·5 to 833·1) 37·0% (4·8 to 76·4) * 8·9 (7·3 to 10·7) 8·0 (6·6 to 9·7) −9·9% (−31·4 to 16·1) Other urinary diseases 44·0 (33·4 to 58·5) 82·8 (65·2 to 102·2) 88·1% (32·5 to 160·1) * 0·9 (0·7 to 1·2) 0·9 (0·7 to 1·2) 2·9% (−27·1 to 41·0) 1281·5 (965·0 to 1715·2) 1925·7 (1463·1 to 2497·9) 50·3% (4·8 to 116·0) * 23·9 (18·0 to 31·8) 22·3 (16·9 to 28·9) −7·0% (−35·1 to 32·8) Gynaecological diseases 5·3 (3·4 to 8·7) 14·1 (7·1 to 25·2) 165·6% (61·5 to 478·3) * 0·1 (0·1 to 0·2) 0·2 (0·1 to 0·3) 61·9% (−2·4 to 251·5) 210·4 (130·8 to 352·3) 502·5 (259·0 to 893·5) 138·7% (41·4 to 424·3) * 3·6 (2·3 to 6·0) 5·9 (3·0 to 10·4) 62·6% (−3·5 to 253·5) Uterine fibroids 1·6 (0·9 to 2·9) 4·0 (2·0 to 7·4) 151·9% (38·4 to 474·7) * 0·0 (0·0 to 0·1) 0·0 (0·0 to 0·1) 61·6% (−11·9 to 266·8) 67·5 (38·8 to 123·6) 159·1 (77·5 to 311·2) 135·4% (24·8 to 439·1) * 1·1 (0·7 to 2·1) 1·9 (0·9 to 3·6) 62·0% (−14·1 to 269·5) Endometriosis 0·0 (0·0 to 0·1) 0·2 (0·0 to 0·5) 260·1% (25·3 to 1199·7) * 0·0 (0·0 to 0·0) 0·0 (0·0 to 0·0) 160·1% (−10·5 to 826·6) 2·2 (0·8 to 5·5) 7·6 (1·5 to 25·5) 245·5% (19·5 to 1118·1) * 0·0 (0·0 to 0·1) 0·1 (0·0 to 0·3) 154·3% (−11·5 to 787·1) Genital prolapse 0·6 (0·3 to 1·1) 1·6 (0·8 to 3·5) 181·4% (14·7 to 706·6) * 0·0 (0·0 to 0·0) 0·0 (0·0 to 0·0) 50·8% (−37·5 to 324·1) 17·2 (8·5 to 33·6) 43·4 (19·3 to 91·8) 152·4% (−9·2 to 616·6) 0·3 (0·2 to 0·6) 0·5 (0·2 to 1·1) 63·2% (−40·3 to 353·9) Other gynaecological diseases 3·1 (1·7 to 5·2) 8·3 (3·9 to 15·2) 168·4% (45·0 to 483·1) * 0·1 (0·0 to 0·1) 0·1 (0·0 to 0·2) 63·2% (−11·4 to 249·0) 123·5 (65·5 to 210·9) 292·5 (134·9 to 525·3) 136·8% (26·7 to 433·0) * 2·1 (1·1 to 3·6) 3·4 (1·6 to 6·1) 61·4% (−13·4 to 260·5) Haemoglobinopathies and haemolytic anaemias 121·9 (88·9 to 183·0) 132·4 (86·7 to 218·0) 8·5% (−33·1 to 57·4) 2·2 (1·7 to 3·3) 1·6 (1·1 to 2·8) −26·4% (−54·4 to 6·3) 6345·0 (4403·3 to 9919·8) 6361·5 (3804·8 to 11 317·4) 0·2% (−42·3 to 55·8) 105·1 (73·4 to 163·8) 84·8 (49·8 to 153·8) −19·4% (−53·9 to 25·2) Thalassaemias 17·9 (13·9 to 24·6) 13·5 (9·1 to 19·6) −24·6% (−55·4 to 19·7) 0·3 (0·2 to 0·4) 0·2 (0·1 to 0·3) −35·7% (−62·2 to 2·9) 1330·1 (1021·3 to 1846·9) 956·2 (629·0 to 1407·7) −28·1% (−58·3 to 15·9) 21·3 (16·3 to 29·6) 13·7 (8·9 to 20·6) −35·7% (−63·0 to 3·7) Sickle cell disorders 45·6 (26·5 to 85·7) 54·0 (27·0 to 110·5) 18·4% (−34·4 to 100·9) 0·7 (0·4 to 1·4) 0·7 (0·4 to 1·5) 0·4% (−44·5 to 71·2) 3290·0 (1894·7 to 6160·7) 3768·4 (1866·6 to 7680·2) 14·5% (−37·1 to 98·2) 51·9 (29·9 to 97·8) 51·9 (25·6 to 107·0) 0·0% (−45·3 to 73·7) G6PD deficiency 12·6 (8·5 to 18·3) 12·9 (7·6 to 21·1) 2·9% (−42·6 to 65·7) 0·2 (0·2 to 0·3) 0·1 (0·1 to 0·2) −34·3% (−63·1 to 4·3) 553·6 (387·9 to 794·2) 516·6 (310·1 to 816·5) −6·7% (−48·2 to 55·1) 9·4 (6·6 to 13·5) 6·2 (3·8 to 9·8) −33·4% (−62·6 to 11·0) Other haemoglobinopathies and haemolytic anaemias 45·9 (36·7 to 60·3) 51·9 (39·7 to 71·8) 13·1% (−21·8 to 52·5) 1·0 (0·8 to 1·3) 0·6 (0·4 to 0·8) −41·2% (−59·3 to −21·0) * 1171·3 (969·0 to 1485·7) 1120·4 (875·8 to 1457·0) −4·4% (−32·6 to 27·7) 22·5 (18·5 to 29·0) 12·8 (10·1 to 16·6) −42·9% (−59·7 to −25·1) * Endocrine, metabolic, blood, and immune disorders 96·9 (84·3 to 108·9) 207·6 (179·5 to 233·9) 114·1% (89·0 to 141·4) * 2·0 (1·7 to 2·2) 2·4 (2·1 to 2·7) 23·4% (9·9 to 39·9) * 3757·6 (3032·0 to 4410·9) 6149·5 (5122·8 to 7402·5) 63·6% (35·7 to 93·7) * 66·2 (53·9 to 77·1) 75·6 (62·2 to 92·1) 14·0% (−5·1 to 35·2) Thyroid diseases 19·6 (14·9 to 25·2) 32·4 (25·6 to 41·1) 65·0% (22·4 to 113·1) * 0·4 (0·3 to 0·5) 0·4 (0·3 to 0·5) −8·0% (−30·6 to 18·2) 674·5 (479·3 to 924·3) 967·1 (712·2 to 1279·4) 43·4% (−3·4 to 101·0) 12·1 (8·8 to 16·3) 11·7 (8·5 to 15·6) −3·4% (−34·4 to 35·5) Other endocrine, metabolic, blood, and immune disorders 77·3 (67·1 to 86·5) 175·2 (153·3 to 197·4) 126·6% (103·1 to 154·9) * 1·5 (1·4 to 1·7) 2·0 (1·8 to 2·3) 31·8% (19·3 to 48·4) * 3083·1 (2538·1 to 3609·7) 5182·4 (4384·7 to 6163·9) 68·0% (43·1 to 96·0) * 54·1 (45·0 to 62·9) 63·9 (53·4 to 77·1) 17·9% (0·2 to 39·7) * Sudden infant death syndrome 56·7 (36·3 to 91·0) 25·6 (15·8 to 40·1) −54·9% (−73·0 to −24·0) * 0·9 (0·6 to 1·5) 0·4 (0·3 to 0·7) −54·7% (−72·9 to −23·7) * 5090·6 (3253·1 to 8163·9) 2296·2 (1414·7 to 3601·8) −54·9% (−73·0 to −24·0) * 82·9 (53·0 to 132·9) 37·5 (23·1 to 58·8) −54·7% (−72·9 to −23·7) * Injuries 4561·0 (4198·4 to 4847·2) 4874·5 (4365·5 to 5278·9) 6·9% (−1·4 to 17·0) 79·0 (73·0 to 83·8) 58·4 (52·3 to 63·4) –26·1% (−31·9 to −19·3) * 239 490·2 (219 550·6 to 255 837·6) 220 643·9 (194 754·8 to 240 020·8) –7·9% (−15·4 to 0·3) 3884·7 (3557·3 to 4148·4) 2756·6 (2426·8 to 2997·9) –29·0% (−34·8 to −22·7) * Transport injuries 1370·0 (1150·1 to 1577·2) 1425·8 (1126·9 to 1685·0) 4·0% (−15·6 to 30·5) 23·0 (19·4 to 26·5) 17·1 (13·5 to 20·2) –25·9% (−40·1 to −7·0) * 73 477·8 (61 024·6 to 85 100·8) 70 704·2 (55 582·2 to 83 652·9) –3·8% (−21·5 to 21·2) 1180·1 (981·8 to 1364·4) 875·7 (687·3 to 1039·1) –25·8% (−39·4 to −6·6) * Road injuries 1285·3 (1073·5 to 1485·5) 1343·7 (1044·8 to 1583·5) 4·5% (−16·0 to 31·7) 21·6 (18·1 to 25·0) 16·1 (12·5 to 19·0) −25·5% (−40·1 to −6·3) * 69 027·2 (57 038·4 to 79 536·6) 66 726·5 (51 479·6 to 79 414·8) −3·4% (−21·7 to 22·6) 1108·4 (917·5 to 1276·3) 826·9 (636·8 to 987·2) −25·4% (−39·6 to −5·4) * Pedestrian road injuries 517·6 (403·1 to 627·3) 401·4 (294·8 to 531·9) −22·5% (−44·5 to 10·0) 8·9 (7·0 to 10·7) 4·8 (3·5 to 6·4) −46·5% (−61·8 to −24·8) * 26 512·5 (20 298·8 to 32 278·7) 18 879·3 (13 593·8 to 25 843·3) −28·8% (−49·4 to −0·1) * 432·5 (331·6 to 526·7) 235·1 (168·4 to 321·0) −45·6% (−61·6 to −24·1) * Cyclist road injuries 62·3 (47·0 to 82·2) 89·1 (61·6 to 127·5) 42·6% (−15·8 to 118·5) 1·1 (0·8 to 1·4) 1·0 (0·7 to 1·5) −5·3% (−44·0 to 44·6) 3040·8 (2295·4 to 4061·4) 3647·8 (2434·3 to 5248·3) 19·7% (−28·2 to 83·2) 49·8 (37·6 to 66·3) 43·4 (29·1 to 62·5) −13·1% (−48·1 to 34·1) Motorcyclist road injuries 216·7 (161·2 to 286·9) 319·3 (216·6 to 416·4) 47·3% (−5·7 to 123·1) 3·5 (2·6 to 4·6) 3·8 (2·6 to 5·0) 9·4% (−30·1 to 65·5) 12 274·6 (8987·1 to 16 339·8) 16 474·0 (11 327·3 to 21 440·9) 34·2% (−15·6 to 102·9) 193·0 (142·0 to 256·8) 202·2 (139·0 to 263·5) 4·7% (−34·3 to 58·1) Motor vehicle road injuries 475·6 (394·0 to 598·0) 518·6 (416·7 to 648·1) 9·0% (−17·7 to 45·1) 7·9 (6·6 to 9·9) 6·3 (5·0 to 7·9) −20·3% (−40·1 to 6·2) 26 488·4 (21 757·2 to 33 135·5) 26 954·9 (21 588·6 to 34 098·7) 1·7% (−23·2 to 35·9) 421·6 (346·7 to 527·4) 336·5 (268·3 to 428·6) −20·2% (−39·9 to 7·0) Other road injuries 13·1 (8·7 to 18·9) 15·4 (10·0 to 22·6) 17·3% (−41·2 to 108·8) 0·2 (0·1 to 0·3) 0·2 (0·1 to 0·3) −16·2% (−58·0 to 49·8) 711·0 (467·5 to 1033·5) 770·5 (491·4 to 1136·7) 8·4% (−47·1 to 97·1) 11·5 (7·5 to 16·6) 9·7 (6·1 to 14·4) −15·4% (−58·9 to 55·1) Other transport injuries 84·7 (60·9 to 110·7) 82·0 (55·8 to 112·2) −3·2% (−37·0 to 47·6) 1·4 (1·0 to 1·9) 1·0 (0·7 to 1·3) −31·6% (−55·3 to 3·4) 4450·6 (3151·6 to 5913·9) 3977·7 (2673·9 to 5532·3) −10·6% (−43·2 to 36·8) 71·6 (50·9 to 94·8) 48·7 (32·7 to 68·1) −32·0% (−56·8 to 3·5) Unintentional injuries 1791·4 (1590·1 to 1985·5) 2078·4 (1786·5 to 2291·5) 16·0% (5·5 to 29·4) * 32·6 (28·9 to 35·9) 24·9 (21·4 to 27·5) –23·5% (−30·2 to −14·8) * 92 652·4 (80 125·4 to 103 949·3) 81 163·1 (69 397·1 to 91 146·1) –12·4% (−21·6 to −2·5) * 1531·5 (1327·0 to 1713·6) 1033·8 (881·6 to 1164·1) –32·5% (−39·5 to −24·7) * Falls 487·5 (426·9 to 562·8) 857·4 (723·5 to 1002·4) 75·8% (51·9 to 105·1) * 10·2 (8·9 to 11·7) 9·9 (8·3 to 11·6) −3·2% (−16·3 to 12·3) 16 299·1 (14 045·6 to 19 638·5) 21 114·3 (17 999·1 to 24 778·3) 29·5% (7·5 to 54·6) * 293·0 (253·6 to 349·4) 250·4 (213·8 to 296·1) −14·6% (−29·6 to 2·3) Drowning 432·5 (372·3 to 512·2) 291·1 (234·0 to 362·8) −32·7% (−46·0 to −11·9) * 7·1 (6·2 to 8·4) 3·7 (3·0 to 4·6) −47·9% (−58·7 to −32·2) * 29 119·6 (24 541·5 to 34 727·6) 16 898·5 (13 180·4 to 21 593·5) −42·0% (−54·9 to −23·5) * 464·9 (392·5 to 554·2) 225·5 (174·9 to 289·3) −51·5% (−62·6 to −36·0) * Fire, heat, and hot substances 134·6 (103·6 to 173·8) 150·7 (102·9 to 205·0) 11·9% (−13·8 to 54·5) 2·4 (1·8 to 3·0) 1·9 (1·3 to 2·6) −21·6% (−39·4 to 9·1) 7268·4 (5293·8 to 9998·4) 7433·1 (4843·5 to 10 612·7) 2·3% (−24·7 to 47·5) 119·7 (87·9 to 163·7) 97·7 (63·0 to 141·3) −18·4% (−39·5 to 18·6) Poisonings 79·0 (65·0 to 99·8) 69·9 (54·4 to 91·7) −11·6% (−37·9 to 24·6) 1·4 (1·1 to 1·7) 0·8 (0·6 to 1·1) −37·8% (−56·7 to −11·9) * 4281·2 (3412·7 to 5626·8) 3335·6 (2479·5 to 4592·5) −22·1% (−48·5 to 18·3) 70·0 (55·9 to 91·7) 42·5 (30·9 to 59·8) −39·3% (−60·0 to −6·7) * Poisoning by carbon monoxide 44·0 (37·4 to 52·6) 31·0 (24·4 to 39·9) −29·7% (−43·1 to −12·7) * 0·8 (0·7 to 0·9) 0·4 (0·3 to 0·5) −52·8% (−61·9 to −40·7) * 2185·4 (1806·8 to 2684·2) 1290·8 (1014·9 to 1743·1) −41·0% (−54·4 to −21·2) * 36·1 (29·9 to 44·0) 15·8 (12·3 to 21·7) −56·4% (−66·5 to −40·9) * Poisoning by other means 35·0 (22·7 to 52·1) 38·9 (24·5 to 55·8) 11·2% (−37·6 to 97·9) 0·6 (0·4 to 0·9) 0·5 (0·3 to 0·7) −18·5% (−54·5 to 46·8) 2095·8 (1309·4 to 3230·7) 2044·8 (1279·7 to 3095·7) −2·5% (−47·0 to 80·7) 33·9 (21·2 to 52·2) 26·8 (16·4 to 41·4) −21·0% (−57·6 to 48·2) Exposure to mechanical forces 127·9 (98·2 to 170·3) 104·1 (74·0 to 148·7) −18·7% (−41·8 to 34·5) 2·1 (1·7 to 2·8) 1·3 (0·9 to 1·8) −41·6% (−58·1 to −2·9) * 7151·8 (5320·4 to 9989·7) 5170·1 (3634·1 to 7802·5) −27·7% (−51·6 to 24·4) 115·1 (85·9 to 160·4) 64·5 (45·2 to 100·2) −43·9% (−62·5 to −3·0) * Unintentional firearm injuries 23·2 (13·8 to 37·9) 16·2 (10·0 to 25·8) −30·1% (−56·8 to 26·7) 0·4 (0·2 to 0·6) 0·2 (0·1 to 0·3) −47·3% (−67·6 to −3·4) * 1340·5 (796·7 to 2191·8) 888·1 (539·5 to 1434·2) −33·7% (−60·1 to 25·4) 21·0 (12·5 to 34·4) 11·1 (6·7 to 18·4) −47·0% (−68·3 to 1·1) Other exposure to mechanical forces 104·7 (80·0 to 141·2) 87·9 (60·6 to 127·5) −16·1% (−39·2 to 35·4) 1·8 (1·4 to 2·4) 1·1 (0·7 to 1·5) −40·4% (−56·8 to −2·3) * 5811·2 (4271·2 to 8200·8) 4282·0 (2889·5 to 6483·0) −26·4% (−49·5 to 24·3) 94·1 (69·5 to 132·4) 53·4 (35·7 to 82·7) −43·3% (−61·0 to −2·9) * Adverse effects of medical treatment 99·3 (77·6 to 127·7) 102·5 (85·3 to 128·6) 3·2% (−23·6 to 39·0) 1·9 (1·5 to 2·4) 1·2 (1·0 to 1·5) −35·4% (−51·7 to −12·3) * 4425·4 (3389·4 to 5958·3) 3802·5 (2940·0 to 5042·3) −14·1% (−40·4 to 22·0) 75·8 (58·4 to 101·4) 49·0 (37·1 to 65·9) −35·4% (−54·7 to −6·9) * Animal contact 102·2 (61·8 to 150·3) 103·1 (61·8 to 148·7) 0·9% (−35·2 to 67·1) 1·7 (1·1 to 2·6) 1·2 (0·7 to 1·8) −28·5% (−53·8 to 18·6) 5869·1 (3456·8 to 8754·7) 5034·6 (3000·3 to 7390·9) −14·2% (−45·0 to 43·4) 95·1 (56·1 to 141·9) 64·1 (38·0 to 94·8) −32·6% (−56·7 to 12·6) Venomous animal contact 92·4 (55·5 to 137·8) 93·7 (56·3 to 137·1) 1·4% (−35·7 to 67·2) 1·6 (0·9 to 2·3) 1·1 (0·7 to 1·7) −28·0% (−54·0 to 18·9) 5338·7 (3104·6 to 8048·5) 4557·1 (2701·9 to 6798·8) −14·6% (−46·6 to 42·3) 86·3 (50·3 to 130·4) 57·8 (34·0 to 87·1) −33·0% (−58·3 to 11·6) Non-venomous animal contact 9·8 (5·9 to 18·1) 9·5 (5·2 to 14·9) −3·5% (−45·4 to 70·9) 0·2 (0·1 to 0·3) 0·1 (0·1 to 0·2) −32·8% (−61·6 to 19·6) 530·3 (300·5 to 1064·2) 477·5 (242·7 to 779·7) −9·9% (−51·6 to 67·8) 8·8 (5·0 to 17·5) 6·2 (3·1 to 10·4) −29·0% (−61·7 to 33·1) Foreign body 102·9 (79·8 to 125·1) 119·8 (91·3 to 148·7) 16·5% (−3·4 to 35·3) 1·9 (1·5 to 2·3) 1·5 (1·1 to 1·9) −19·1% (−32·2 to −4·5) * 6041·1 (4342·0 to 7516·9) 5517·9 (3934·6 to 7185·8) −8·7% (−28·9 to 12·5) 100·7 (72·9 to 124·7) 77·0 (54·0 to 100·7) −23·6% (−40·7 to −4·7) * Pulmonary aspiration and foreign body in airway 99·3 (77·0 to 119·7) 117·6 (90·0 to 144·7) 18·4% (−1·0 to 37·8) 1·8 (1·5 to 2·2) 1·5 (1·1 to 1·9) −17·8% (−31·1 to −2·8) * 5818·3 (4173·9 to 7253·5) 5414·8 (3882·7 to 6977·6) −6·9% (−27·9 to 15·4) 97·1 (70·1 to 120·4) 75·6 (53·3 to 98·9) −22·1% (−39·9 to −1·9) * Foreign body in other body part 3·6 (1·5 to 5·6) 2·3 (1·3 to 3·8) −36·6% (−63·1 to 3·7) 0·1 (0·0 to 0·1) 0·0 (0·0 to 0·0) −55·6% (−74·0 to −29·3) * 222·8 (80·8 to 360·1) 103·0 (49·1 to 181·1) −53·8% (−76·0 to −22·9) * 3·7 (1·3 to 5·9) 1·4 (0·6 to 2·4) −62·6% (−80·7 to −39·4) * Electrocution 56·7 (29·5 to 88·4) 42·4 (22·0 to 57·4) −25·2% (−45·3 to 12·6) 0·9 (0·5 to 1·4) 0·5 (0·3 to 0·7) −41·8% (−57·5 to −11·6) * 3443·9 (1765·2 to 5304·9) 2525·8 (1306·1 to 3478·2) −26·7% (−47·1 to 8·0) 54·1 (27·8 to 83·6) 32·6 (16·7 to 45·4) −39·8% (−56·8 to −10·4) * Environmental heat and cold exposure 56·3 (42·6 to 69·6) 83·4 (71·5 to 95·7) 48·1% (20·8 to 80·9) * 1·0 (0·8 to 1·3) 0·9 (0·8 to 1·1) −9·2% (−25·8 to 10·4) 2292·9 (1710·6 to 2936·1) 2650·0 (2235·1 to 3102·6) 15·6% (−5·8 to 43·1) 39·7 (29·7 to 50·5) 30·6 (25·6 to 36·1) −22·9% (−37·2 to −5·4) * Exposure to forces of nature 9·0 (8·2 to 9·9) 88·6 (80·7 to 97·4) 882·0% (882·0 to 882·0) * 0·2 (0·1 to 0·2) 1·1 (1·0 to 1·2) 598·5% (598·5 to 598·5) * 545·5 (496·7 to 599·7) 4274·0 (3891·6 to 4698·5) 683·5% (683·5 to 683·5) * 8·8 (8·0 to 9·7) 56·8 (51·7 to 62·4) 543·4% (543·4 to 543·4) * Other unintentional injuries 103·4 (59·7 to 176·9) 65·2 (39·7 to 104·3) −36·9% (−64·3 to 17·1) 1·7 (1·0 to 2·9) 0·8 (0·5 to 1·3) −53·8% (−73·8 to −14·8) * 5914·5 (3294·4 to 10 442·9) 3406·8 (2026·0 to 5684·8) −42·4% (−69·2 to 8·5) 94·5 (53·0 to 166·1) 43·1 (25·5 to 72·6) −54·4% (−75·6 to −14·7) * Self-harm and interpersonal violence 1399·6 (1273·1 to 1514·3) 1370·4 (1252·7 to 1496·8) –2·0% (−10·9 to 7·7) 23·4 (21·3 to 25·3) 16·4 (15·0 to 17·9) –29·9% (−36·4 to −22·8) * 73 359·9 (66 978·1 to 79 476·6) 68 776·6 (62 700·9 to 75 042·7) –6·2% (−14·7 to 3·9) 1173·1 (1069·1 to 1271·3) 847·1 (771·6 to 925·4) –27·8% (−34·5 to −19·8) * Self-harm 819·5 (707·3 to 905·0) 766·7 (675·7 to 857·9) −6·3% (−17·0 to 6·2) 14·1 (12·2 to 15·6) 9·0 (7·9 to 10·1) −36·4% (−43·6 to −27·9) * 39 034·8 (33 419·7 to 43 263·2) 34 358·5 (29 835·6 to 38 613·6) −11·9% (−23·2 to 0·1) 636·2 (544·4 to 704·3) 413·9 (358·2 to 465·7) −34·9% (−43·2 to −26·4) * Self-harm by firearm 67·3 (50·2 to 98·4) 66·6 (51·5 to 86·1) −1·1% (−24·1 to 35·0) 1·2 (0·9 to 1·7) 0·8 (0·6 to 1·0) −32·8% (−47·6 to −9·7) * 3262·0 (2317·0 to 4873·2) 2910·7 (2156·2 to 3887·0) −10·8% (−34·1 to 25·9) 53·0 (38·1 to 78·9) 34·9 (25·8 to 46·8) −34·1% (−50·6 to −7·8) * Self-harm by other specified means 752·2 (642·7 to 839·1) 700·2 (609·7 to 787·9) −6·8% (−18·3 to 6·6) 13·0 (11·1 to 14·5) 8·2 (7·1 to 9·3) −36·7% (−44·5 to −27·8) * 35 772·8 (30 493·1 to 39 978·1) 31 447·9 (26 807·0 to 35 588·2) −12·0% (−23·9 to 0·5) 583·2 (498·2 to 651·3) 378·9 (322·4 to 428·9) −35·0% (−43·9 to −25·8) * Interpersonal violence 464·3 (420·2 to 539·4) 435·7 (384·1 to 507·9) −6·2% (−21·5 to 12·1) 7·5 (6·8 to 8·7) 5·3 (4·7 to 6·2) −28·9% (−40·6 to −15·0) * 26 564·8 (23 942·0 to 31 034·3) 24 148·6 (21 130·2 to 28 446·6) −9·1% (−24·0 to 9·0) 418·9 (377·6 to 489·5) 302·4 (264·5 to 358·0) −27·8% (−39·7 to −13·2) * Physical violence by firearm 162·0 (145·0 to 185·9) 185·6 (167·5 to 209·2) 14·6% (−3·7 to 34·1) 2·6 (2·3 to 2·9) 2·3 (2·1 to 2·6) −11·1% (−25·5 to 3·8) 9524·1 (8520·1 to 10 959·9) 10 535·3 (9479·3 to 11 925·5) 10·6% (−7·5 to 29·9) 148·0 (132·4 to 170·4) 131·2 (118·0 to 148·6) −11·4% (−25·9 to 3·9) Physical violence by sharp object 116·7 (94·2 to 140·4) 89·9 (67·3 to 125·8) −23·0% (−42·0 to 7·1) 1·9 (1·5 to 2·3) 1·1 (0·8 to 1·5) −42·2% (−56·5 to −19·5) * 6511·2 (5234·5 to 7903·5) 4848·9 (3572·3 to 6814·3) −25·5% (−44·6 to 3·9) 102·7 (82·6 to 124·4) 60·0 (44·0 to 84·5) −41·6% (−56·6 to −18·3) * Physical violence by other means 185·6 (155·8 to 236·6) 160·2 (125·3 to 204·7) −13·7% (−35·1 to 16·4) 3·1 (2·6 to 3·9) 2·0 (1·5 to 2·5) −35·7% (−51·5 to −13·1) * 10 529·4 (8776·0 to 13 612·8) 8764·4 (6699·7 to 11 310·6) −16·8% (−37·8 to 14·9) 168·2 (140·5 to 216·7) 111·2 (84·4 to 144·2) −33·9% (−50·5 to −8·5) * Conflict and terrorism 108·7 (94·2 to 145·1) 159·1 (125·6 to 208·6) 46·3% (31·7 to 54·5) * 1·7 (1·4 to 2·2) 2·0 (1·6 to 2·6) 19·3% (7·7 to 25·9) * 7348·6 (6362·3 to 9833·7) 9771·2 (7782·4 to 12 730·0) 33·0% (20·6 to 39·9) * 111·5 (96·5 to 149·2) 124·6 (99·5 to 162·0) 11·7% (1·6 to 17·4) * Police conflict and executions 7·1 (5·5 to 9·1) 8·9 (6·3 to 13·3) 25·8% (−19·5 to 74·9) 0·1 (0·1 to 0·1) 0·1 (0·1 to 0·2) −3·3% (−38·1 to 36·2) 411·7 (325·1 to 527·2) 498·2 (349·4 to 747·7) 21·0% (−22·3 to 68·8) 6·4 (5·1 to 8·3) 6·2 (4·4 to 9·3) −3·8% (−38·1 to 35·3) Total cancers 7002·9 (6615·8 to 7281·6) 10 443·4 (9608·6 to 11 041·7) 49·0% (41·0 to 57·5) * 142·5 (134·4 to 148·4) 115·6 (106·3 to 122·1) –18·9% (−22·7 to −14·5) * 195 148·9 (185 805·2 to 202 090·3) 264 464·0 (249 927·7 to 277 556·8) 35·4% (29·4 to 43·6) * 3696·7 (3518·2 to 3830·4) 2950·4 (2789·1 to 3094·1) –20·2% (−23·7 to −15·4) * Total burden related to hepatitis B 586·6 (522·9 to 656·6) 628·4 (537·2 to 707·3) 7·1% (−7·8 to 24·1) 11·0 (9·9 to 12·4) 7·0 (6·0 to 7·9) –36·3% (−45·4 to −25·8) * 21 517·4 (19 085·4 to 24 352·8) 21 106·8 (18 086·9 to 23 933·9) –1·9% (−17·8 to 15·7) 382·5 (338·7 to 429·2) 241·8 (207·1 to 274·7) –36·8% (−47·0 to −25·3) * Total burden related to hepatitis C 387·4 (339·4 to 445·3) 497·2 (426·4 to 566·3) 28·3% (12·2 to 48·2) * 7·6 (6·6 to 8·7) 5·5 (4·7 to 6·3) –27·2% (−36·3 to −15·8) * 12 328·0 (10 658·9 to 14 400·8) 14 408·7 (12 311·5 to 16 728·9) 16·9% (0·1 to 36·2) * 226·2 (196·2 to 261·9) 161·6 (138·3 to 187·6) –28·6% (−38·5 to −16·3) * Total burden related to non-alcoholic fatty liver disease 72·7 (57·5 to 91·2) 131·5 (103·4 to 164·9) 80·8% (62·1 to 98·8) * 1·5 (1·2 to 1·8) 1·4 (1·1 to 1·8) –1·1% (−10·7 to 8·9) 2076·1 (1604·1 to 2619·0) 3505·5 (2755·4 to 4412·3) 68·9% (52·9 to 86·0) * 39·3 (30·4 to 49·7) 38·8 (30·6 to 48·9) –1·2% (−11·1 to 9·6) Total cancers excluding non-melanoma skin cancer 6972·7 (6588·6 to 7250·5) 10 379·5 (9553·2 to 10 971·7) 48·7% (40·8 to 57·3) * 141·8 (133·8 to 147·8) 114·9 (105·7 to 121·3) –19·0% (−22·9 to −14·6) * 194 470·7 (185 196·6 to 201 427·7) 263 224·6 (248 820·8 to 276 246·5) 35·3% (29·2 to 43·4) * 3683·1 (3505·6 to 3817·3) 2936·6 (2777·0 to 3078·5) –20·3% (−23·8 to −15·5) * Values in parentheses are 95% uncertainty intervals. G6PD=glucose-6-phosphate dehydrogenase. NASH=non-alcoholic steatohepatitis. YLLs=years of life lost. * Statistically significant percentage changes. Global death and YLL numbers, age-standardised rates per 100 000, and percentage change between 2000 and 2023 for all sexes combined for all GBD causes and Levels 1–4 of the cause hierarchy Values in parentheses are 95% uncertainty intervals. G6PD=glucose-6-phosphate dehydrogenase. NASH=non-alcoholic steatohepatitis. YLLs=years of life lost. Statistically significant percentage changes. Figure 1 shows the global rankings of the leading Level 3 causes of age-standardised mortality rates over the period studied. From 1990 to 2023, ischaemic heart disease and stroke consistently ranked as the first and second leading causes, respectively—except in 2021, when COVID-19 temporarily ranked as the leading cause of age-standardised deaths. In 2021, the rankings of the leading five Level 3 causes, in descending order, were COVID-19, ischaemic heart disease, stroke, chronic obstructive pulmonary disease (COPD), and lower respiratory infections. In 2023, COVID-19 dropped to the 20th leading cause of death, with ischaemic heart disease, stroke, COPD, lower respiratory infections, and neonatal disorders ranking as the leading five causes. Although the rankings of the leading two causes of death in 2023, ischaemic heart disease and stroke, were the same as they were in 1990, the age-standardised mortality rates for each have decreased: ischaemic heart disease decreased from 161·4 deaths (95% UI 146·9–172·6) per 100 000 population in 1990, to 99·8 deaths (89·9–108·4) per 100 000 in 2023; while stroke declined from 157·2 deaths (141·1–171·3) per 100 000 in 1990 to 75·9 deaths (67·8–83·5) per 100 000 in 2023. Other notable shifts in the rankings of leading causes of death have occurred over the past three decades. Four causes showed declines in age-standardised mortality rates between 1990 and 2023: diarrhoeal diseases (67·4 deaths [55·6–85·5] per 100 000 in 1990 to 14·2 deaths [10·6–19·2] per 100 000 in 2023), tuberculosis (42·6 deaths [32·4–54·2] per 100 000 in 1990 to 11·6 deaths [9·2–14·4] per 100 000 in 2023), stomach cancer (23·3 deaths [20·6–26·5] per 100 000 in 1990 to 10·3 deaths [8·8–11·9] per 100 000 in 2023), and measles (18·1 deaths [7·8–30·4] per 100 000 in 1990 to 2·2 deaths [0·9–3·9] per 100 000 in 2023). By contrast, some causes exhibited an increase in age-standardised mortality rates between 1990 and 2023, such as diabetes, chronic kidney disease, Alzheimer's disease and other dementias, and HIV/AIDS. Figure 1 Leading Level 3 causes of global deaths and age-standardised mortality rate per 100 000 population for all sexes combined, 1990, 2019, 2021, and 2023 The 20 leading causes of death are shown in descending order. Causes are connected by lines between time periods; solid lines represent an increase or lateral shift in rank and dashed lines represent decreases in rank. Alzheimer's disease=Alzheimer's disease and other dementias. Cirrhosis=cirrhosis and other chronic liver diseases. COPD=chronic obstructive pulmonary disease. Lung cancer=tracheal, bronchus, and lung cancer. Leading Level 3 causes of global deaths and age-standardised mortality rate per 100 000 population for all sexes combined, 1990, 2019, 2021, and 2023 The 20 leading causes of death are shown in descending order. Causes are connected by lines between time periods; solid lines represent an increase or lateral shift in rank and dashed lines represent decreases in rank. Alzheimer's disease=Alzheimer's disease and other dementias. Cirrhosis=cirrhosis and other chronic liver diseases. COPD=chronic obstructive pulmonary disease. Lung cancer=tracheal, bronchus, and lung cancer. The percentage change among leading Level 3 causes of death varied over the study period between females and males at the global level ( figure 2 ). The age-standardised mortality rates for HIV/AIDS, urinary diseases, chronic kidney disease, and COPD increased more among females than males. Likewise, those for falls, asthma, and hypertensive heart disease decreased more among males than females. Deaths from conflict and terrorism were particularly disparate by sex and location ( appendix 2 table S18). Between 1995 and 2023, 51·3% (95% UI 45·9–53·9) of female deaths due to conflict and terrorism occurred in north Africa and the Middle East, despite only 7·2% of the global female population residing in this region. Eastern Europe contributed 7·5% (6·3–8·3) of female deaths from this cause, despite having only 3·4% of the global female population. Over the same time period, 52·0% (46·3–54·7) of male deaths due to conflict and terrorism occurred in north Africa and the Middle East, which accounts for only 7·7% of the global male population, and 8·0% (6·6–9·1) in eastern Europe, with only 2·9% of the global male population ( appendix 2 table S18). In 2023, Palestine had the highest age-standardised mortality rate due to conflict and terrorism of any country in the world (385·8 deaths [351·3–424·1] per 100 000 population), more than five times that of the second-leading country, Ukraine (70·1 deaths [67·2–73·2] per 100 000). Sudan ranks as the third highest country in terms of age-standardised mortality rates for conflict and terrorism, while Russia and Burkina Faso follow as the fourth and fifth leading countries, in 2023 ( appendix 2 table S7). Figure 2 Percentage change in global age-standardised mortality rate from 1990 to 2023 among the leading 30 Level 3 causes of death, for males and females Figure shows the top 30 causes according to their global age-standardised mortality rate, sorted by percentage change from 1990 to 2023 in females, in descending order. COVID-19 and causes affecting only one sex (ie, cervical cancer) were omitted. Percentage change in global age-standardised mortality rate from 1990 to 2023 among the leading 30 Level 3 causes of death, for males and females Figure shows the top 30 causes according to their global age-standardised mortality rate, sorted by percentage change from 1990 to 2023 in females, in descending order. COVID-19 and causes affecting only one sex (ie, cervical cancer) were omitted. Over the study period, neonatal disorders remained the leading Level 3 cause of global YLLs, despite a decrease in age-standardised YLL rates, from 4487·8 YLLs (95% UI 4212·3–4761·6) per 100 000 population in 1990 to 2398·9 YLLs (2219·7–2575·4) per 100 000 in 2023, representing a decrease of 46·5% (–51·2 to –41·6; appendix 2 table S13). In 2021, however, COVID-19 temporarily surpassed neonatal disorders as the leading cause of global age-standardised YLLs, before dropping to the 25th position in 2023 ( appendix figure S2). Since the year 2000, there has been a reduction of 37·6% (32·6–42·6) in total YLLs due to neonatal disorders, from 235 000 in 2000 to 146 000 in 2023 ( table 1 ). In 1990, the total YLLs for vaccine-preventable diseases—including diphtheria, pertussis, tetanus, measles, varicella and herpes zoster, yellow fever, rabies, liver cancer due to hepatitis B, cervical cancer, chronic hepatitis B with cirrhosis, and acute hepatitis B—amounted to a sum of 178 million (95% UI 122–239) years ( appendix 2 table S4). By 2023, this number had decreased by 66·5% (57·4–71·9) to 59·8 million (49·6–72·1) years. Similarly, for other preventable diseases that went through major international cooperation and large-scale interventions between 1990 and 2023, total YLLs also showed a decline. In 1990, total YLLs for these diseases were 1·07 billion (1·01–1·12) years; by 2023, they had decreased by 51·6% (48·8–54·4) to 516 million (488–543) years ( appendix 2 table S4). Between 2020 and 2023, COVID-19 had an immense global impact, resulting in 18·0 million (95% UI 17·2–18·7) total deaths ( appendix 2 table S5). Among these, 10·5 million (10·1–10·9) deaths were in males, and 7·53 million (6·98–7·96) deaths were in females. During 2020, the first year of the pandemic, there were 5·47 million (5·22–5·65) COVID-19 deaths. The highest number of COVID-19 deaths was recorded in 2021 (9·42 million [9·04–9·70] deaths) followed by 2·36 million (2·19–2·47) deaths in 2022, and the lowest number of deaths occurred in 2023 (797 000 deaths [723 000–857 000]). The age group most affected by COVID-19 varied over the years: the highest numbers of deaths occurred in the 70–74 years age group in 2020 and 2021, but in the 80–84 years age group in 2022, and in the 85–89 years age group in 2023 ( appendix 2 figure S3). From 2020 to 2023, the five countries with the highest numbers of total COVID-19 deaths (in descending order) were India (3·08 million [2·92–3·28] deaths), the USA (1·21 million [1·10–1·27] deaths), Russia (1·06 million [1·00–1·09] deaths), Indonesia (849 000 deaths [780 000–920 000]), and Brazil (795 000 deaths [748 000–821 000]; appendix 2 table S5). In mortality rates, the countries with the highest burden (in descending order) were Tunisia (245·4 deaths [227·9–256·9] per 100 000), Bolivia (229·0 deaths [215·5–241·4] per 100 000), Peru (220·6 deaths [213·4–228·5] per 100 000), Montenegro (215·2 deaths [197·9–229·3] per 100 000), and Moldova (207·3 deaths [199·4–212·7] per 100 000; appendix 2 table S5). Globally, between 2000 and 2023, all 5-year age groups from 10 years to 70 years showed decreases in age-specific mortality rates, ranging from –27·1% to –35·0% ( table 2 ; appendix 2 table S19). However, this trend varied by country, region, sex, and cause of death. Among the 21 GBD regions, only four—high-income Asia Pacific, central Asia, east Asia, and south AsiA&Mdash;consistently showed decreases in death rates across all 5-year age groups by sex and Level 1 causes from 2000 to 2023. By contrast, the Caribbean region showed increases in death rates for 40 distinct Level 1 cause-sex-age groups; the largest of these increases was observed in females aged 30–34 years, in whom deaths from NCDs increased by 52·6%, and in females aged 25–29 years, in whom NCD deaths rose by 48·9%. Similarly, in high-income North America, there was an increase in death rates across 37 distinct Level 1 cause-sex-age groups. The most notable rise was in males aged 25–29 years, where NCD-related deaths rose by 130·5%, while injury-related deaths increased by 26·4% in males aged 60–64 years. Globally, we found the increase in NCD deaths was primarily due to drug use disorders, while the rise in injury-related deaths was linked to intentional injuries. Other notable injury-related increases around the globe include the conflicts in Palestine and Ukraine, as well as specific natural disasters such as the 2023 earthquake in Türkiye and the 2022–23 heatwaves in Europe ( appendix 2 table S19). Table 2 Percentage change in age-specific mortality rate between 2000 and 2023 for Level 1 causes Age 10–14 years Age 15–19 years Age 20–24 years Age 25–29 years Age 30–34 years Age 35–39 years Age 40–44 years Age 45–49 years Age 50–54 years Age 55–59 years Age 60–64 years Age 65–69 years Communicable, maternal, neonatal, and nutritional diseases Caribbean Male −32·0% −22·6% −33·9% −46·5% −50·7% −53·6% −53·5% −49·7% −39·8% −32·1% −29·3% −26·5% Female −23·6% −16·3% −24·6% −38·1% −36·2% −35·2% −38·5% −36·6% −37·9% −35·7% −33·2% −26·8% High-income North America Male −11·1% −22·5% −20·9% −38·1% −54·0% −62·6% −56·2% −46·4% −16·2% 13·8% 33·1% 37·1% Female −23·7% −21·6% −18·5% −20·0% −24·4% −26·6% −23·8% −12·4% 23·1% 34·1% 44·1% 47·7% Central sub-Saharan Africa Male −59·9% −66·8% −67·2% −65·6% −64·5% −61·5% −61·0% −57·0% −53·6% −52·5% −50·0% −49·2% Female −56·6% −52·3% −56·3% −60·4% −61·1% −59·9% −56·3% −53·0% −52·2% −52·3% −49·8% −47·5% Oceania Male −34·2% −30·9% −18·5% −18·6% −20·0% −16·9% −16·4% −15·9% −19·1% −19·2% −26·2% −26·1% Female −32·1% −27·4% −13·1% −5·1% −0·7% −4·8% −7·9% −10·8% −11·7% −10·2% −15·2% −12·9% Western sub-Saharan Africa Male −48·0% −43·3% −46·4% −53·9% −59·6% −59·0% −57·3% −54·2% −50·6% −48·9% −46·6% −46·8% Female −44·8% −48·6% −56·7% −58·2% −56·6% −53·7% −51·6% −48·6% −48·9% −48·4% −49·7% −48·1% Southern sub-Saharan Africa Male −9·0% 37·4% −42·0% −72·8% −75·8% −73·9% −63·8% −58·0% −50·0% −42·7% −41·7% −40·5% Female −16·9% −37·9% −71·6% −81·3% −75·6% −68·3% −55·9% −52·4% −51·9% −51·2% −46·5% −39·2% Southern Latin America Male −19·0% −6·0% −17·0% −42·1% −49·4% −26·0% −5·2% 16·8% 46·7% 49·7% 53·9% 59·5% Female −20·8% −13·5% −17·5% −25·0% −21·5% −1·6% 28·6% 47·0% 67·2% 83·6% 96·7% 110·6% Tropical Latin America Male −20·8% −8·7% −10·6% −27·0% −42·0% −40·7% −33·5% −26·7% −17·7% −10·4% −4·7% 6·8% Female −28·0% −21·0% −24·1% −32·7% −37·1% −28·2% −20·8% −15·3% −10·9% −11·6% −7·6% 6·1% Eastern sub-Saharan Africa Male −63·2% −61·4% −61·9% −71·3% −76·1% −78·4% −76·1% −71·7% −63·4% −59·5% −57·1% −57·9% Female −64·5% −64·6% −72·2% −78·8% −79·0% −78·6% −73·3% −68·3% −62·8% −60·7% −59·2% −57·8% North Africa and Middle East Male −52·1% −30·7% −27·9% −35·2% −37·5% −41·1% −43·0% −46·0% −44·5% −39·1% −39·7% −27·7% Female −55·9% −41·5% −44·4% −45·0% −44·3% −46·1% −43·8% −38·3% −39·4% −36·3% −36·9% −22·8% Eastern Europe Male −40·5% −57·4% −78·1% −62·0% −35·7% −30·7% −36·1% −50·2% −59·0% −56·0% −47·0% −21·4% Female −33·3% −41·3% −44·9% −2·3% 35·7% 45·0% 44·2% 14·7% −3·6% −6·1% 20·0% 53·1% Central Latin America Male −33·7% −22·7% −30·0% −31·5% −30·5% −28·8% −20·9% −15·9% −11·2% −8·7% −11·6% −13·2% Female −35·2% −26·8% −28·7% −27·7% −22·1% −23·0% −18·1% −11·6% −15·4% −10·7% −13·6% −15·8% Central Europe Male −67·2% −17·0% −6·0% −13·4% −19·1% −18·1% −27·3% −18·5% 4·4% 14·0% 36·9% 63·4% Female −63·5% −26·0% −24·9% −22·4% −25·8% −19·1% −16·2% −7·4% 19·7% 28·8% 51·8% 64·7% Western Europe Male −46·9% −51·5% −56·4% −68·3% −73·7% −74·3% −63·3% −46·0% −30·3% −21·1% −10·7% −11·7% Female −43·6% −49·9% −42·2% −52·3% −57·0% −55·5% −44·9% −34·5% −23·7% −18·3% −9·8% −9·7% Southeast Asia Male −50·6% −47·0% −43·6% −54·7% −58·0% −51·3% −42·9% −36·0% −38·5% −37·7% −40·2% −36·3% Female −49·9% −52·5% −50·6% −53·1% −51·4% −44·0% −45·7% −41·5% −43·1% −42·4% −45·9% −41·1% Andean Latin America Male −39·1% −39·2% −39·2% −40·5% −40·0% −35·9% −29·6% −25·3% −18·9% −3·7% −3·7% −1·3% Female −36·7% −47·2% −46·4% −46·7% −45·6% −42·1% −36·7% −30·9% −28·6% −18·4% −19·9% −14·4% Australasia Male −29·1% −50·8% −44·1% −66·6% −62·6% −66·8% −57·2% −46·0% −35·1% −30·4% −29·9% −29·7% Female −42·0% −50·7% −38·6% −45·4% −49·7% −40·4% −21·0% −17·5% −17·0% −15·1% −21·3% −27·1% South Asia Male −74·2% −71·2% −71·8% −73·1% −70·3% −70·2% −65·8% −68·1% −68·4% −65·7% −68·1% −69·1% Female −70·6% −75·6% −76·2% −74·3% −71·0% −70·6% −67·7% −65·3% −67·5% −59·9% −67·3% −67·6% High-income Asia Pacific Male −54·1% −59·7% −50·2% −49·5% −58·8% −64·0% −64·0% −57·1% −46·3% −45·3% −38·0% −39·2% Female −57·1% −52·2% −45·3% −51·3% −58·3% −49·4% −49·3% −47·2% −44·0% −47·1% −46·4% −49·9% East Asia Male −60·6% −56·6% −38·2% −22·9% −24·3% −24·0% −24·2% −24·4% −30·2% −40·6% −45·2% −42·4% Female −69·8% −71·9% −72·5% −69·7% −67·5% −56·1% −46·4% −38·3% −43·4% −51·8% −52·8% −46·9% Central Asia Male −48·9% −57·3% −75·4% −79·2% −75·0% −66·7% −61·7% −60·5% −60·1% −50·1% −39·9% −19·0% Female −48·5% −53·6% −65·4% −68·0% −62·3% −53·8% −50·6% −47·2% −47·2% −39·8% −23·1% −7·5% Non-communicable diseases Caribbean Male −4·4% 2·1% 3·1% 14·9% 17·8% 19·3% 17·8% 9·8% 2·7% 5·1% 3·5% 3·7% Female 13·0% 8·0% 17·4% 48·9% 52·6% 44·6% 27·5% 13·1% 2·5% 4·1% −0·9% −1·9% High-income North America Male −9·7% 29·5% 79·3% 130·5% 122·5% 70·4% 24·1% −3·6% −9·2% −14·0% −18·7% −26·4% Female −9·5% 16·3% 50·5% 67·0% 63·3% 30·4% 10·9% −2·7% −8·8% −15·1% −18·9% −26·0% Central sub-Saharan Africa Male −13·9% −30·2% −31·7% −28·2% −15·7% 14·5% 9·4% 1·5% 0·2% −1·7% 5·6% 8·8% Female −4·7% −6·6% −9·5% 30·0% 56·5% 81·1% 71·3% 68·9% 49·2% 26·2% 10·2% 7·3% Oceania Male −12·8% −18·5% −1·1% 16·1% 10·0% 3·3% −4·3% −11·1% −8·6% −8·5% −10·9% −12·2% Female −13·4% −17·7% 0·9% 28·0% 46·9% 31·2% 14·8% 5·9% 4·1% 3·0% −1·8% −1·2% Western sub-Saharan Africa Male −18·3% −19·6% −22·3% −19·7% −11·2% 11·4% 5·3% −6·2% −8·0% −10·5% −4·2% −1·3% Female −23·0% −24·9% −30·5% 1·2% 16·3% 38·2% 24·3% 28·2% 18·8% 4·1% −5·0% −7·3% Southern sub-Saharan Africa Male −15·6% −27·8% −26·1% −21·2% −16·4% −2·7% 0·0% −19·1% −32·2% −24·0% −19·3% −9·7% Female −21·8% −13·5% −5·1% 8·9% 23·9% 44·8% 54·1% 56·5% 27·4% 9·5% −8·3% −7·5% Southern Latin America Male −23·9% −14·4% −6·9% −10·1% −20·6% −22·1% −30·1% −36·3% −37·3% −35·7% −31·5% −29·7% Female −23·5% −12·4% −9·6% −8·8% −13·8% −11·7% −19·8% −26·1% −28·9% −26·0% −21·9% −21·3% Tropical Latin America Male 1·3% 12·9% 14·0% −0·3% −15·8% −24·2% −30·4% −30·1% −27·5% −26·7% −25·6% −23·2% Female 0·4% 2·9% 7·0% 3·2% −6·9% −16·0% −23·3% −26·5% −27·7% −28·2% −28·5% −25·8% Eastern sub-Saharan Africa Male −20·1% −26·8% −30·6% −24·9% −17·1% 2·4% −2·3% −5·3% −8·7% −6·7% −0·3% 0·7% Female −27·9% −32·0% −30·5% −0·4% 12·6% 22·5% 18·3% 35·1% 23·6% 12·2% 1·1% 0·2% North Africa and Middle East Male −28·3% −16·5% −7·0% −5·6% −12·2% −26·4% −34·5% −37·9% −35·7% −25·4% −25·4% −21·5% Female −33·7% −25·8% −11·9% −6·2% −2·7% −12·0% −19·4% −22·6% −29·6% −21·1% −27·4% −23·9% Eastern Europe Male −28·8% −39·7% −62·2% −49·1% −30·6% −28·6% −35·6% −40·2% −39·1% −38·0% −38·8% −35·5% Female −32·2% −37·8% −39·7% −26·8% −16·5% −18·7% −25·8% −36·0% −39·1% −40·8% −42·0% −43·0% Central Latin America Male 0·0% 7·6% 5·4% 5·5% 3·7% −2·6% −3·6% −3·3% −3·2% −6·6% −8·1% −11·2% Female 2·9% 1·5% −0·5% −1·4% 3·5% −1·6% −4·9% −9·0% −13·2% −16·1% −18·8% −20·5% Central Europe Male −45·4% −31·8% −23·1% −19·1% −20·2% −29·2% −43·0% −45·8% −39·8% −34·2% −30·0% −28·2% Female −30·7% −25·4% −22·4% −22·0% −22·4% −31·0% −41·1% −43·4% −38·9% −34·0% −29·5% −33·6% Western Europe Male −30·0% −33·7% −31·5% −29·4% −24·1% −24·4% −34·3% −40·1% −34·4% −32·9% −31·2% −32·3% Female −20·4% −22·0% −19·0% −21·8% −18·6% −24·4% −31·2% −32·8% −26·9% −23·8% −19·2% −21·3% Southeast Asia Male −23·7% −22·7% −13·8% −6·8% −10·5% −9·3% −3·6% 3·4% −0·8% −5·8% −13·1% −16·7% Female −14·3% −10·2% −5·1% 0·1% 7·4% 9·3% 8·1% 4·9% 1·4% −0·9% −8·2% −13·3% Andean Latin America Male −6·5% −5·1% −11·0% −5·8% −10·2% −13·1% −14·2% −18·4% −16·9% −12·8% −14·6% −13·9% Female 14·0% −5·6% −7·0% −5·2% −3·2% −5·8% −11·2% −15·3% −16·9% −14·5% −19·7% −16·0% Australasia Male −35·5% −43·8% −42·7% −46·5% −32·2% −23·6% −20·9% −19·1% −22·7% −28·7% −34·7% −42·5% Female −33·4% −40·1% −32·6% −35·6% −33·2% −25·2% −24·1% −20·8% −22·3% −27·5% −31·6% −36·0% South Asia Male −39·5% −47·3% −44·6% −41·5% −33·4% −27·3% −17·6% −17·8% −17·9% −9·5% −15·4% −16·2% Female −39·7% −44·6% −35·1% −26·9% −11·7% −10·6% −10·0% −13·1% −7·1% −0·2% −9·4% −7·5% High-income Asia Pacific Male −32·9% −35·2% −33·1% −37·3% −45·0% −50·2% −52·1% −44·7% −41·9% −41·9% −38·0% −33·7% Female −28·0% −25·4% −23·4% −30·9% −37·0% −30·6% −31·2% −26·8% −32·8% −35·9% −35·8% −36·4% East Asia Male −47·6% −49·4% −57·8% −54·2% −52·2% −46·1% −43·1% −38·0% −37·9% −45·0% −44·1% −47·8% Female −49·5% −58·1% −65·5% −66·7% −64·4% −61·2% −59·1% −55·9% −55·6% −60·5% −59·4% −57·8% Central Asia Male −19·6% −32·9% −46·0% −50·4% −44·6% −37·5% −36·3% −38·7% −42·5% −33·6% −33·4% −30·8% Female −16·0% −24·9% −38·2% −41·4% −36·0% −31·8% −34·5% −39·1% −44·0% −40·3% −39·4% −35·8% Injuries Caribbean Male −5·2% 31·0% 26·4% 35·3% 36·8% 38·1% 34·5% 27·0% 13·1% 14·9% 10·9% 9·1% Female 10·1% 11·6% 24·2% 45·7% 42·4% 33·4% 20·0% 9·3% −3·6% −0·9% −3·4% −6·9% High-income North America Male −23·3% −21·9% −19·2% 1·6% 20·0% 12·8% 8·9% 2·1% 13·1% 18·9% 26·4% 19·8% Female −18·9% −31·0% −7·5% 6·3% 14·6% 0·6% 1·7% 1·6% 11·4% 11·5% 13·1% 10·5% Central sub-Saharan Africa Male −4·9% −23·1% −23·2% −15·9% 2·8% 39·5% 32·2% 18·1% 13·1% 7·7% 13·8% 15·1% Female 2·3% 5·1% 4·3% 51·8% 66·9% 83·8% 75·3% 73·4% 57·2% 36·2% 21·3% 23·8% Oceania Male −19·8% −24·8% −6·3% 8·5% 1·0% −3·9% −9·3% −13·1% −9·1% −8·4% −10·4% −11·7% Female −12·6% −15·9% 9·4% 30·6% 45·8% 29·9% 18·9% 10·1% 13·4% 11·0% 9·5% 10·7% Western sub-Saharan Africa Male −19·2% −19·4% −23·4% −21·6% −12·9% 17·6% 8·6% −4·9% −8·0% −11·8% −1·4% −1·5% Female −27·6% −33·0% −30·2% −1·7% 7·1% 22·6% 10·8% 14·6% 6·3% −5·0% −15·1% −11·6% Southern sub-Saharan Africa Male −38·2% −37·0% −26·2% −20·4% −16·5% −5·2% −6·7% −25·6% −38·5% −32·9% −30·1% −23·6% Female −42·4% −16·7% −11·0% −2·2% 0·4% 10·5% 15·8% 17·3% 1·8% −14·0% −27·1% −25·7% Southern Latin America Male −53·0% −31·2% −22·0% −21·1% −24·3% −25·9% −30·6% −36·1% −38·0% −38·9% −37·6% −35·3% Female −45·7% −26·3% −15·1% −15·0% −22·8% −24·4% −28·8% −30·9% −35·7% −33·5% −32·8% −31·4% Tropical Latin America Male −47·2% −14·1% −6·2% −6·5% −11·5% −14·8% −17·7% −17·1% −13·3% −12·5% −11·7% −5·6% Female −38·7% −14·9% 2·8% 5·2% −1·9% −8·4% −10·3% −11·8% −12·6% −15·3% −14·2% −7·5% Eastern sub-Saharan Africa Male −27·8% −63·3% −55·1% −35·1% −24·8% −4·8% −7·1% −14·7% −17·3% −22·4% −11·0% −2·3% Female −47·2% −49·0% −50·0% −20·7% −17·5% −10·8% −8·2% 1·4% −2·5% −4·2% −12·1% −8·1% North Africa and Middle East Male −9·1% −0·1% 15·1% −5·7% −14·0% −25·6% −32·7% −33·6% −30·9% −20·7% −30·3% −14·6% Female 30·4% 24·2% 55·2% 45·4% 50·3% 13·2% −2·4% −8·4% −5·7% 26·5% −3·1% 64·6% Eastern Europe Male −48·7% 9·2% −2·3% −11·4% −21·6% −38·0% −44·4% −50·7% −55·5% −53·9% −49·7% −44·0% Female 1·1% −30·6% −37·0% −45·1% −47·6% −50·4% −49·8% −52·0% −54·8% −56·0% −51·3% −46·6% Central Latin America Male −35·2% −24·5% −21·5% −13·7% −7·8% −12·1% −15·1% −21·0% −24·7% −29·3% −31·7% −32·6% Female −19·9% −12·2% −4·6% −0·5% 3·4% −6·7% −12·4% −20·5% −27·6% −30·2% −33·2% −35·3% Central Europe Male −64·9% −51·2% −45·5% −41·2% −38·6% −40·4% −43·9% −41·6% −30·1% −23·7% −15·3% −15·8% Female −52·9% −43·3% −43·0% −40·2% −38·1% −42·7% −46·5% −43·0% −32·6% −29·9% −28·4% −30·7% Western Europe Male −57·2% −51·2% −47·6% −41·5% −31·8% −23·0% −16·7% −8·0% 8·4% 13·5% 13·9% 5·7% Female −51·4% −49·7% −38·7% −34·5% −29·0% −28·3% −24·0% −16·0% −4·1% 1·1% 3·4% 0·4% Southeast Asia Male −43·0% −36·2% −35·1% −34·7% −32·6% −27·6% −20·1% −14·0% −11·1% −11·9% −17·2% −19·4% Female −39·2% −27·6% −22·5% −21·9% −15·2% −14·3% −12·8% −17·6% −9·7% −9·3% −15·3% −21·1% Andean Latin America Male −30·6% −12·1% 1·6% 11·2% 1·4% −6·2% −11·7% −19·4% −20·2% −17·0% −20·6% −20·9% Female −2·4% −4·2% 0·5% 4·8% 0·5% −6·7% −12·7% −20·8% −26·0% −23·1% −26·5% −22·8% Australasia Male −51·4% −53·3% −46·9% −48·2% −40·4% −36·8% −26·1% −8·8% −3·8% 2·2% −1·4% −8·3% Female −47·0% −45·1% −29·2% −34·3% −35·7% −30·4% −24·2% −9·5% −6·9% −13·0% −21·8% −25·2% South Asia Male −46·2% −42·2% −33·0% −24·3% −15·7% −12·0% −4·2% −13·4% −17·4% −16·2% −23·3% −28·4% Female −47·3% −48·5% −46·3% −36·4% −28·3% −24·4% −19·4% −22·7% −23·8% −16·9% −26·8% −25·7% High-income Asia Pacific Male −51·6% −48·3% −35·5% −32·5% −38·9% −40·3% −41·2% −39·8% −41·1% −44·7% −37·9% −33·9% Female −35·5% −13·8% −1·8% −6·1% −17·1% −14·4% −16·0% −14·5% −26·3% −37·6% −43·3% −44·3% East Asia Male −67·3% −68·8% −73·6% −70·7% −70·5% −67·4% −63·0% −54·2% −50·1% −54·0% −51·2% −51·3% Female −66·1% −71·2% −78·3% −79·7% −78·6% −75·6% −71·5% −66·3% −63·8% −64·9% −61·4% −60·6% Central Asia Male −36·8% −39·4% −50·7% −54·3% −52·2% −49·8% −46·8% −45·2% −52·5% −44·3% −43·1% −33·3% Female −34·1% −19·6% −40·4% −49·3% −48·6% −47·7% −47·4% −51·6% −57·6% −53·0% −52·8% −44·8% Regions are ordered by the total number of cause-age combinations that showed an increase across all three Level 1 causes. Percentage change in age-specific mortality rate between 2000 and 2023 for Level 1 causes Regions are ordered by the total number of cause-age combinations that showed an increase across all three Level 1 causes. The mean age at death for all causes varied by sex and location ( appendix 2 tables S15, S16, S17). The global mean age at death increased from 46·8 years (95% UI 46·6–47·0) in 1990 to 63·4 years (63·1–63·7) in 2023, for all sexes combined. For males, the mean age at death in 1990 was 45·4 years (45·1–45·7) and increased to 61·2 years (60·7–61·6) in 2023. For females, it was 48·5 years (48·1–48·8) in 1990 and 65·9 years (65·5–66·3) in 2023. The highest mean age at death observed in 2023 was found in the high-income super-region. Within this super-region, mean age at death for females reached 80·9 years (80·9–81·0), and was even higher in the high-income Asia Pacific region (85·1 years [85·1–85·2]), with Japan having the highest mean among all countries globally (86·0 years [86·0–86·1]). For males in the high-income super-region, the mean age at death was 74·8 years (74·8–74·9). In high-income Asia-Pacific, it was 78·6 years (78·5–78·6), and Japan also recorded the highest male mean age at death at 79·8 years (79·8–79·8). At the other end of the spectrum, the lowest mean age at death in 2023 occurred in sub-Saharan Africa, where females had a mean age at death of 38·0 years (95% UI 37·5–38·4; appendix 2 table S16). For males, it was 35·6 years (35·2–35·9; appendix 2 table S17). Within this super-region, western sub-Saharan Africa had a mean age at death of 33·2 years (32·5–34·0) for females and 31·9 years (31·2–32·6) for males. Niger recorded the lowest mean age at death, with 21·5 years (20·3–22·8) for females and 21·8 years (20·6–23·2) for males. In 2023, the gap between the observed and the expected mean age at death varied across causes, locations, and sexes ( figure 3 ; appendix 2 figure S4, appendix 2 table S6). For the global leading cause of death, ischaemic heart disease, females in Switzerland died at the highest mean age of 88·4 years (95% UI 87·8–88·8), which is 6·8 years (6·1–7·5) higher than the expected age of 81·6 (80·7–82·4). By contrast, females in South Sudan died from the same cause at the lowest mean age of 61·2 years (58·9–63·5), which is 7·3 years (4·8–10·1) below the expected age of 68·5 years (67·1–70·2). For tracheal, bronchus, and lung cancer—the sixth-leading cause of death—females in Japan died at the highest mean age of 82·8 years (81·3–83·5), which is 4·2 years (3·6–4·6) later than the expected age of 78·6 (77·4–79·4). However, in Malawi, females died from this cause at the lowest mean age of 55·6 years (53·9–57·9), which is 12·8 years (10·4–14·6) earlier than the expected age of 68·4 (67·2–69·3). For the ninth-leading cause of death, chronic kidney disease, females in Spain died at the second highest mean age of 89·4 years (89·0–89·7), 9·8 years (8·8–11·1) later than the expected age of 79·6 (78·0–80·8). Meanwhile, in Angola, the same cause resulted in a mean age at death of just 46·1 years (42·9–50·3), which is 12·5 years (9·2–15·6) earlier than the expected age of 58·6 (56·1–61·2). Figure 3 Comparison of age at death for ischaemic heart disease between four regions for males and females Graphs show the distribution of ischaemic heart disease deaths by age and sex within each region. Percentages represent the number of ischaemic heart disease deaths for a given age-sex group out of the total ischaemic heart disease deaths within a region (all ages and sexes combined), or the total number of individuals in a given age-sex group out of the total population in the region. The expected mean age at death is the result of calculating the mean age at death after applying the global mortality rate to a country's population by age and sex for a given cause; a positive difference indicates that the observed mean age at death is higher than expected. Comparison of age at death for ischaemic heart disease between four regions for males and females Graphs show the distribution of ischaemic heart disease deaths by age and sex within each region. Percentages represent the number of ischaemic heart disease deaths for a given age-sex group out of the total ischaemic heart disease deaths within a region (all ages and sexes combined), or the total number of individuals in a given age-sex group out of the total population in the region. The expected mean age at death is the result of calculating the mean age at death after applying the global mortality rate to a country's population by age and sex for a given cause; a positive difference indicates that the observed mean age at death is higher than expected. The observed mean age at death in 2023 shows a moderate relationship ( r 2 ≥0·50) with SDI across 96 of 141 Level 3 causes of death ( appendix 2 table S14). Where SDI explains greater than 50% of the variance seen in the mean age at death, the relationship is positive: as SDI improves, the observed mean age at death increases. After controlling for any relationship SDI has with population structure by comparing observed and expected mean ages and examining their correlation with SDI, the results remain varied by sex. When comparing observed and expected mean ages for females, a total of 118 causes show a positive correlation with SDI ( appendix 2 table S14). Some causes, such as self-harm, exhibit a negative correlation—meaning that females in higher SDI countries died at younger ages than expected from self-harm compared to those in lower SDI countries. All of the causes that had a negative correlation with SDI were considered weak relationships ( r 2 <0·50). For females, the difference between the observed and expected mean age at death in the following nine Level 3 causes showed a moderate positive correlation with SDI: ischaemic heart disease, stroke, breast cancer, pancreatic cancer, leukaemia, brain and central nervous system cancer, ovarian cancer, kidney cancer, and invasive non-typhoidal Salmonella . When comparing observed and expected mean ages for males, a total of 110 causes show a positive correlation with SDI ( appendix 2 table S14). Similar causes, such as drug use disorders, self-harm, and conflict and terrorism exhibited a negative correlation—indicating that males in higher SDI countries died at younger ages than expected from these causes compared to those in lower SDI countries. All negatively correlated causes were found to have weak relationships with SDI just as females did. For males, the difference between the observed and expected mean age at death in only six Level 3 causes showed a moderate correlation with SDI. These were leukaemia, brain and central nervous system cancer, other malignant neoplasms, other intestinal infectious diseases, kidney cancer, and invasive non-typhoidal Salmonella . Across every GBD super-region and region, 70q0 from all causes combined decreased for both males and females between 2000 and 2023 ( appendix 2 table S11). However, there was variation in these percentage changes between regions. For males, 70q0 in the Caribbean decreased 2·2%, and in high-income North America it decreased 9·6%. Conversely, in high-income Asia Pacific, this decrease was 36·0%, and in east Asia it was 43·8%. For females, 70q0 in Oceania decreased 2·6% and in the Caribbean 6·0%, while in eastern Europe the decrease was 35·6% and in east Asia it was 58·2%. National-level trends in 70q0 also varied ( figure 4 , appendix 2 table S11). For males, between 2000 and 2023, an increase in 70q0 occurred in six countries: Palestine (40·6%), Lebanon (19·4%), Guam (14·9%), Paraguay (14·6%), Dominican Republic (9·2%), and Venezuela (3·5%). For females, for the same period, 12 countries had an increase in 70q0: Libya (19·6%), Palestine (14·2%), Lebanon (13·7%), Venezuela (12·8%), Tonga (12·0%), Solomon Islands (7·8%), Samoa (6·6%), Guam (4·9%), Marshall Islands (4·7%), Paraguay (4·6%), Dominican Republic (1·2%), and Fiji (0·8%). For males, the primary cause of death driving these increases for Palestine and Lebanon was conflict and terrorism, while in Paraguay and Guam the primary driver was drug use disorders. Among females, the primary cause responsible for the increases remained conflict and terrorism for Palestine and Lebanon. Additionally, chronic kidney diseases contributed the most to the increases in Libya, and malaria the most to the increases in Venezuela ( appendix 2 table S6) Figure 4 70q0 in males and females (A) 2000. (B) 2023. 70q0=probability of death before age 70 years. 70q0 in males and females (A) 2000. (B) 2023. 70q0=probability of death before age 70 years. Among the top 50 global causes of death for females, the 15 causes with the largest amount of increase in 70q0 between 2000 and 2023 were interstitial lung disease and pulmonary sarcoidosis (+74·8% change; 70q0 in 2023 0·1%); drug use disorders (+68·0%; 0·1%); lip and oral cavity cancer (+54·7%; 0·1%); atrial fibrillation and flutter (+52·2%; <0·1%); Alzheimer's disease and other dementias (+46·2%; 0·2%); diabetes (+42·7%; 0·8%); hypertensive heart disease (+40·9%; 0·4%); pancreatic cancer (+37·7%; 0·2%); Parkinson's disease (+36·7%; <0·1%); ovarian cancer (+36·5%; 0·3%); other cardiovascular and circulatory diseases (+35·9%; 0·1%); breast cancer (+33·6%; 1·0%); endocrine, metabolic, blood, and immune disorders (+29·9%; 0·1%); chronic kidney disease (+27·7%; 0·6%); and non-rheumatic valvular heart disease (+26·2%; <0·1%; appendix 2 table S6). Among the top 50 global causes for males, the 15 causes with the largest amount of increase in 70q0 between 2000 and 2023 were diabetes (+75·6% change; 70q0 in 2023 1·0%); drug use disorders (+56·8%; 0·2%); atrial fibrillation and flutter (+51·1%; <0·1%); interstitial lung disease and pulmonary sarcoidosis (+48·2%; 0·1%); Alzheimer's disease and other dementias (+45·9%; 0·1%); Parkinson's disease (+44·4%; 0·1%); endocrine, metabolic, blood, and immune disorders (+41·3%; 0·1%); pancreatic cancer (+34·9%; 0·3%); lip and oral cavity cancer (+29·2%; 0·2%); prostate cancer (+24·7%; 0·2%); non-rheumatic valvular heart disease (+23·9%; <0·1%); chronic kidney disease (+18·6%; 0·7%); colon and rectum cancer (+18·0%; 0·6%); urinary diseases and male infertility (+18·0%; 0·1%); and other cardiovascular and circulatory diseases (+15·1%; 0·1%; appendix 2 table S6). Among the top 50 causes for which a global increase in 70q0 occurred, we observed several notable declines at the super-region level between 2000 and 2023 ( appendix 2 table S6). For example, 70q0 due to drug use disorders increased by 56·8% in males and 68·0% in females globally, yet decreased in southeast Asia, east Asia, and Oceania by 73·9% for males and 81·5% for females. For diabetes, 70q0 increased by 75·6% for males and 42·7% for females globally, but decreased by 9·0% for males and 34·6% for females in the high-income super-region. For ovarian cancer, there was a 36·5% increase in 70q0 in females globally, but a 25·5% decrease in the high-income super-region. For chronic kidney disease, 70q0 increased by 18·6% for males and 27·7% for females globally, but in central Europe, eastern Europe, and central Asia, it decreased by 10·4% for males and 15·3% for females. Alternatively, some causes of death showed increased national 70q0 where there has otherwise been global progress to reduce 70q0. For example, a 47·4% decrease in 70q0 due to lower respiratory infections occurred among males globally, yet there were substantial increases in countries such as Poland (98·8%), Thailand (82·7%), and Argentina (66·0%). Similarly, for females, there was a 51·2% decrease in 70q0 due to lower respiratory infections globally, but notable increases in a number of countries, including Argentina (101·5%), Poland (48·2%), and Thailand (17·1%). Road injuries are another example: a 21·1% decline in 70q0 among males occurred globally, despite increases in many countries, most notably in Sierra Leone (259·8%), Uganda (180·5%), and Malawi (155·0%). For road injuries among females, there was a 20·3% decrease in 70q0 globally, with notable increases in the Democratic Republic of the Congo (158·5%), Sierra Leone (122·1%), and Pakistan (121·7%). Additionally, stroke showed global decreases in 70q0 of 15·6% among males and 20·7% among females, but increases in many countries for males (eg, Rwanda [97·0%], Burundi [85·7%], and Ethiopia [75·6%]) and females (eg, Ethiopia [128·4%], Zimbabwe [106·7%], and South Sudan [106·7%]). From 2000 to 2023, notable variation was observed between sexes when investigating the 70q0 and mean age at death metrics for the top 20 causes of death by super-region (figures 5, 6). For females in sub-Saharan Africa, several of the leading causes showed an increase in 70q0 and a mean age that was lower than expected: ischaemic heart disease (70q0 increased 81·1%, with mean age at death 3·4 years lower than expected); stroke (70q0 increased 51·7%, with mean age at death 2·7 years lower than expected); and breast cancer (70q0 increased 227·9%, with mean age at death 3·8 years lower than expected). There were six additional causes that showed this same pattern. For females in south Asia, 70q0 due to tracheal, bronchus, and lung cancer increased by 192·6%, with a mean age at death 4·3 years lower than expected ( figure 5 ). In addition, ischaemic heart disease, stroke, breast cancer, chronic kidney disease, and colon and rectum cancer also had increasing 70q0 and lower mean age at death compared with expected age in south Asia. In this super-region, there were also five causes that had an increase in 70q0 only (with mean age at death not lower than expected), and five causes had a mean age at death lower than expected without an increased 70q0. In females in the high-income super-region, only COPD showed both increasing 70q0 and lower mean age at death than expected. Chronic kidney disease, diarrhoeal diseases, and hypertensive heart disease had increasing 70q0, but the mean age at death was not lower than expected. In females in southeast Asia, east Asia, and Oceania, there were only two causes among the leading 20 that had an increased 70q0, breast cancer and diabetes, but both of those causes had mean ages at death below the expected values ( figure 5 ). Figure 5 Change in 70q0 between 2000 and 2023 and the observed versus expected mean age at death in 2023 for females The contents of each cell are as follows: percentage change in 70q0 from 2000 to 2023 (70q0 in 2000 to 70q0 in 2023); observed vs expected mean age at death in years. 70q0=probability of death before age 70 years. Change in 70q0 between 2000 and 2023 and the observed versus expected mean age at death in 2023 for females The contents of each cell are as follows: percentage change in 70q0 from 2000 to 2023 (70q0 in 2000 to 70q0 in 2023); observed vs expected mean age at death in years. 70q0=probability of death before age 70 years. In males in sub-Saharan Africa, 11 of the top 20 causes of death showed an increase in 70q0 and a mean age that was lower than expected: ischaemic heart disease; stroke; tracheal, bronchus, and lung cancer; cirrhosis and other chronic liver diseases; diabetes; COPD; chronic kidney disease; stomach cancer; colon and rectum cancer; falls; and hypertensive heart disease ( figure 6 ). Additionally, road injuries, self-harm, interpersonal violence, and congenital birth defects had an increase in 70q0, but the mean age at death was not lower than expected. In males in south Asia, eight of the top 20 causes of death showed an increase in 70q0 and a mean age at death that was lower than expected: ischaemic heart disease, stroke, tracheal, bronchus, and lung cancer, COPD, self-harm, chronic kidney disease, stomach cancer, and colon and rectum cancer. Additionally, road injuries, diabetes, falls, and hypertensive heart disease had an increase in 70q0 only. In males in the high-income super-region, 70q0 due to interpersonal violence decreased slightly but had a mean age at death that was more than 3 years lower than expected. Additionally, 70q0 for chronic kidney disease, diarrhoeal diseases, and hypertensive heart disease also increased. Figure 6 Change in 70q0 between 2000 and 2023 and the observed versus expected mean age at death in 2023 for males The contents of each cell are as follows: percentage change in 70q0 from 2000 to 2023 (70q0 in 2000 to 70q0 in 2023); observed vs expected mean age at death in years. 70q0=probability of death before age 70 years. Change in 70q0 between 2000 and 2023 and the observed versus expected mean age at death in 2023 for males The contents of each cell are as follows: percentage change in 70q0 from 2000 to 2023 (70q0 in 2000 to 70q0 in 2023); observed vs expected mean age at death in years. 70q0=probability of death before age 70 years.

This study offers valuable new insights into global causes of human mortality over the past several decades, building upon and expanding previous iterations of GBD research. In a post-COVID-19-pandemic world, our study highlights several encouraging patterns in global health. Across many leading causes of death, there were declines in overall mortality within the period studied, despite disrupted rankings during the height of the COVID-19 pandemic. The rate of total YLLs have also reduced considerably relative to 1990, and particularly for many of the vaccine-preventable diseases, illustrating successes in reductions to preventable causes of death. Patterns in 70q0 show improvements across the globe, with overall declines observed in every GBD super-region, region, and in most countries. Additionally, the all-cause global mean age at death has been rising, indicating that people are generally dying later in life. While these broad-level improvements show considerable promise—particularly in the aftermath of a pandemic—they sometimes conceal disparities occurring at local levels. Differences by sex, age, and location underscore the complexity of global health progress and the persistent challenges in addressing causes of death. We highlight some of these inequalities below. Over the past three decades, we found large reductions in age-standardised rates of YLLs for four causes—respiratory infections and tuberculosis, nutritional deficiencies, other infectious diseases, and enteric infections—which had individual declines ranging from 58·9% to 79·0%. This achievement was facilitated by many years of sustained international cooperation with local governments. If we expand this scope to include maternal and neonatal disorders, neglected tropical diseases, malaria, HIV/AIDS, and sexually transmitted infections, and categorise them into two groups—vaccine-preventable diseases and other diseases under international intervention plans—we see that the first group had a 66·5% reduction in YLLs, while the second had a 51·6% decline. These findings highlight the profound impact of sustained funding, vaccination, international collaboration, and targeted support programmes with local governments in addressing public health challenges. Previous studies, including GBD 2021, have highlighted the importance of controlling infectious diseases as a key factor in improving life expectancy. 14 Many of these diseases are concentrated in specific populations and locations, making their control an achievable goal. 14 During a time of uncertainty regarding the future of global health funding, it is essential to maintain these efforts, as discontinuing them could jeopardise the gains made in public health. The COVID-19 pandemic produced a challenge to global health that has not been seen in recent history, including the difficulties associated with accurately recording and analysing deaths from a novel pandemic. GBD 2021 estimated COVID-19 mortality using confirmed COVID-19 death estimates and excess mortality, an approach which measured the total toll of the pandemic but had limitations for understanding how many deaths were directly attributable to COVID-19. 14 GBD 2023 addresses the issues related to COVID-19 reporting by applying a method for identifying and correcting misclassified COVID-19 deaths in vital registration data in the years 2020–23. This has allowed us to more accurately quantify the COVID-19 pandemic, as well as to correct for inaccurate spikes in mortality from other causes that were instead misclassified COVID-19 deaths. The applied correction occurs after garbage code redistribution to ensure that any deaths from COVID-19 are correctly identified and that other changes in garbage code practices do not result in cause-specific excess deaths. The additional 2 years of analysis since GBD 2021 allows for a more complete picture of COVID-19 mortality. We estimated a total of 18·0 million people died from COVID-19 globally between 2019 and 2023. This profound loss of life underscores shortcomings in global health systems and a need to fill critical gaps in preparedness for epidemic diseases. Necessary steps to better prepare for the next pandemic should include strengthening health-care infrastructure, enhancing global surveillance, improving vaccine development and delivery, ensuring equitable access to essential and preventive health services, and improving global collaboration to include data sharing and advanced disease monitoring. 32 , 33 In 2020 and 2021, the global mortality rate from COVID-19 for people younger than 70 years was several times higher than the rates for lower respiratory infections before the pandemic, in 2019. In 2023, the rate of COVID-19 deaths decreased to be lower than the sum of all other lower respiratory infections for those younger than 70 years. A similar pattern holds true for those aged 70 years and older. This suggests that COVID-19's impact on mortality could be comparable to other individual lower respiratory infections in future years, and that health-care systems should prepare for and expect future COVID-19 seasons to be endemic. 34 Measuring the impact of a pandemic is inherently challenging; we recognise that future estimates might be subject to continued improvements as more data become available. The last pandemic of this nature to occur was the 1918 H1N1 influenza pandemic that killed between 21 million and 100 million people within 2 years. 35 , 36 The true death toll of the 1918 influenza pandemic still remains uncertain, and even with improved records, there will likely always be some ambiguity surrounding the COVID-19 estimates as well. With all other factors held constant, the age-specific death rate for teenagers, young adults, and older adults (aged 10–69 years) should decline over time, reflecting improvements in health care, socioeconomic conditions, and public health measures. 7 However, this trend has not been universal across all 21 GBD regions. Only four regions—high-income Asia Pacific, central Asia, east Asia, and south AsiA&Mdash;have had a declining age-specific death rate for both males and females across all 5-year age groups for the three Level 1 GBD causes: CMNN diseases, NCDs, and injuries. In regions displaying an increase in NCDs, primary drivers vary by region; however, we commonly observed high rates of diabetes and kidney disease, cardiovascular disease, substance use disorders, and neoplasms. There were two regions where the increase in NCDs was primarily driven by an increase in drug use disorders: high-income North America and central Europe. The regions facing large increases in neoplasms were north Africa and the Middle East, southeast Asia, tropical Latin America, the Caribbean, and all four regions of sub-Saharan Africa. Diabetes and kidney disease largely contributed to the increase in central Europe, the Caribbean, central Latin America, and southern sub-Saharan Africa. Addressing these trends requires targeted public health interventions, improved health-care access, and socioeconomic policies to mitigate the underlying risk factors. Among regions displaying an increase in injuries, there was similar variation by region, although common drivers included increases in self-harm, interpersonal violence, conflict and terrorism, environmental heat and cold exposure, and falls. In north Africa and the Middle East and eastern Europe, the rise in injury-related deaths was primarily due to collective and interpersonal violence, in addition to the earthquake in Türkiye. In central and eastern Europe, heatwaves have been occurring more frequently over the past decade. At the same time, increases in high-income North America, central Latin America, and tropical Latin America were all driven by increasing rates of self-harm. Our study shows several noteworthy patterns in deaths from violent causes occurring throughout the world. Trends of interpersonal violence showed global-level improvements with regional heterogeneity. Although global mortality from interpersonal violence has generally declined, the regions most heavily affected have seen worsening trends. The primary drivers associated with deaths from interpersonal violence are highly variable across locations. 37 In some parts of the world, the drug trade fuels deaths from this form of violence by driving territorial conflicts, organised crime, and competition over illicit markets. 37 Deaths from interpersonal violence can also be linked to several important social determinants of health, including adverse childhood experiences, alcohol and drug use disorders, and lack of social support, among others. 38 , 39 Deaths from conflict and terrorism are stochastic in nature and have fluctuated over the past three decades, displaying periods of declines and increases influenced by complex regional dynamics. In recent years, the area of conflict has begun to shift from north Africa and the Middle East to central Europe, eastern Europe, and central Asia, due to the war between Russia and Ukraine. Although the regional mortality rates of north Africa and the Middle East are no longer the highest, we found that Palestine had the highest mortality rate and 70q0 due to conflict and terrorism of any country in the world. These findings align with the recently reported number of fatalities in the Gaza Strip, 40 and an estimated 30-year loss in life expectancy within the first 12 months of the war—a conservative estimate that nearly halves the pre-war life expectancy in Palestine. 41 Global self-harm rates have been trending downwards since the early 1990s, but this progress conceals spikes in self-harm occurring in some locations. 42 We observed an increase in self-harm in central Latin America, and more moderate increases occurring in Andean Latin America, high-income North America, high-income Asia Pacific, and tropical Latin America. There were, however, declines in self-harm in east Asia, particularly in China, where improved economic and social conditions, along with tailored and specified campaigns to reduce self-harm, have been useful in supporting population wellbeing. 43 , 44 We also observed that the mean age at death from self-harm has been increasing globally over the past three decades, a finding that potentially reflects both successes and failures with regard to self-harm prevention. 42 While an increase in mean age at death due to self-harm could signal that intervention strategies tailored to younger groups have yielded improvements, increased deaths in older ages might indicate missed opportunities in addressing risk factors that are more relevant in older age groups, such as social isolation, economic insecurity, and increased chronic illness. 45 Taken together, the findings that self-harm persists as a leading cause of death in young people in several regions while the global mean age at death due to self-harm increases suggest pivotal opportunities for further prevention strategies that must be carefully tailored to the intended demographic. The mean age at death measure provides a clear, easily interpretable metric for summarising the population affected by a given disease or injury. Interventions at both the individual and population levels vary depending on the age of those affected. For example, strategies to improve health outcomes for ischaemic heart disease in South Sudan, where the mean age at death due to this cause is 61·2 years for females, would be likely to focus on prevention strategies and early detection, whereas strategies to improve health outcomes for the same disease in Switzerland, where the mean age at death is 88·4 for females, might focus more on palliative care and limit treatment options. Identifying who is being affected by a disease using a single, interpretable measure could help policy makers to make informed decisions in complex situations. There are some challenges when drawing comparisons in the observed mean age at death between populations with different age structures. An older population is likely to have an older mean age at death for a given cause than a population with a younger age structure. For this reason, comparing mean ages at death between locations with different population structures is not a good measure for how well a disease is being treated. To account for this, an evaluation of the expected mean age at death reflecting the given demographic's population structure is needed for comparison between locations. The difference between the expected and observed mean age at death can reflect important factors and risks, beyond just the age distribution, that vary between and within different locations. When the observed mean age at death is lower than expected, it shows that people are dying younger than global rates would suggest. These differences across countries underscore notable inequalities. Causes of death that strongly correlate with SDI and differences between expected and observed mean ages at death are indicative of areas in which the global community has the capacity to improve health outcomes—yet resources and interventions remain unevenly distributed across locations. A lower mean age at death compared with the expected indicates weakness in public health, particularly in preventive measures, early diagnosis, and timely treatment that could delay or prevent deaths. Many examples of lower mean age at death are seen in cardiovascular diseases, cancers, and chronic respiratory diseases in low-income regions, suggesting challenges in both prevention and treatment. We included the probability of death between the ages of 0 and 70 years (70q0) in this study to assess the likelihood that an individual born today will die from a specific cause before reaching 70 years of age, assuming that current age-specific mortality rates remain unchanged. The 70q0 measure incorporates competing risks, acknowledging that individuals might die from other causes before reaching the high-risk ages for a particular cause. In other words, our goal was to provide a more comprehensive assessment of the 70q0 from a specific cause over the entire lifespan, assuming survival from other causes. In 2024, the Global Health 2050 report set a target to cut global premature mortality in half by the year 2050, a goal referred to as 50 by 50. 5 In support of this target, we aimed to better position GBD to provide the current state of national premature mortality estimates across causes and locations, which could be useful to track progress on future developments. We used an analysis of 70q0 to detail substantial sources of health loss that most contribute to premature death before age 70 years, providing a roadmap to help countries address their primary contributors to premature mortality. Several studies suggest that probability of death is a valuable indicator, and providing 70q0 by cause of death highlights areas in which countries can improve the observed age at death for specific causes, drawing attention to locations and causes that have not kept pace with global progress in cause-specific mortality. 5 , 46 The probability of death measure also illustrates global and regional success stories in which, as a global health community, we have successfully reduced mortality rates for specific causes in people younger than 70 years. For instance, lower respiratory infections declined 51·2% among females and 47·4% among males between 2000 and 2023 due to reductions in the case-fatality rate and various risk factors, 47 including reductions in household air pollution, a decrease in the prevalence of childhood wasting, and improved vaccine coverage, all of which were effective in reducing the burden of lower respiratory infections. 48 Vaccines against Haemophilus influenzae type b and Streptococcus pneumoniae are particularly crucial in the reduction of lower respiratory infections in 70q0. 49 Global improvements were also observed in diarrhoeal diseases, with declines of over 70% in 70q0 for males and females. There have been many multisectoral approaches that have contributed to a reduction in diarrhoeal deaths globally in 70q0, many of which have focused on diarrhoeal deaths in children younger than 5 years. These interventions include oral rehydration therapy, enhanced water, sanitation, and hygiene infrastructure, and the rollout of the rotavirus vaccination. 50 The global reduction of 70q0 due to tuberculosis from 2000 to 2023 is another success story. There was an overall decline of 60·0% in females and 58·0% in males, and notable improvements in some super-regions, particularly central Europe, eastern Europe, and central Asia, where a 78·5% decrease among males and a 71·8% decrease among females occurred in that period. The analysis of 70q0 is more optimistic than other literature on tuberculosis, because the slowest progress in tuberculosis mortality has been in older adults. 47 While we have seen success in reducing 70q0 from tuberculosis, with improvements in mortality for those aged 15 years and younger, more work is needed to reduce tuberculosis mortality in individuals aged 50 years and older, 47 , 51 and to reach WHO's End TB Strategy. 52 Further reductions to tuberculosis-related risk factors, such as smoking, alongside early diagnosis and treatment, and the development of less toxic and shorter-duration tuberculosis treatments, are crucial for continued improvements to reach WHO targets by 2035. 47 Lastly, improvements in 70q0 for neonatal disorders globally, decreasing by 51·5% for males and females, reflect the success of efforts to reduce mortality in those younger than 5 years across health sectors and multilaterally. This is generally cited as one of public health's biggest achievements of the 20th century. 53 There are many lessons to be learned from this progress, including the importance of public health standards and measures adopted globally, such as the rollout of the S pneumoniae vaccine to prevent lower respiratory infections and the rotavirus vaccine for diarrhoea prevention. Sustainable Development Goal Target 3.2, which aims to end preventable deaths of newborns and children younger than 5 years by 2030, will build on the progress already made in reducing neonatal mortality and support ongoing efforts toward an 80% reduction in tuberculosis cases by 2030, as measured by WHO. 54 Unfortunately, not all causes of death show an optimistic picture in terms of 70q0. There remain large disparities by cause and location. First, as the epidemiological transition continues, we see rising probabilities of deaths from NCDs in sub-Saharan Africa, Latin America and the Caribbean, south Asia, and southeast Asia, east Asia, and Oceania. With global progress in 70q0, there are outliers where increased mortality rates have occurred during this period. Ten countries saw an increase in 70q0 across all causes between 2000 and 2023; the largest increase was in Palestine at 33·1%, more than double that of the next-largest increase in Lebanon with 15·3%. The staggering increase in Palestine is driven almost entirely by the conflict between Israel and Palestine, with an increase in 70q0 of 8980% due to conflict and terrorism. Despite a substantial rise in 70q0 due to conflict and terrorism in many countries, including the remainder of the top ten countries (Sudan, Ukraine, Russia, Burkina Faso, Myanmar, Israel, Somalia, Syria, and Yemen), none of these countries had an overall increase in their all-cause 70q0 due to their increased risk of conflict deaths. Rising NCDs worldwide, especially in low-income areas, will represent a significant global health challenge moving forward. 55 , 56 Historically, low-income countries have been disproportionately affected by the burden of infectious diseases, but shifts towards more chronic conditions are a reflection of the ongoing global epidemiological transition. 57 In 1990, the three regions with the highest overall mortality rates from all causes were western, eastern, and central sub-Saharan Africa, where 73·4% of deaths came from CMNN diseases. By 2023, CMNN diseases in these regions dropped to 51·4% of all deaths, representing a 30·0% decrease from 1990. Our findings also show that age-standardised mortality rates and 70q0 for both cardiovascular diseases and neoplasms are increasing in sub-Saharan Africa and in south Asia ( appendix 2 figure S5). As further reductions in communicable diseases continue, it is likely that deaths from these NCDs could become the dominant sources of mortality in future years. Findings from our study are in agreement with many studies drawing attention to the surge in NCDs occurring in low-income settings. 57 , 58 Although the concept of the epidemiological transition is not new, the speed and scale of the rise in NCDs in low-income regions is increasingly concerning. 57 There are several important implications for health systems when disease burdens transition from communicable diseases to those from non-communicable sources. 10 , 57 Health-care infrastructure might face a range of growing challenges associated with increased care needs for chronic disease management requiring long-term care and ongoing treatment. Low-resourced locations remain poorly equipped to address the rising burden of NCDs, with health-care systems often underfunded and unable to provide adequate preventive care or treatment options. 57 Collaborative and focused efforts—including coordinated policy initiatives and prevention programmes targeting key risk factors—are needed to alleviate immediate health challenges related to the rising burden of NCDs in low-income regions and to achieve long-term improvements in global health outcomes. As with any study of this scope, there are several important limitations to consider. We provide cause-specific limitations for every GBD cause of death in detail in appendix 1 (section 3). Here, we highlight limitations with applicability across many causes. First, accuracy of cause-of-death estimates can be affected by data sparsity or unreliability from some regions, time periods, or age groups. In locations for which we have scarce or unreliable data, estimates are interpolated from neighbouring regional patterns by relying on predictive covariates. Second, the cause-of-death estimates rely on medically verifiable sources of cause-of-death data, for which quality can vary. Some datasets do not cover all deaths in a given age, sex, location, and year, and some have high levels of garbage-coded underlying causes of death, which require redistribution algorithms to correct. For transparency about data quality, we publish a star rating of the quality of all vital registration and verbal autopsy data (a 1–5 score compiled based on percentage completeness and percentage garbage). These scores are available in appendix 1 and in a publicly available visualisation tool . Third, for causes with limited data, it is preferable to provide estimates with appropriate uncertainty, rather than providing no information. Fourth, reporting lags in medically verifiable cause-of-death data are a factor in data availability for recent years, particularly 2023; therefore, estimates for these years rely more heavily on the modelling process. Fifth, there are several limitations that pertain to our COVID-19 estimates. While GBD 2023 reflects the most comprehensive set of COVID-19 estimates published by GBD to date, we still have a limited availability of time series for some locations from 2020 to 2023, particularly for 2023. Some location-cause-age-sex groups have a small enough sample size that their time series are stochastic by default, making the development of a counterfactual model difficult. To our knowledge, estimates from GBD 2023 reflect the best account of COVID-19 and miscoded COVID-19 to date. However, as we learn more about the virus and its presentation, it is possible our corrections will be updated to reflect new knowledge in the field. Sixth, mean age at death calculations also have limitations, as they are not standardised for different population age structures. Aggregate estimates are therefore influenced by the most populated areas. As a result, it can be unclear whether the increase in the mean age at death is attributed to a reduction of deaths in younger ages, or if it is simply a result of an ageing population. Our calculation of mean age at death is also limited by the granularity of GBD results. Here, each death is assigned an age group, whereas in reality, each death occurred at a specific age. This strategy does not capture effects within age groups, and it does not show how cohorts age from year to year. Seventh, 70q0 is a broad age group that does not capture improvements made in younger ages if the death occurs before age 70 years. For example, if the mean age at death improved from 30 years to 50 years in a period of time, but the overall mortality rate remained the same, 70q0 would not show this improvement. Lastly, data for stochastic events such as natural disasters and conflicts are generally reported without age and sex detail and instead leverage age-sex splitting using the available detailed data to split the deaths into the granular GBD age groups. These types of events are particularly subject to a lag in reporting, and these estimates will continue to be improved in the future. GBD cause of death studies are fundamental for understanding mortality trends and aligning them with public health decision making. While progress has been made in reducing deaths from infectious diseases on a global scale, the rising burden of NCDs presents new challenges, particularly for low-income nations. Patterns in premature mortality across the globe have been changing, signifying priority areas for public health intervention. Findings from GBD 2023 show a crucial need for continued investment in health care, improved data collection, and targeted interventions to address both emerging and persistent health issues. Tackling the global health challenges of the future will require sustained international collaboration in the prevention and treatment of both communicable and non-communicable diseases. Strengthening access and quality of health care in low-income and middle-income countries is needed for improving the prevention and treatment of NCDs in particular, which continue to rise as major health threats. A unified global effort will also be necessary to combat the growing number of deaths from drug use and violence, both of which require comprehensive strategies for prevention, treatment, and support. By fostering greater international cooperation and focusing on these key areas, we can make significant progress towards reducing global mortality rates and improving health outcomes for populations worldwide. For detailed information on data sources and estimates, please visit the GHDx GBD 2023 website at http://ghdx.healthdata.org/gbd-2023 .

Measuring causes of death is a foundational step towards developing effective strategies to improve human health. The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) provides comprehensive and systematic analyses of causes of death worldwide and across time. The utility of GBD cause of death estimates has been particularly valuable during the onset of COVID-19. 1 , 2 , 3 However, GBD estimates have uses beyond informing preparation for stochastic events, such as a novel virus or new pandemic; these estimates are used integrally as tools for understanding public health trends, shaping health policy, and monitoring progress toward global health goals. 4 As a global public good, GBD 2023 contributes freely available, updated, and comprehensive estimates of causes of death to the existing body of scientific literature. In addition to presenting the routinely updated estimates of causes of death, the current study expands our analysis to further explore the relationship between age and cause of death. This study investigates important age patterns in mortality by estimating the probability of dying from any given cause before the age of 70 years (70q0). The probability of death measure is a fundamental indicator in public health because it can effectively capture improvements in survival within all age groups before age 70 years. 5 In recent publications, it has become common practice to classify deaths occurring before 70 years of age as premature. 6 Some studies, including the Global Health 2050 report from the Lancet Commission on Investing in Health, have shown that the probability of all-cause mortality before age 70 years has decreased globally and across major regions. 5 The Global Health 2050 report concluded that further reductions, by as much as 50%, are attainable by mid-century with targeted health investments, a goal referred to as 50 by 50. 5 To support progress towards 50 by 50, our study aims to address remaining questions, including which causes of death deviate from the broader improvements in premature mortality, and where disparities might exist in the likelihood of dying before age 70 years within specific populations. These are pressing concerns for policy makers and health-planning teams at both national and international levels. Another primary objective of GBD 2023 was to calculate the mean age at the time of death across causes and locations. This metric allows for straightforward observations of national and regional disease burdens in relation to global values. Related studies find that the overall mortality rate from all causes has been decreasing over the past 75 years, 7 and the mean age at the time of death has been trending upward for many countries. 8 Estimates of mean age at death are influenced not only by a population's age distribution but also by disease characteristics, health-care access, socioeconomic status, comorbidities, and other risk factors. 8 , 9 Although some of this general upward trend can be attributed to shifts in age structure and sex distribution by location, in certain areas and for specific causes, the mean age is much higher or lower than expected. 8 Quantifying the difference between the expected mean age at death (based only on population age structure and disease characteristics) and the observed mean age at death provides policy makers with additional population-level understanding beyond simply comparing age-standardised death rates between locations. These quantified differences could be linked to modifiable factors within a community, such as high blood pressure or the use of alcohol, tobacco, or drugs, which can be targeted through public health interventions. 10 Research in context Evidence before this study The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) is a worldwide research initiative that provides comprehensive and timely assessments of mortality, morbidity, and risk factors disaggregated to granular levels that are meaningful for policy development. In the last iteration, the GBD 2021 causes-of-death publication marked a major advancement in the evidence base; the study delineated cause-specific mortality to provide insights on the primary causes of death influencing life expectancy across locations. It also identified several causes with shifting mortality trends that had important implications for targeted policy initiatives—causes that were once widespread across the globe but became increasingly localised and in need of tailored reduction strategies. The GBD 2021 causes-of-death analysis was also the first of its kind to publish worldwide estimates of deaths from the initial years of the COVID-19 pandemic, quantifying its effect on life expectancy and offering comparisons to deaths from other causes. While estimates from other studies are published periodically that assess specific causes of death among a subset of populations or across a narrower timeframe, GBD remains the only research effort to offer cause-specific estimates of mortality to this degree of time and location detail and to produce these assessments in peer-reviewed and GATHER-compliant publications. Added value of this study This study provides new and more robust evidence of mortality patterns across the globe, updating and extending the analysis from GBD 2021, and reanalysing the entire time series to supersede all previous GBD publications. We provide estimates of cause-specific mortality for 292 causes of death within 204 countries and territories and 660 subnational locations, disaggregated by age and sex, from 1990 to 2023. These estimates include 11 474 new sources compared with GBD 2021. This update advances mortality measurements in several ways. First, we present the probability of death before age 70 years (70q0) by sex and year to enable measurements of premature mortality by individual causes. We describe causes of death that are not following global improvements in 70q0 to highlight locations where disparities are occurring in the likelihood of dying before age 70 years. Second, we calculate the mean age at death by assigning the midpoint age of each age group for every death, followed by computing the overall mean across all deaths attributed to a given cause. Our analysis of mean age of death offers insights into a country's ability to manage different disease burdens relative to global benchmarks, independent of local population structure. Additionally, our study examines the correlation between mean age at death and the Socio-demographic Index (SDI) to evaluate whether countries at the higher end of the SDI exhibit older mean ages at death for a given cause compared with countries with a lower SDI value, while controlling for SDI's effect on population structure. This approach adds a novel dimension to understanding how sociodemographic factors influence both the risk and timing of mortality. This study also builds upon our estimates from GBD 2021 to include 2 additional years of COVID-19 analysis, providing a more comprehensive picture of COVID-19 mortality worldwide. Lastly, we report estimates for several newly disaggregated causes of death, including ulcerative colitis; Crohn's disease; thyroid disease; other endocrine, metabolic, and blood and immune disease; and electrocution. Implications of all the available evidence Our study offers a thorough analysis of causes of death over the past 34 years, including new findings into the full duration of the COVID-19 pandemic. We highlight causes of death that have declined in certain locations, which could lend insight for policy change and implementation. We also identify causes that persist as major sources of mortality across populations, signifying priority areas for future intervention. Additionally, our study investigated important age patterns in mortality by estimating the probability of dying from any given cause before age 70 years, thereby advancing our understanding of the relationship between age and cause of death. The Global Health 2050 report set a target to reduce the probability of premature deaths by 50% by 2050. We aim to complement and support this goal by offering an in-depth analysis of 70q0 across time, sex, and geographical locations. Lastly, our mean age of death analysis is a valuable metric for comparing observed mortality levels with expected patterns to help identify locations that are keeping pace with development trends and those that might be falling behind. Evidence from this study can be used to examine epidemiological patterns and trends across time and locations, and to gauge progress in global development goals. These findings can also guide future policy initiatives aimed at furthering reductions in cause-specific mortality and, in particular, achieving better pandemic preparedness within the context of specific locations. In aggregate, cyclical updates to GBD reflect improvements in data availability and enhanced methodology that reduce bias and improve transparency, supporting the development and implementation of new evidence-based health policies worldwide. Evidence before this study The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) is a worldwide research initiative that provides comprehensive and timely assessments of mortality, morbidity, and risk factors disaggregated to granular levels that are meaningful for policy development. In the last iteration, the GBD 2021 causes-of-death publication marked a major advancement in the evidence base; the study delineated cause-specific mortality to provide insights on the primary causes of death influencing life expectancy across locations. It also identified several causes with shifting mortality trends that had important implications for targeted policy initiatives—causes that were once widespread across the globe but became increasingly localised and in need of tailored reduction strategies. The GBD 2021 causes-of-death analysis was also the first of its kind to publish worldwide estimates of deaths from the initial years of the COVID-19 pandemic, quantifying its effect on life expectancy and offering comparisons to deaths from other causes. While estimates from other studies are published periodically that assess specific causes of death among a subset of populations or across a narrower timeframe, GBD remains the only research effort to offer cause-specific estimates of mortality to this degree of time and location detail and to produce these assessments in peer-reviewed and GATHER-compliant publications. Added value of this study This study provides new and more robust evidence of mortality patterns across the globe, updating and extending the analysis from GBD 2021, and reanalysing the entire time series to supersede all previous GBD publications. We provide estimates of cause-specific mortality for 292 causes of death within 204 countries and territories and 660 subnational locations, disaggregated by age and sex, from 1990 to 2023. These estimates include 11 474 new sources compared with GBD 2021. This update advances mortality measurements in several ways. First, we present the probability of death before age 70 years (70q0) by sex and year to enable measurements of premature mortality by individual causes. We describe causes of death that are not following global improvements in 70q0 to highlight locations where disparities are occurring in the likelihood of dying before age 70 years. Second, we calculate the mean age at death by assigning the midpoint age of each age group for every death, followed by computing the overall mean across all deaths attributed to a given cause. Our analysis of mean age of death offers insights into a country's ability to manage different disease burdens relative to global benchmarks, independent of local population structure. Additionally, our study examines the correlation between mean age at death and the Socio-demographic Index (SDI) to evaluate whether countries at the higher end of the SDI exhibit older mean ages at death for a given cause compared with countries with a lower SDI value, while controlling for SDI's effect on population structure. This approach adds a novel dimension to understanding how sociodemographic factors influence both the risk and timing of mortality. This study also builds upon our estimates from GBD 2021 to include 2 additional years of COVID-19 analysis, providing a more comprehensive picture of COVID-19 mortality worldwide. Lastly, we report estimates for several newly disaggregated causes of death, including ulcerative colitis; Crohn's disease; thyroid disease; other endocrine, metabolic, and blood and immune disease; and electrocution. Implications of all the available evidence Our study offers a thorough analysis of causes of death over the past 34 years, including new findings into the full duration of the COVID-19 pandemic. We highlight causes of death that have declined in certain locations, which could lend insight for policy change and implementation. We also identify causes that persist as major sources of mortality across populations, signifying priority areas for future intervention. Additionally, our study investigated important age patterns in mortality by estimating the probability of dying from any given cause before age 70 years, thereby advancing our understanding of the relationship between age and cause of death. The Global Health 2050 report set a target to reduce the probability of premature deaths by 50% by 2050. We aim to complement and support this goal by offering an in-depth analysis of 70q0 across time, sex, and geographical locations. Lastly, our mean age of death analysis is a valuable metric for comparing observed mortality levels with expected patterns to help identify locations that are keeping pace with development trends and those that might be falling behind. Evidence from this study can be used to examine epidemiological patterns and trends across time and locations, and to gauge progress in global development goals. These findings can also guide future policy initiatives aimed at furthering reductions in cause-specific mortality and, in particular, achieving better pandemic preparedness within the context of specific locations. In aggregate, cyclical updates to GBD reflect improvements in data availability and enhanced methodology that reduce bias and improve transparency, supporting the development and implementation of new evidence-based health policies worldwide. The timeframe of this analysis allows for important new insights into COVID-19, including two additional years of estimation since GBD 2021, new data collected, and improved methodology. As we mark 5 years since the onset of the COVID-19 pandemic—declared officially by WHO in March, 2020 11 —it is important to reflect on its impact. Substantial declines in deaths from COVID-19 were not noted until 2023, after a period of extraordinary global disruption. 7 Since that time, countries with robust vital registration systems have been able to publish mortality data for the years with the highest number of COVID-19 deaths. In addition, localised studies revealed shifts in mortality patterns occurring for certain causes of death during the height of the pandemic. 12 As additional vital registration data become available, a more comprehensive understanding of the long-term effects of COVID-19 on global mortality will continue to unfold. Key questions remain regarding the total number of deaths attributed to COVID-19, the populations most affected, and which causes of death—and to what extent—were affected by the COVID-19 pandemic. This study provides new insights related to trends in 70q0 and the mean age at death, and identifies and delineates causes that most heavily affect mortality across populations. An updated understanding of how the COVID-19 pandemic interrupted or altered previous trajectories in mortality by cause, age, sex, or location is another important contribution of GBD 2023. At the same time, tracking changes in 70q0 and the mean age at death across causes, populations, and over time—alongside metrics such as the number of deaths, age-standardised mortality rates, and years of life lost (YLLs), offers more actionable insights to improve health at the population level. These patterns can be an essential guide for policy makers when shaping health priorities. This manuscript was produced as part of the GBD Collaborator Network and in accordance with the GBD Protocol. 13

J Ärnlöv reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from AstraZeneca, Boehringer Ingelheim, and Novartis; participation on a Data Safety Monitoring Board or Advisory Board with AstraZeneca, Boehringer Ingelheim, and Astella; all outside the submitted work. D Abramov reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from AstraZeneca and Bayer; participation on a Data Safety Monitoring Board or Advisory Board with BridgeBio; all outside the submitted work. S Afzal reports support for the present manuscript from Institute of Public Health Lahore for study material, manuscripts, medical writings and library resources; grants or contracts from the Dean Institute of Public Health Lahore; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from the Dean Institute of Public Health Lahore; support for attending meetings and/or travel from the Dean Institute of Public Health Lahore; participation on a Data Safety Monitoring Board or Advisory Board with Pakistan National Bioethics Committee as a Member, Institutional Review Board of Fatima Jinnah Medical University as a Member, Ethical Review Board and Data Monitoring Board Institute of Public Health Lahore Pakistan as a Member, Clinical Research Organization King Edward Medical University, Annals of King Edward Medical University Advisory Board as a Member; leadership or fiduciary roles in other board, society, committee or advocacy group, paid or unpaid, with Pakistan Higher Education Commission Research Committee as a Member, Pakistan Medical and Dental Commission Research and Journals Committee as a Member, Pakistan National Bioethics Committee as a Member, Pakistan Society of Internal Medicine as a Member, Pakistan Association of Medical Editors as a Member, Medical Microbiology and Infectious Diseases Society as a Member, Leads International as a Fellow, Faculty of Public Health UK as a Fellow, College of Physicians and Surgeons Pakistan as a Fellow; receipt of equipment, materials, drugs, medical writing, gifts or other services from Bergen University Norway; other financial or non-financial interests with Dean Institute of Public Health Birdwood Lahore; all outside the submitted work. C A Sobrinho reports grants or contracts from Fundação para a Ciência e Tecnologia (FCT) via grant CEECINST/00093/2021/CP2815/CT0001, outside the submitted work. R Ancuceanu reports consulting fees from Abbvie and Merck Romania; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Abbvie, Laropharm, Reckitt, Merck Romania, and MagnaPharm; support for attending meetings and/or travel from Merck Romania and Reckitt; all outside the submitted work. O C Baltatu reports support for the present manuscript from the National Council for Scientific and Technological Development Fellowship (CNPq, 304224/2022–7), the Anima Institute (AI) Research Professor Fellowship, and Alfaisal University; leadership or fiduciary roles in other board, society, committee or advocacy group, paid or unpaid, with VividiWise Analytics as Managing Partner and São José dos Campos Tech Park—CITE as Biotech Advisory Board Member; all outside the submitted work. S Barteit reports support for attending meetings and/or travel from Wellcome Trust, September 2023+January 2025; stock or stock options in Climate Change and Health Evaluation and Response System (€4,200 in shares); all outside the submitted work. A Beloukas reports grants or contracts from Gilead for a research grant and sponsorship to the University of West Attica, and from GSK/ViiV for a Research Sponsorship to the University of West Attica; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Gilead and GSK paid to the University of West Attica; support for attending meetings and/or travel from Gilead and GSK paid to the University of West Attica; receipt of equipment, materials, drugs, medical writing, gifts or other services from Cepheid in the form of FOC reagents for a research project; all outside the submitted work. P J G Bettencourt reports the following patents issued or pending: WO2020229805A1, BR112021022592A2, EP3965809A1, OA1202100511, US2023173050A1, EP4265271A2, EP4275700A2, EP4265271A3, EP4275700A3; all outside the submitted work. S Bhaskar reports grants or contracts from Japan Society for the Promotion of Science (JSPS), Japanese Ministry of Education, Culture, Sports, Science and Technology (MEXT), Grant-in-Aid for Scientific Research (KAKENHI; grant ID: 23KF0126), JSPS and the Australian Academy of Science, JSPS International Fellowship (grant ID P23712 ); leadership or fiduciary roles in other board, society, committee or advocacy group, paid or unpaid, with Rotary District 9675, Sydney, Australia as District Chair, Diversity, Equity, Inclusion & Belonging, with Global Health & Migration Hub Community, Global Health Hub Germany, Berlin, Germany as Chair, Founding Member and Manager, with PLOS One, BMC Neurology, Frontiers in Neurology, Frontiers in Stroke, Frontiers in Public Health, Journal of Aging Research, Neurology International, Diagnostics, & BMC Medical Research Methodology as an Editorial Board Member, with College of Reviewers, Canadian Institutes of Health Research (CIHR), Government of Canada as a Member, with World Headache Society, Bengaluru, India as Director of Research, with Cariplo Foundation, Milan, Italy as an Expert Adviser/Reviewer, with National Cerebral and Cardiovascular Center, Department of Neurology, Division of Cerebrovascular Medicine and Neurology, Suita, Osaka, Japan as Visiting Director, with Cardiff University Biobank, Cardiff, UK as a Member, Scientific Review Committee, with Rotary Reconciliation Action Plan as Chair, and with Japan Connect, Osaka, Japan as a Healthcare and Medical Adviser; all outside the submitted work. A Biswas reports consulting fees from LUPIN Pharmaceuticals Ltd, INTAS Pharmaceuticals Ltd, Alkem Laboratories Ltd, and Torrent Pharmaceuticals Ltd; all outside the submitted work. R Cairns reports grants or contracts from Reckitt for an untied educational grant to study poisoning; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from The Pharmacy Guild of Australia and Reckitt; all outside the submitted work. M C D de Carvalho reports other financial or non-financial interests with LAQV/REQUIMTE, University of Porto, Porto, Portugal, and from FCT/MCTES under the scope of the project UIDP/50006/2020 (DOI 10.54499/UIDP/50006/2020); all outside the submitted work. A L Catapano reports grants or contracts from Chiesi, Amarin, and Ultragenyx; consulting fees from Amarin, Amgen, AstraZeneca, Chiesi, Daiichi Sankyo, Eli Lilly, Esperion, Ionis Pharmaceutical, Medscape, Menarini, MSD, Novartis, NovoNordisk, Regeneron, Sanofi, Ultragenyx, and Viatris; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Amarin, Amgen, AstraZeneca, Chiesi, Daiichi Sankyo, Eli Lilly, Esperion, Ionis Pharmaceutical, Medscape, Menarini, MSD, Novartis, NovoNordisk, Regeneron, Sanofi, Ultragenyx, and Viatris; participation on a Data Safety Monitoring Board or Advisory Board with Amarin, Amgen, AstraZeneca, Chiesi, Daiichi Sankyo, Eli Lilly, Esperion, Ionis Pharmaceutical, Medscape, Menarini, MSD, Novartis, NovoNordisk, Regeneron, Sanofi, Ultragenyx, and Viatris; all outside the submitted work. H Christensen reports grants or contracts from Velux Foundation, Novo Foundation, Br Hartman Fonden, Tværsfonden, and Lundbeck Foundation; participation on a Data Safety Monitoring Board or Advisory Board with Atricure: LEEAPS trial—DSMB; leadership or fiduciary roles in other board, society, committee or advocacy group, paid or unpaid, with Action Plan for Stroke in Europe as Past Chair; all outside the submitted work. F Cohen reports consulting fees from Abbvie and Pfizer; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Abbvie and Axsome; all outside the submitted work. J Conde reports grants or contracts from OncoNanoAI: Artificial intelligence to discover the next generation of personalised nanoparticles for triple-negative breast cancer therapy (2025–2027) (FCT grant LISBOA2030-FEDER-00862500-149983); patents issued or pending: “TRPV2 Antagonists” US Application (number US11273152B2), “Surfactant-based cellulose hydrogel methods and uses thereof” (PCT/IB2025/051694, 17/02/2025), “Self-immolative micelle, methods and uses thereof” (EP25165757, 24/03/2025); all outside the submitted work. S E Congly reports grants or contracts paid to their institution from AstraZeneca, Merck, Ipsen, Bausch Health, Oncoustics, Boehringer Ingelheim, and Gilead Sciences Canada; consulting fees paid to them from GSK and Boehringer Ingelheim; participation on a Data Safety Monitoring Board or Advisory Board with Boehringer Ingelheim, Gilead Sciences Canada, and AstraZeneca; leadership or fiduciary roles in other board, society, committee or advocacy group, paid or unpaid, with Canadian Association for the Study of the Liver as a Member of the Board of Directors and Alberta Society of Gastroenterology as Vice President; all outside the submitted work. N Conrad reports grants or contracts paid to their institution from Wellcome Trust Career Development Award (grant number 318034/Z/24/Z), Research Foundation Flanders (grant number 12ZU922N), and KU Leuven (internal funding); all outside the submitted work. S Cortese reports grants or contracts from the National Institute for Health and Care Research (NIHR) and the European Research Agency; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from the Association for Child and Adolescent Mental Health (ACAMH), the British Association of Psychopharmacology (BAP), Medice; support for attending meetings and/or travel from the Association for Child and Adolescent Mental Health (ACAMH), the British Association of Psychopharmacology (BAP), Medice; leadership or fiduciary roles in other board, society, committee or advocacy group, paid or unpaid, with the European ADHD Guideline Group (EAGG); all outside the submitted work. E C Dee reports support for the present manuscript from Prostate Cancer Foundation Young Investigator Award and through the Cancer Center Support grant from the US National Cancer Institute (P30 CA008748). A K Demetriades reports non-fiduciary leadership roles in other board, society, committee or advocacy group with EANS (European Association of Neurosurgical Societies) as a Board member, AO SPINE as a Steering Committee Member for Knowledge Forum Degenerative, Global Neuro Foundation as a Board Member, AO SPINE as a Steering Committee Member for Knowledge Forum Degenerative; all outside the submitted work. X Ding reports grants or contracts from American Heart Association for a 2-year predoctoral fellowship (DOI: 10.58275/AHA.25PRE1373497.pc.gr.227106); quarterly payments made to their institution; all outside the submitted work. L L M Ebraheim reports support for the present manuscript from the Gates Foundation, and royalties or licenses from the Institute for Health Metrics and Evaluation outside the submitted work. A Faro reports support for the present manuscript from National Council for Scientific and Technological Development (CNPq, Brazil) for a personal grant “Researcher at CNPq—Level 1B”. A A Fomenkov reports support for the present manuscript from the Ministry of Science and Higher Education of the Russian Federation (theme number 122042600086–7). L M Force reports support for the present manuscript from Gates Foundation, St. Jude Children's Research Hospital; grants or contracts from St. Baldrick's Foundation, Conquer Cancer Foundation, NIH Loan Repayment Program; leadership or fiduciary roles in other board, society, committee or advocacy group, unpaid, with the Lancet Oncology International Advisory Board; all outside the submitted work. R C Franklin reports support for attending meetings and/or travel from ACTM—Annual Conference 2022–2024; leadership or fiduciary roles in other board, society, committee or advocacy group, paid or unpaid, with Australasian College of Tropical Medicine as President, Kidsafe Australia as President, Royal Life Saving Society Australia as a Board Member, and Auschem Training as a Board Member; all outside the submitted work. A Guha reports grants or contracts from American Heart Association and US Department of Defense; leadership or fiduciary roles in other board, society, committee or advocacy group, paid or unpaid, with ZERO Cancer health disparities working group; all outside the submitted work. A A Harris reports grants or contracts from the Gates Foundation and Gavi; all outside the submitted work. A Hassan reports consulting fees from Novartis, Sanofi Genzyme, Biologix, Astra Zeneca, Pfizer, Merz, Roche, Merck, Hikma Pharma, Janssen, Inspire Pharma, Future Pharma, and Elixir Pharma; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Novartis, Allergan, Abbvie, Merck, Biologix, Viatris, Pfizer, Eli Lilly, Janssen, Roche, Sanofi Genzyme, Bayer, AstraZeneca, Hikma Pharma, Al Andalus, Chemipharm, Lundbeck, Elixir, EvaPharma, Inspire Pharma, Future Pharma and Habib Scientific Office, and Everpharma; support for attending meetings and/or travel from Novartis, Allergan, Merz, Pfizer, Merck, Biologix, Roche, Sanofi Genzyme, Bayer, Hikma Pharma, Chemipharm, Al Andalus and Clavita Pharm; leadership or fiduciary roles in other board, society, committee or advocacy group, paid or unpaid, with MENA Headache Society as Vice President, Multiple Sclerosis Chapter of the Egyptian Society of Neurology as a Board Member, Headache Chapter of the Egyptian Society of Neurology as a Board Member, The International Headache Society (IHS) as a Member of the committee of education, the membership committee, and regional committee; all outside the submitted work. P J Hotez is a co-inventor on non-revenue generating patents for neglected tropical diseases owned by Baylor College of Medicine (BCM). He is also a co-inventor of a COVID-19 recombinant protein vaccine technology owned by BCM that was licensed by Baylor Ventures non-exclusively and with no patent restrictions to several companies committed to advance vaccines for low- and middle-income countries. The co-inventors have no involvement in license negotiations conducted by BCM. Similar to other research universities, a long-standing BCM policy provides its faculty and staff, who make discoveries and that result in a commercial license, a share of any royalty income. Any such distribution will be undertaken in accordance with BCM policy. P J Hotez is also the author of several books published by academic presses (ASM-Wiley) and Johns Hopkins University Press, and he receives modest royalty income from this activity. I M Ilic reports support for the present manuscript from Ministry of Science, Technological Development and Innovation of the Republic of Serbia; number 451–03–137/2025–03/200110. M D Ilic reports support for the present manuscript from Ministry of Science, Technological Development and Innovation of the Republic of Serbia number 451–03–47/2023–01/200111. N E Ismail reports leadership or fiduciary roles in other board, society, committee or advocacy group, unpaid, with Malaysian Academy of Pharmacy, Malaysia as the Bursar and Council Member and Malaysian Pharmacists Society Education Chapter Committee as a Committee Member; all outside the submitted work. I O Iyamu reports grants or contracts from Canadian Institutes for Health Research (CIHR) Health Systems Impact Fellowship (Funding Reference number IF8–196153), Michael Smith Health Research BC Trainee Award (award number HSIF-2024–04465), and CIHR Canadian HIV Trials Network (CTN+) post-doctoral fellowship; consulting fees from Excellence Community Education Welfare Scheme; support for attending meetings and/or travel from Pacific Public Health Foundation; leadership or fiduciary roles in other board, society, committee or advocacy group, paid or unpaid, with Public Health Association of British Columbia as Vice President; all outside the submitted work. V Jha reports consulting fees from Bayer, AstraZeneca, Boehringer Ingelheim, Baxter, Vera, Visterra, Otsuka, Novartis, Timberlyne, Biogen, Chinook, and Alpine; All payments to the George Institute; all outside the submitted work. T Joo reports support for the present manuscript from EU4Health Programme 2021–2027 under grant agreement 101126953 (The Joint Action on CARdiovascular diseases and DIabetes—JACARDI). The views and opinions expressed are those of the author(s) only and do not necessarily reflect those of the European Union or the European Health and Digital Executive Agency (HaDEA). Neither the European Union nor the granting authority can be held responsible for them; and National Research, Development and Innovation Office in Hungary (RRF-2.3.1-21-2022-00006, Data-Driven Health Division of National Laboratory for Health Security for funding of participation in the research project. J J Jozwiak reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Novartis, Adamed, Amgen, Boehringer Ingelheim, Servier, Novo Nordisk; all outside the submitted work. R Kalani reports grants or contracts from the National Institutes of Health (NIH) (USA) 1R01NS138297; all outside the submitted work. M Kivimäki reports grants or contracts paid to their university from the Wellcome Trust (221854/Z/20/Z), Medical Research Council (MR/Y014154/1), National Institute on Aging (R01AG056477, R01AG062553) and Research Council of Finland (350426); all outside the submitted work. J M Kocarnik reports support for the present manuscript from Institute for Health Metrics and Evaluation as an employee, the Gates Foundation for funding to his institution, and American Lebanese Syrian Associated Charities for funding to his institution. K Krishan reports other financial or non-financial interests with non-financial support from the UGC Centre of Advanced Study, CAS II, awarded to the Department of Anthropology, Panjab University, Chandigarh, India, outside the submitted work. T Lallukka reports support for the present manuscript from the Research Council of Finland (330527), payments made to their institution. M-C Li reports grants or contracts from the National Science and Technology Council, Taiwan (NSTC 113–2314-B-003–002) and the “Higher Education Sprout Project” of National Taiwan Normal University; leadership or fiduciary roles in other board, society, committee or advocacy group, paid or unpaid, with Journal of the American Heart Association as Technical Editor; all outside the submitted work. D Lindholm reports stock or stock options in AstraZeneca during time of employment (>2.5 years ago); other financial or non-financial interests with AstraZeneca as a former employee (>2.5 years ago); all outside the submitted work. H Liu reports other financial or non-financial interests as a mentor of National Medical Research Association (NMRA, U.K.), a member of British Society for Cardiovascular Research (BSCR, U.K.), and a member of and Cardiovascular Analytics Group (CVAG, HKSAR of China), all are not-for-profit organisations; all outside the submitted work. J Liu reports support for the present manuscript from the National Natural Science Foundation (72474005) and Beijing Natural Science Foundation (L222027, Z240004); grants of contracts the National Natural Science Foundation (72474005) and Beijing Natural Science Foundation (L222027, Z240004), outside the submitted work. V Lohner reports support for the present manuscript from Marga and Walter Boll Foundation, Kerpen, Germany. S Lorkowski reports grants or contracts paid to their institution from dsm-firmenich (formerly DSM Nutritional Products); consulting fees from Danone, Novartis Pharma, and Swedish Orphan Biovitrum (SOBI); payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from AMARIN Germany, Amedes Holding, AMGEN, Berlin-Chemie, Boehringer Ingelheim Pharma, Daiichi Sankyo Deutschland, Danone, Hubert Burda Media Holding, Janssen-Cilag, Lilly Deutschland, Novartis Pharma, Novo Nordisk Pharma, Roche Pharma, Sanofi-Aventis, Swedish Orphan Biovitrum (SOBI), SYNLAB Holding Deutschland; support for attending meetings and/or travel from AMGEN; participation on a Data Safety Monitoring Board or Advisory Board with AMGEN, Daiichi Sankyo Deutschland, Novartis Pharma, Sanofi-Aventis; all outside the submitted work. K S-K Ma reports grants or contracts from the International Team for Implantology outside the submitted work. P Maffia reports grants or contracts from British Heart Foundation, NextGenerationEU PNRR, Heart Research UK, Italian Ministry of University, BBSRC International Partnerships Funding, and Scottish Founding Council; leadership or fiduciary roles in other board, society, committee or advocacy group, paid or unpaid, with Translational Section for the International Union of Basic and Clinical Pharmacology (IUPHAR) as Vice-Chair, the Translational Research Medical Review Panel for Heart Research UK (HRUK) as Chair, the European Society of Cardiology (ESC) Working Group on Atherosclerosis & Vascular Biology and Cell Biology of the Heart as a Nucleus Member, the British Atherosclerosis Society (BAS) as an Executive Committee Member, Immunotherapy Committee of the International Union of Immunological Societies (IUIS) as a Member, and the Translational Clinical Studies (TCS) Grant Panel for the Chief Scientist Office (CSO) as a Member; all outside the submitted work. H R Marateb reports grants or contracts from Universitat Politècnica de Catalunya . Barcelona Tech—UPC; all outside the submitted work. S Masi reports grants or contracts from Servier for personal contracts for consulting activities, lectures, presentations, manuscript writing and educational events, Tuscany Region for grants for research projects in the field of arterial hypertension and management of SARS-CoV2 infection, and Italian Ministry of University and Research for grants for research projects in the field of heart failure; consulting fees from Servier (2022-Present); payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Servier (2018-Present); support for attending meetings and/or travel from Servier (2018-Present); participation on a Data Safety Monitoring Board or Advisory Board with Servier on advisory board for the lunch of new drugs (2024-Present); all outside the submitted work. R J Maude reports support for the present manuscript from Wellcome Trust. This research was supported in part by Wellcome Trust (grant number 220211) as it provides core funding for Mahidol Oxford Tropical Medicine Research and contributes to their salary. They are required by Wellcome to acknowledge this grant in all publications. S A Meo reports grants or contracts from the Ongoing Research Funding Program (ORF-2025–47), King Saud University, Riyadh, Saudi Arabia; all outside the submitted work. T R Miller reports grants or contracts from National Institute for Mental Health (USA), AB InBev Foundation, Santa Clara County Public Health Department (California); payment for expert testimony from lawyers representing state & local plaintiffs in opioid litigation; all outside the submitted work. H M Mohamed reports support for the present manuscript from Higher Colleges of Technology; participation on a Data Safety Monitoring Board or Advisory Board with FIP Technology Advisory Group as a Member; leadership or fiduciary roles in other board, society, committee or advocacy group, paid or unpaid, with ISPOR UAE chapter as Education Committee Member; all outside the submitted work. L Monasta reports support for the present manuscript from the Italian Ministry of Health (Ricerca Corrente 34/2017), payments made to the Institute for Maternal and Child Health IRCCS Burlo Garofolo. R da Silveira Moreira reports grants or contracts from CNPq (National Council for Scientific and Technological Development) for a CNPq Research Productivity Scholarship (scholarship registration number is 316607/2021–5); all outside the submitted work. J F Mosser reports support for the present manuscript from the Gates Foundation; grants or contracts from Gavi; honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Providence Medical Center for CME presentation; support for attending meetings and/or travel from the Gates Foundation; all outside the submitted work. F Mughal reports support for the present manuscript paid to their institution from the National Institute for Health and Care Research (NIHR) (USA) (300957). Views expressed in this manuscript are those of the authors and not of the NHS, NIHR, or DHSC. S Nomura reports support for the present manuscript from Ministry of Education, Culture, Sports, Science and Technology of Japan (24H00663) and the Japan Science and Technology Agency for Precursory Research for Embryonic Science and Technology (JPMJPR22R8). B OANCEA reports support for the present manuscript from Ministry of Research, Innovation and Digitalization through the Core Program of the National Research, Development and Innovation Plan 2022–2027, project number PN 23-02-0101, contract number 7N/2023; PNRR/2022/C9/MCID/I8 project 760096. R Olum reports grants or contracts from Gilead Sciences Inc. through the Gilead Research Scholars Program for Public Health; all outside the submitted work. S Onie reports support for the present manuscript from National Health and Medical Research Council, Australia for an Investigator Grant; consulting fees from WHO for the amount of USD$9000 from November 2023 to date; support for attending meetings and/or travel from Suicide Prevention Australia for travel and attendance fees for annual conference and International Association for Suicide Prevention for conference attendance fees; leadership or fiduciary roles in other board, society, committee or advocacy group, paid or unpaid, with International Association for Suicide Prevention as Vice President and Indonesian Association for Suicide Prevention as President; stock or stock options in Wellspring Indonesia, a local mental health clinic in Indonesia (not majority shareholder); all outside the submitted work. R Ornello reports consulting fees from Teva; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Novartis, Eli Lilly, Teva, AbbVie, Bayer, Pfizer, Lundbeck, Organon; support for attending meetings and/or travel from Teva and Novartis; participation on an Advisory Board with Eli Lilly and AbbVie; receipt of equipment, materials, drugs, medical writing, gifts or other services from Novartis; all outside the submitted work. A Ortiz reports grants or contracts from Sanofi paid to their institution The Fundación Jiménez Díaz Health Research Institute (IIS-FJD UAM) and as Director of the Catedra AstraZeneca-UAM of chronic kidney disease and electrolytes paid to their institution Universidad Autonoma de Madrid (UAM); consulting fees from Astellas, AstraZeneca, Bioporto, Boehringer Ingelheim, Fresenius Medical Care, GSK, Bayer, Sanofi-Genzyme, Lilly, Chiesi, Otsuka, Novo-Nordisk, and Sysmex; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Astellas, AstraZeneca, Bioporto, Boehringer Ingelheim, Fresenius Medical Care, GSK, Bayer, Sanofi-Genzyme, Sobi, Menarini, Lilly, Chiesi, Otsuka, Novo-Nordisk, Sysmex and Vifor Fresenius Medical Care Renal Pharma and Spafarma; support for attending meetings and/or travel from Astellas, AstraZeneca, Fresenius Medical Care, Boehringer-Ingelheim, Bayer, Sanofi-Genzyme, Chiesi, Sobi, and Bayer; participation on a Data Safety Monitoring Board or Advisory Board with Astellas, AstraZeneca, Boehringer-Ingelheim, Fresenius Medical Care, Bayer, Sanofi-Genzyme, Chiesi, Otsuka, Novo Nordisk, and Sysmex; leadership or fiduciary roles in other board, society, committee or advocacy group, unpaid, with Council ERA. SOMANE; all outside the submitted work. P K Pal reports grants or contracts paid to their institution from Indian Council of Medical Research (ICMR), Department of Science & Technology(DST)-Science and Engineering Research Board, Department of Biotechnology (DBT), DST-Cognitive Science Research Initiative, Wellcome Trust UK-India Alliance DBT, PACE scheme of BIRAC, Michael J. Fox Foundation, SKAN (Scientific Knowledge for Ageing and Neurological ailments)-Research Trust; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from the International Parkinson and Movement Disorder Society, and Movement Disorder Societies of Korea, Taiwan and Bangladesh, Japanese Society of Neurology, Teva Pharmaceutical Industries and Elsevier Inc (payment of one-thirds of the honorarium to their institute); support for attending meetings and/or travel from the National Institute of Mental Health and Neurosciences (NIMHANS), International Parkinson and Movement Disorder Society, and Movement Disorder Societies of Korea, Taiwan and Bangladesh, Japanese Society of Neurology and Asian Oceanian Congress of Neurology.; leadership or fiduciary roles in other board, society, committee or advocacy group with Indian Academy of Neurology as Past President, Asian and Oceanian subsection of International Parkinson and Movement Disorder Society (MDS-AOS) as Past Secretary, Annals of Movement Disorders as Past Editor-in-Chief, the Parkinson Society of Karnataka as President, Infection Related Movement Disorders Study Group of MDS as Chair, Rare Movement Disorders Study Group of International Parkinson and Movement Disorder Society (IPMDS) as a Member, Education Committee of IAPRD as a Member, Rating Scales Education and Training Program Committee of IPMDS as a Member, Neurophysiology Study Group of IPMDS as a Member, Movement Disorders in Asia Study Group as a Member, Post-Stroke Movement Disorders as a Member, Ataxia Study Group of IPMDS as a Member, Ataxia Global Initiative as a Member, Movement Disorders Society of India as President, and the Education Committee of International Parkinson and Movement Disorder Society (IPMDS) as Chair—all unpaid posts except Annual Leadership stipend for 2023–2025, of which one-thirds to be paid to their institute; all outside the submitted work. S K Panda reports support for the present manuscript from Siksha ‘O’ Anusandhan (deemed to be university) in the form of a salary; grants or contracts from file number 17-59/2023-24/CCRH/Tech./Coll./ICMR-Diabetes/960 as co-investigator; all outside the submitted work. G D Panos reports support for attending meetings and/or travel (expenses covered without receiving direct payment) from Roche and Bayer AG; all outside the submitted work. R Passera reports participation on a Data Safety Monitoring Board or Advisory Board with the Data Safety Monitoring Board dello studio “Consolidation with ADCT-402 (loncastuximab tesirine) after immunochemotherapy: a phase II study in BTKi-treated/ineligible Relapse/Refractory Mantle Cell Lymphoma (MCL) patients”—FIL, Fondazione Italiana Linfomi, Alessandria (Italy), unpaid; leadership or fiduciary roles in other board, society, committee or advocacy group, paid or unpaid, with the EBMT Statistical Committee, European Society for Blood and Marrow Transplantation, Paris (France) as a member, and the IRB/IEC Comitato Etico AO SS. Antonio e Biagio Alessandria-ASL AL-VC (Italy) as a past Member (2020–2023); all outside the submitted work. A E Peden reports support for the present manuscript from the (Australian] National Health and Medical Research Council (grant number APP2009306). V C F Pepito reports grants or contracts from Sanofi Consumer Healthcare for study self-care in the Philippines, and Zuellig Family Foundation for health systems strengthening; all outside the submitted work. P Ionela-Roxana reports grants or contracts from the project ‘Societal and Economic Resilience within multi-hazards environment in Romania’ funded by European Union—NextgenerationEU and Romanian Government, under National Recovery and Resilience Plan for Romania, contract number 760050/ 23.05.2023, cod PNRR-C9-I8-CF 267/ 29.11.2022, through the Romanian Ministry of Research, Innovation and Digitalization, within Component 9, Investment I8; all outside the submitted work. L Ronfani reports support for the present manuscript from the Italian Ministry of Health (Ricerca Corrente 34/2017), payments made to the Institute for Maternal and Child Health IRCCS Burlo Garofolo. P S Sachdev reports grants or contracts from National Health and Medical Research Council of Australia, APP1169489 and National Institutes of Health, USA; grants 1RF1AG057531–01 and 2R01AG057531–02A1; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Alkem Labs for a lecture as part of the Frontiers of Psychiatry 2023 seminar, Mumbai, India, June 2023; participation on a Data Safety Monitoring Board or Advisory Board with Biogen Australia Medical Advisory committee in 2020 and 2021 Roche Australia Medical Advisory Committee in 2022, Eli Lilly, Expert Advisory Panel, 2025; leadership or fiduciary roles in other board, society, committee or advocacy group, unpaid, with International Neuropsychiatric Association as Executive Board Member and World Psychiatric Association as Planning Committee Member; all outside the submitted work. Y L Samodra reports grants or contracts from NSTC—NTU Institute of Epidemiology and Preventive Medicine, Taiwan for a post-doctoral fellow contract; leadership or fiduciary roles in other board, society, committee or advocacy group, paid or unpaid, with Benang Merah Research Center, Indonesia as Co-Founder; other financial or non-financial interests with Jago Beasiswa (idebeasiswa.com) as a scholarship mentor; all outside the submitted work. A E Schutte reports consulting fees from AstraZeneca, Medtronic, Sky Labs, Servier, and Roche; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from AstraZeneca, Medtronic, Sky Labs, Servier, Omron, and Aktiia; support for attending meetings and/or travel from Medtronic, Servier; all outside the submitted work. M Šekerija reports consulting fees from Roche; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Astellas; all outside the submitted work. V Sharma reports other financial or non-financial interests with DFSS (MHA)'s research project (DFSS28(1)2019/EMR/6) at Institute of Forensic Science & Criminology, Panjab University, Chandigarh, India, outside the submitted work. V Shivarov reports one patent issued or pending with the Bulgarian Patent Office; other financial or non-financial interests with ICON plc. in the form of a salary; all outside the submitted work. J P Silva reports support for the present manuscript from Portuguese Foundation for Science and Technology for payment of a salary (contract with reference 2021.01789.CEECIND/CP1662/CT0014). L M L R Da Silva reports grants or contracts from SPRINT, Sport Physical Activity and Health Research e Innovation Center, Polytechnic of Guarda, 6300–559 6 Guarda, Portugal; and collaborate with RISE—UBI, Health Sciences Research Centre, University of Beira Interior, 6201–506 Covilhã, Portugal; all outside the submitted work. J A Singh reports consulting fees from ROMTech, Atheneum, Clearview healthcare partners, American College of Rheumatology, Yale, Hulio, Horizon Pharmaceuticals, DINORA, ANI/Exeltis, USA Inc., Frictionless Solutions, Schipher, Crealta/Horizon, Medisys, Fidia, PK Med, Two labs Inc., Adept Field Solutions, Clinical Care options, Putnam associates, Focus forward, Navigant consulting, Spherix, MedIQ, Jupiter Life Science, UBM LLC, Trio Health, Medscape, WebMD, and Practice Point communications; and the National Institutes of Health; Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Simply Speaking; Support for attending meetings and/or travel from Simply Speaking; Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid as a past steering committee member of the OMERACT, an international organisation that develops measures for clinical trials and receives arm's length funding from 12 pharmaceutical companies, and as a Chair of the Veterans Affairs Rheumatology Field Advisory Committee, and as editor and the Director of the UAB Cochrane Musculoskeletal Group Satellite Center on Network Meta-analysis; Stock or stock options in Atai life sciences, Kintara therapeutics, Intelligent Biosolutions, Acumen pharmaceutical, TPT Global Tech, Vaxart pharmaceuticals, Atyu biopharma, Adaptimmune Therapeutics, GeoVax Labs, Pieris Pharmaceuticals, Enzolytics Inc., Seres Therapeutics, Tonix Pharmaceuticals Holding Corp., Aebona Pharmaceuticals, and Charlotte's Web Holdings, Inc. and previously owned stock options in Amarin, Viking, and Moderna Pharmaceuticals; outside the submitted work. I N Soyiri reports leadership or fiduciary roles in board, society, committee or advocacy groups, unpaid as Trustee of the Citizens Advice Bureau for Hull & East Riding, United Kingdom; outside the submitted work. D J Stein reports consultancy honoraria from Discovery Vitality, Kanna, L’Oreal, Lundbeck, Orion, Servier, Seaport Therapeutics, Takeda, and Wellcome; all outside the submitted work. J Sundström reports direct or indirect stock ownership in companies (Anagram kommunikation AB, Sence Research AB, Symptoms Europe AB, MinForskning AB) providing services to companies and authorities in the health sector including Amgen, AstraZeneca, Bayer, Boehringer, Eli Lilly, Gilead, GSK, Göteborg University, Itrim, Ipsen, Janssen, Karolinska Institutet, LIF, Linköping University, Novo Nordisk, Parexel, Pfizer, Region Stockholm, Region Uppsala, Sanofi, STRAMA, Takeda, TLV, Uppsala University, Vifor Pharma, WeMind; all outside the submitted work. R Tabarés-Seisdedos reports grants or contracts from Valencian Regional Government's Ministry of Education (PROMETEO/CIPROM/2022/58) and the Spanish Ministry of Science, Innovation and Universities (PID2021–129099OB-I00). The funders were not involved in the design of the manuscript or decision to submit the manuscript for publication, nor will they be involved in any aspect of the study's conduct; all outside the submitted work. J H V Ticoalu reports leadership or fiduciary roles in other board, society, committee or advocacy group, paid or unpaid, with Benang Merah Research Center, Indonesia as Co-Founder; all outside the submitted work. D Trico reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from AstraZeneca, Eli Lilly, and Novo Nordisk; support for attending meetings and/or travel from AstraZeneca; participation on a Data Safety Monitoring Board or Advisory Board with Amarin, Boehringer Ingelheim, Novo Nordisk; leadership or fiduciary roles in other board, society, committee or advocacy group, paid or unpaid, with EASD Early Career Academy and EASD Committee on Clinical Affairs; receipt of equipment, materials, drugs, medical writing, gifts or other services from Abbott and PharmaNutra; all outside the submitted work. S J Tromans reports grants or contracts paid to University of Leicester, their institution, as part of the 2023/4 Adult Psychiatric Morbidity Survey team, collecting epidemiological data on community-based adults living in England (a contracted study from NHS Digital, via the Department of Health and Social Care. Contributions on chapters of the 2023/4 Adult Psychiatric Morbidity Survey report), as lead on a study funded by the National Institute for Health and Care Research Clinical Research Network, on optimising the survey design for people with learning disability and autism, as lead on a study from the National Institute for Health and Care Research related to reviewing a national training programme for health and social care professionals relating to learning disability and autism, and as Co-applicant on study funded by the National Institute for Health and Care Research related to Identification, recording, and reasonable adjustments for people with a learning disability and autistic people in NHS electronic clinical record systems; support for attending meetings and/or travel from the Royal College of Psychiatrists; leadership or fiduciary roles in board, society, committee or advocacy groups, paid or unpaid as Academic Secretary for the Neurodevelopmental Psychiatry Special Interest Group and Psychiatry of Intellectual Disability Faculty at the Royal College of Psychiatrists, as Editorial Board Member for Progress in Neurology and Psychiatry, Advances in Mental Health and Intellectual Disability , Advances in Autism , BMC Psychiatry , and BJPsych Open , and as Editor of Psychiatry of Intellectual Disability Across Cultures (Oxford University Press); outside the submitted work. V-S Tseriotis reports grants or contracts from the European Academy of Neurology, European Committee for Treatment and Research in Multiple Sclerosis; support for attending meetings and/or travel from Inovis, Genesis Pharma, and Novartis; all outside the submitted work. E Upadhyay reports patents issued or pending for “A system and method of reusable filters for anti-pollution mask” (Published); “A system and method for electricity generation through crop stubble by using microbial fuel cells” (Published); “A system for disposed personal protection equipment (PPE) into biofuel through pyrolysis and method” (Published); “A novel herbal pharmaceutical aid for formulation of gel and method thereof” (Published); “Herbal drug formulation for treating lung tissue degenerated by particulate matter exposure” (Published); “A method to transform cow dung into the wall paint by using natural materials and composition thereof” (Filed); “Biodegradable packaging composition and method of preparation thereof” (Filed); “Eco-friendly bio-shoe polish from banana and turmeric” (Filed); “Honey-based polyherbal syrup composition to treat air pollution-induced inflammation and preparation method thereof” (Filed); “Process for preparing a caffeine free, antioxidant and nutrient rich beverage” (Filed); leadership or fiduciary roles in other board, society, committee or advocacy group, paid or unpaid, with Meteorological Society, Jaipur (India) as Executive Council Member, Indian Chapter and DSTPURSE Program as member Secretary; all outside the submitted work. E Vounzoulaki reports grants or contracts from a National Institute for Health and Care Research (NIHR) Development and Skills Enhancement Award (DSE) until July 2026, outside the submitted work. Yichen Wang reports grants or contracts from Mayo Clinic Center for Digital Health and Mayo Clinic Office of Belonging (formerly the Office of Inclusion and Diversity) with support from Dalio Philanthropies, 2024 for an Artificial Intelligence-Machine Learning Award; support for attending meetings and/or travel from The International Foundation for Gastrointestinal Disorders and University of Kansas Health Center; a provisional patent, “A Method to Automate International Classification of Diseases Coding using Large Language Model”; all outside the submitted work. J W Ward reports grants or contracts from Abbott, Gilead, AbbVie, Merck, Siemens, GSK, Cepheid, Zydus Life, governmental agencies, and philanthropic organisations to the Task Force for Global Health for the general support of the Coalition for Global Hepatitis Elimination; all outside the submitted work. P Willeit reports consulting fees from Novartis Pharmaceuticals; outside the submitted work. J F Wu reports grants or contracts from the National Heart, Lung, and Blood Institute (R38HL167238) and prior funding from the American Society of Hematology Hematology Opportunities for the Next Generation of Research Scientists (HONORS) Award; all outside the submitted work. Y Yasufuku reports grants or contracts from Shionogi & Co, Ltd; their employment expenses are paid from the joint research fund provided by this pharmaceutical company to The University of Osaka, outside the submitted work. S Zadey reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Think Global Health, The Hindu, and Harvard Public Health Magazine; leadership or fiduciary roles in other board, society, committee or advocacy group, paid or unpaid, with Association for Socially Applicable Research (ASAR) as Cofounding Director, Asia Working Group, The G4 Alliance as Chair, Lancet Citizens’ Commission as a Fellow, Duke GEMINI Research Center as Research Aide Sr., Maharashtra State Mental Health Policy as a Drafting Committee Member, and Dr D. Y. Patil University as Adjunct Research Faculty; all outside the submitted work. G Zamagni reports support for the present manuscript from the Italian Ministry of Health (Ricerca Corrente 34/2017), payments made to the Institute for Maternal and Child Health IRCCS Burlo Garofolo. M Zielińska reports other financial or non-financial interests with Alexion and AstraZeneca Rare Disease as an employee; all outside the submitted work.